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Abstract
The steroid metabolising enzyme 1 IB-hydroxysteroid dehydrogenase (11B-HSD)
interconverts active and inactive glucocorticoids; in rats corticosterone and 11-
dehydrocorticosterone, thus regulating access of glucocorticoids to intracellular
receptors. Two 11B-HSD isozymes exist; type 1 (11B-HSD1) is NADPH-dependent,
widely distributed and is highly expressed in liver, where it acts predominantly as a
reductase in intact cells thereby generating active glucocorticoids from inactive
substrates. Type 2 11B-HSD (11B-HSD2) is an NAD-dependent exclusive
dehydrogenase, expressed in placenta where it protects the foetus from maternal
glucocorticoids, and in aldosterone target tissues such as kidney, where it plays a well
characterised role in conferring mineralocorticoid specificity upon the
mineralocorticoid receptor.
The role of 11B-HSD1 remains unclear, however, it is likely to play a central role in
determining cellular sensitivity to glucocorticoids. Attenuation of hepatic 11B-HSD1
expression is associated with increased insulin sensitivity, decreased blood glucose
levels and reduced expression of glucocorticoid-inducible genes involved in
gluconeogenesis in liver.
The aim of the work described in this thesis was to elucidate the molecular
mechanisms which govern transcription of this important steroid metabolising enzyme,
primarily in liver, the site of highest expression of 11G-HSD1.
Work from this laboratory, investigating activity of the rat 11B-HSD1 promoter in
transfected HepG2 cells (a liver derived cell line) has shown the importance of the
region between -812 and +47 in conferring C/EBPa inducibility upon a linked reporter
gene, and has also demonstrated the presence of a repressor element between -812 and
-599.
Within this region I have shown 13 sites to which proteins from rat liver nuclear
extract bind; 11 of these sites were similarly bound by bacterially expressed C/EBPa.
One of these sites was a high affinity C/EBPa binding site spanning the transcription
start and was investigated in some detail. The majority of complexes formed by rat
liver nuclear extract on the transcription start contained C/EBPa and/or C/EBPB.
Furthermore, a minimal promoter (-88 to +8), containing this site and 2 additional
weak C/EBP binding sites at -54 to -36 and -75 to -62 was transcriptionally active in
vitro in nuclear extract from rat liver but not from HeLa cells, which lack C/EBP.
A longer region of the promoter between, -599 and +8, is transcriptionally active in
vitro in rat liver nuclear extract to a similar or slightly greater extent than the -88 to +8
promoter. This region contained 6 sites of liver nuclear protein binding between -599
and -88, all of which corresponded to recognition sites for C/EBP, suggesting that
C/EBP-related transcription factors may be the major factors in liver which directly
contact the 11B-HSD1 promoter between -599 and -88.
Within the repressor region between -812 and -599 were 3 specific sites of protein
binding by liver nuclear extract, one of these sites did not bind C/EBPa. One site, at
-792 to -780, was similarly bound by liver nuclear extract and recombinant C/EBPa;
the second site was protected by liver nuclear extract between -711 and -663, and
within this site C/EBPa bound between -696 and -677; the third site was protected by
liver nuclear extract only. The 2 sites of C/EBPa interaction with the promoter at -790
and -690 were further characterised. Protein-DNA complexes formed at -690
contained predominantly C/EBPa and C/EBPB; analysis of the -790 site on which
DNase I footprints were formed by rat liver nuclear extract and recombinant C/EBPa
failed to show distinct protein complexes, and did not bind recombinant C/EBPa
protein.
Preliminary experiments to investigate the factors which may regulate 11B-HSD1
transcription in other tissues (bovine adrenal cortex and undifferentiated/differentiated
3T3-F442A cells, a preadipocyte cell line) show a different spectrum of proteins
binding to the 11B-HSD1 promoter from that seen in liver.
11B-HSD1 is expressed and regulated in a tissue-specific manner. The results
described in this thesis suggest that this occurs through the tissue-specific transcription
factors which bind to the 11B-HSD1 promoter. In liver, the central role played by
C/EBP in the expression of 11B-HSD1 suggests that C/EBP may at least in part
modulate glucocorticoid effects indirectly by altering the transcription of 116-HSD1,
and is consistent with the involvement of C/EBPa in regulating energy supply, and the
role of C/EBPB in the acute phase response.
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Steroid hormones are all derived from cholesterol and are synthesised by three
embryologically related tissues; the testis, the ovary and the adrenal gland. The major
classes of steroid hormone are androgens, oestrogens, progestins and corticosteroids.
Androgens and oestrogens are synthesised and secreted by the gonads and play a role
in reproduction and sexual behaviour. Progesterone is secreted by the corpus luteum
and placenta, and plays a central role in female reproduction (Lydon et al., 1995).
There are two types of corticosteroids; glucocorticoids and mineralocorticoids, both
of which are synthesised in the adrenal cortex. Glucocorticoids play central roles in
the maintenance of homeostasis, mood, behaviour and the stress response, while
mineralocorticoids maintain salt and water balance. The action of steroid hormones
can be modulated at a number of levels; synthesis, secretion, binding to plasma
proteins e.g. corticosteroid binding globulin (CBG), sex steroid binding globulin
(SHBG) (also called testosterone binding globulin) and albumin, uptake by tissues,
binding and retention in tissues, metabolism within tissues, presence of receptors in
cells, availability and activity of receptors inside cells and transcriptional activity of
receptors in the nucleus.
This thesis is concerned with the tissue specific regulation of 1113-HSD1, a crucial
steroid metabolising enzyme which regulates intracellular access of glucocorticoids
to corticosteroid receptors. In this chapter I shall review the processes which control
the action of glucocorticoids, the biology and regulation of the 1 lB-hydroxysteroid
dehydrogenase enzymes and the process by which tissue-specific controls of gene
transcription are achieved, with particular attention to hepatic gene transcription.
1.1.1 The adrenal cortex and biosynthesis ofadrenocortical hormones
The adrenal cortex is divided into three morphologically distinct regions based on
differences in vascular and connective tissue; the zona glomerulosa, the zona
fasciculata, and the zona reticularis (Arnold, 1866). The narrow outer zona
glomerulosa lies below the adrenal capsule and is the site of biosynthesis of the
mineralocorticoid aldosterone. The bulk of the cortex is formed by the zona
fasciculata/reticularis which lies below the glomerulosa and which secretes
glucocorticoids, and in humans, dehydroepiandrosterone (DHEA) and other weak










Figure 1.1 Basic steroid ring structure
The rings are named A-D and the numbers refer to the conventional designation of
carbon atoms.
Cholesterol, the precursor to all steroid hormones, is either taken up from circulating
blood by the adrenal gland or is synthesised de novo. The basic structure of steroid
hormones is shown in Figure 1.1. The major steps in steroid biosynthesis are outlined
in Figure 1.2 and involve 4 cytochrome P-450 enzymes and 38-hydroxysteroid
dehydrogenase (38-HSD). The rate limiting step in the synthesis of all steroid
hormones is the removal of the side chain from cholesterol to form the C21 steroid
pregnenolone by cytochrome P-450Scc (side chain cleavage enzyme). Subsequent
reactions by 36-HSD, P450C17 (17,20-lyase), P450C2i (21-hydroxylase) and P450Cn
(11-hydroxylase) result in the production of predominantly corticosterone (in rats) or
Cortisol (in humans) (Figure 1.2). The unique expression in the zona glomerulosa of
aldosterone synthase (related to P450C11, but the product of a separate gene) is
responsible for the conversion of corticosterone to aldosterone, and thus the
production of mineralocorticoid by the glomerulosa (Domalik et al., 1991).
1.1.2 Control ofcorticosteroid synthesis and secretion
There is a natural diurnal rhythm of glucocorticoid synthesis and secretion, with peak



























Figure 1.2 Biosynthesis ofadrenocortical steroids
Adrenal steroid biosynthetic pathways in the cortex. Pathways for glucocorticoid,
mineralocorticoid and androgen biosynthesis are shown. DHEA,
Dehydroepiandrosterone; ASD, Androstenedione (Modified from Orth et al., 1992).
secretion during stress. Adrenal steroid hormones are not stored by the adrenal gland
but are released into the circulation once synthesised.
Synthesis of the glucocorticoids Cortisol and corticosterone, by the zona
fasciculata/reticularis, is controlled by the interaction of hormonal and neuronal
stimuli and their subsequent actions on the hypothalamus, anterior pituitary and
adrenal cortex (HPA axis) (Figure 1.3). At the adrenal cortex, the main stimulus of
glucocorticoid synthesis is adrenocorticotrophic hormone (ACTH) (Waterman &
Simpson, 1989; White et al., 1994), secreted by the pituitary from the precursor
polypeptide, proopiomelanocortin (POMC). ACTH binds to cell surface receptors on
the adreno-cortical cell, subsequently resulting in increased intracellular cyclic AMP
(cAMP). Within minutes, there is an increase in the activity of P-450scc, the rate
limiting step in steroidogenesis. Additionally, over a period of hours/days, ACTH
causes an increase in the synthesis of steroidogenic enzymes and proteins required
for steroidogenesis e.g. adrenodoxin (reviewed in Simpson & Waterman, 1983).
ACTH synthesis and secretion from the pituitary is in turn regulated by multiple
hormonal factors, the most important of which are corticotrophin releasing hormone
(CRH) and arginine vasopressin (AVP) both of which are released from the
hypothalamus. CRH and AVP are both synthesised in the parvicellular neurones of
the paraventricular nucleus of the hypothalamus, and AVP is synthesised in the
magnocellular neurones of the supraoptic and paraventricular nuclei, released into
the hypophyseal portal blood which delivers CRH and AVP to the pituitary where
they act to increase production of ACTH (Orth et al., 1992). In addition to direct
simulation by these factors, AVP also potentates the action of CRH on the anterior
pituitary (Antoni, 1993).
Activation of HPA axis activity is terminated by the actions of glucocorticoids,
which negatively feedback at the levels of the hypothalamus (to decrease CRH and
AVP secretion), the pituitary (to decrease POMC synthesis and secretion)
(Lundbland & Roberts, 1988) and also the hippocampus (Bayer et al., 1988; Davis et















Figure 1.3 The HPA axis
Schematic representation of the HPA axis
1.1.3 Control ofmineralocorticoid secretion
Secretion of aldosterone is controlled primarily by the renin-angiotensin system.
When sodium concentrations in the distal tubule of the kidney nephron are low or if
there is low renal arterial blood pressure, the juxta-glomerular cells release renin into
the bloodstream (Orth et al., 1992). In the blood, renin acts to form angiotensin I
from angiotensinogen (Goodfriend et al., 1980). Angiotensin I is converted to the
active octapeptide angiotensin II by angiotensin converting enzyme (ACE) in the
vasculature and lungs. Angiotensin II stimulates the release of aldosterone from the
adrenal glomerulosa cells by binding to a G protein-linked receptor leading to
activation of phospholipase C, and an increase in steroid production (Quinn &
Williams, 1988).
1.1.4 Plasma steroid binding proteins
In the bloodstream, circulating steroid hormones are reversibly bound to plasma
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proteins, namely CBG, SHBG, and albumin. 90% of Cortisol and 80% of
corticosterone are found associated with CBG, with remaining glucocorticoids
normally associated with albumin (Dunn et al., 1981). Aldosterone in plasma is also
associated with steroid binding proteins, but a higher percentage are 'free' with only
20% bound to CBG and 40% to albumin (Dunn et ah, 1981; Pardridge, 1981).
1.1.5 Actions ofglucocorticoids
Glucocorticoids affect many diverse physiological functions, for example, fuel
metabolism, immunological and inflammatory function, electrolyte and fluid
homeostasis, muscle and bone formation, mood, behaviour, and the stress response
(Orth et ah, 1992). The profound effects of glucocorticoids are apparent in patients
with glucocorticoid deficiency (Addison's Disease) who typically have muscle
weakness and weight loss. In contrast, patients with glucocorticoid excess (Cushing's
syndrome) frequently have hypertension, wasting of muscles, osteoporosis, and fat
redistribution. Excessive exposure to glucocorticoids during development may also
be detrimental to the foetus resulting in a higher risk of hypertension in adult life
(Seckl etah, 1995).
1.1.5.1 Effects on metabolism
Glucocorticoids are involved in the metabolism of carbohydrates, proteins and lipids
and, together with insulin and glucagon, regulate blood glucose. After a high
carbohydrate meal, blood glucose increases, resulting in insulin secretion from the
pancreas (Cryer, 1992). Insulin inhibits gluconeogenesis and together with
glucocorticoids causes the rapid uptake of glucose, its storage as glycogen and the
use of glucose in liver (Cryer, 1992). Insulin in liver also promotes the conversion of
excess glucose into fatty acids, which are transported to adipose tissue and deposited
as fat (Cryer, 1992). In muscle, insulin decreases the release of amino acids thus
decreasing the availability of precursors to gluconeogenesis (Cryer, 1992). During
fasting, glucocorticoid have a permissive effect on the actions of glucagon (Exton,
1979), which is released from the pancreas and essentially has opposite effects to
insulin, increasing blood glucose by promoting glycogenolysis and gluconeogenesis
e.g. by activating phosphoenolpyruvate carboxykinase (PEPCK) and glucose 6-
phosphatase (G6Pase) (Exton, 1979). Glucocorticoids also directly inhibit glucose
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transport into cells (Munck, 1962) and activate the breakdown of lipids in adipose
tissue (Fain, 1979).
1.1.5.2 Immunologicalfunction and inflammatory processes
A normal physiological role of glucocorticoids is to suppress the immune response
following initial activation (Graham & Tucker, 1984). Macrophages and T- and B-
lymphocytes attack and destroy invading bacteria and viruses. During inflammation,
glucocorticoids inhibit the movement of fluid and immune cells into the site of
inflammation (Zweifach et al., 1953) and inhibit the action of mediators involved in
the inflammatory response, for example, by inhibiting prostaglandin and cytokine
synthesis (Hong & Levine, 1976). They also decrease thymus derived lymphocytes
(T-cells) and bone marrow derived lymphocytes (B-cells) by inhibiting their
generation (Cupps et al., 1985; Gillis et al., 1979). Glucocorticoids have the same
effect on monocytes (the precursors of macrophages) and inhibit the phagocytotic
and cytotoxic effects of macrophages (Reinehart et al., 1982).
1.1.5.3 Glucocorticoids and the stress response
Stresses such as trauma, illness and psychological stress activate the HPA axis,
resulting in increased plasma ACTH and Cortisol levels. The mechanisms by which
stress induces these changes are not known, but result in CRH and/or AVP being
released from the hypothalamus, consequently increasing ACTH secretion from the
pituitary (Orth et al., 1992). Negative feedback action by glucocorticoids terminates
the stress response by acting on the pituitary to decrease ACTH production and
transcription of its precursor POMC, as well as exerting feedback effects on the
hypothalamus, reducing CRH and AVP production (Orth et al., 1992).
1.1.5.4 Other effects ofglucocorticoids
Glucocorticoids under normal physiological conditions have well described effects
on development. Particularly well documented is the requirement of glucocorticoids
for normal maturation of the lung, where they act on type II pneumocytes to increase
surfactant production (Ballard, 1987), thereby allowing the lungs to function
normally at birth. In the generation of the adrenal gland glucocorticoids are required
for regulating formation of chromaffin cells from neural crest epithelial cells
(Federoff et al., 1988). Mice homozygous for a targeted disruption of the
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glucocorticoid receptor gene die of respiratory problems caused by a lack of
surfactant production, and have defective chromaffin cell development (Cole et al.,
1995). Glucocorticoids in excess cause retention of fluids, resulting in hypertension
(Krakoff et al., 1975; Saruta et al., 1986).
Excess glucocorticoids cause muscular weakness which is frequently seen in patients
with Cushing's Disease due to loss of proteins from muscle and their use as
substrates for gluconeogenesis (Exton, 1979). Additionally, glucocorticoids promote
loss of creatine from muscle, associated with oedema and fibrosis and inhibit bone
formation by osteoblasts (Hahn et al., 1979). Excess glucocorticoids have many
effects on mood and behaviour, and Cushings patients commonly have psychological
disturbances; typically cognitive/memory dysfunction and depression (Jeffcoate et
al., 1979; Plotz, 1952; Starkman et al., 1986). Glucocorticoids are also important in
prenatal programming, if the foetus is exposed to high levels of glucocorticoids then
there may be a retardation of foetal growth (Reinisch et al., 1978) and, in later adult
life, a higher risk of hypertension (Benediktsson et al., 1993).
1.1.6 Actions ofmineralocorticoids
As implied by the name, the actions of mineralocorticoids are concerned with
maintaining salt and water homeostasis. The main site of mineralocorticoid action is
at the kidney where aldosterone acts on the distal convoluted tubule and the
collecting ducts; mineralocorticoids also affect the colon, sweat and salivary glands.
In general, aldosterone causes sodium absorption and potassium excretion, and hence
increased fluid retention, which increases blood pressure (see for example Orth et al.,
1992). In addition, mineralocorticoids act on the central nervous system to regulate,
for example, salt appetite (McEwen et al., 1986).
1.2 Steroid hormone receptors
It has long been assumed that steroid hormones enter cells by diffusion, however,
recent evidence from yeast suggests that an active mechanism transports steroids into
cells (Kralli et al., 1995). Inside target cells, steroid hormone action is mediated by
specific receptor proteins. Steroid receptors (including the classical steroid receptors,
glucocorticoid receptor (GR), mineralocorticoid receptor (MR), progesterone
receptor (PR), oestrogen receptor (ER) and androgen receptor (AR)) all belong to the
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nuclear receptor superfamily (summarised in Table 1.1). Members of this family also
include receptors for other ligands including thyroid hormone (T3), Vitamin D3,
retinoic acid, 9-cis retinoic acid, the insect hormone ecdysone and 15-deoxy-A12'14-
prostaglandin J2 (an endogenous ligand for PPARy) (Evans, 1988; Forman et al.,
1995; Isseman & Green, 1990; Koelle et al., 1991), and receptors for which no ligand
exists, or has yet been identified (the 'orphan' receptors) (reviewed in Beato, 1989;
Evans, 1988; O'Malley, 1990) (for classification of receptors see Section 1.2.5).
These receptors all act in the nucleus, bind to DNA and share a common domain
structure, conserved across species, from insects to mammals (Section 1.2.1, Figure
1.4), and play diverse roles, controlling homeostasis, development, differentiation
and reproduction.
Receptors for which the
ligand is known
Orphan Receptors Drosophila Proteins
Glucocorticoid (GR) COUP-TF I/COUP-TF II Seven-up
Progesterone (PR) Ear-2




Retinods (RARa, 13, y)
(RXRa, 6, y)
PPARoc/13 Ecdysone Receptor
Thyroid hormone (T3Ra,G) NGFI-B DHR3




Table 1.1 The nuclear receptor superfamily
Compilation of some members of the nuclear receptor family, taken from Amero et
al., 1992; Forman et al., 1995; Laudet & Adelmant, 1995; Laudet et al., 1992.
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The members of the steroid receptor superfamily probably number in the hundreds,
and their properties are variable. All classical receptors and most other receptors are
only active as dimers; a few orphan receptors, and possibly T3 receptor (T3R)
probably also act as monomers (Section 1.2.5). Some (including GR), are complexed
with heat shock proteins (Section 1.2.2), although most are not, and others repress
transcription in the absence of ligand (e.g., T3R) (Brent et al., 1989; Zhang et al.,
1991). To review in detail the properties of all nuclear receptors is not practical for
the purpose of this thesis, so I will provide a general review of the characteristics of
this family of proteins concentrating largely on GR.
1.2.1 Steroid hormone receptor structure
The glucocorticoid receptor cDNA was the first steroid receptor cDNA to be cloned,
and it showed homology to v-ERBA, subsequently found to be the oncogenic variant
of T3Ra (Hollenberg et al., 1985). Comparison of cDNA sequences encoding
members of the nuclear receptor family has shown that all share a conserved domain
structure (Figure 1.4). Various functions have been ascribed to these domains and
these will be discussed below.
A/B D E/F















Figure 1.4 Domain structure ofsteroid receptors
The functions of domains are indicated. Domains A-F refer to terminology adopted
for steroid receptor structure, originally assigned to the human ER (Krust et al.,
1986).
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Figure 1.5 Activation ofnuclear receptors
The top part of the diagram represents the prevalent model for transcriptional
activation by steroid receptors. Steroid hormones (purple boxes) are released from
plasma proteins (P), they enter the cell and dissociate receptors (green boxes) from
the hsp complex resulting in receptor dimerisation, translocation into the nucleus and
gene activation. The bottom part of the diagram represents activation by receptors
which are not associated with hsp in the cytoplasm. The ligand enters the nucleus















The steroid receptors contain a highly conserved DNA binding domain (domain C)
located roughly in the middle of the receptor (Section 1.2.4), connected by a less well
conserved 'hinge' domain (domain D) to a C-terminal ligand binding domain (domain
E/F), which confers specificity for ligand and which shows a moderate degree of
conservation, particularly between receptors which bind the same ligand e.g. RARa,
13 and y(Krust et al., 1989).
The N-terminus (domain A/B) is generally variable in size and amino acid sequence,
and is involved in cell type specific transcriptional regulation (Carlstedt-Duke et al.,
1982). It is not required for hormone binding (Rusconi & Yamomoto, 1987), receptor
activation (Gehring & Arndt, 1985), dimerisation (Eriksson & Wrange, 1990), DNA
recognition (Freedman et al., 1988) or for transport into the nucleus (Jewell et al.,
1995) and has been termed the modulatory domain. It is, however, required for full
transcriptional activity of GR (Miesfeld et al., 1987), and loss of the N-terminal
domain results in altered protein-protein contacts in the dimer which affects the
interaction with DNA (Eriksson and Wrange, 1990).
1.2.2 Ligand binding domain
The original two step model for the activation of steroid hormone receptors proposed
that in the absence of ligand steroid hormone receptors were retained in the
cytoplasm (Jensen, 1990). Following binding of steroid to receptor, the steroid-
receptor complex transformed into the active form of the receptor and translocated to
the nucleus (Jensen et al., 1968). Data now suggests that the exact location of the
steroid hormone receptor differs depending on the individual receptor type (reviewed
by Jenson, 1990; Walters, 1985).
In the absence of ligand, heat shock proteins (hsp) (hsp90, hsp70 and hsp56) are
found associated with certain steroid receptors, in a complex that is unable to bind to
DNA (Rehberger et al., 1992; Rexin et al., 1992; Segnitz & Gehring, 1995),
including GR (Dalman et al., 1990; Dalman et al., 1991). Binding of ligand to the
ligand binding domain (domain E), leads to the dissociation of receptor from hsp's,
followed by receptor dimerisation to form a complex capable of interacting with
DNA and regulating gene transcription (Figure 1.5), (reviewed in Baniahmed & Tsai,
1993; Glass, 1994). This domain also contains a trans-activating function; deletions
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in this domain of GR abolish ligand binding and activation of transcription
(Godowski et al., 1987). Recent evidence from ER suggests that domain E interacts
with coactivators (Cavailles et al., 1995; Le Dovarin et al., 1995; vom Baur, et al.,
1996).
1.2.3 Nuclear translocation ofsteroid hormone receptors
All proteins are synthesised in the cytoplasm, therefore, all nuclear receptors have a
nuclear localisation signal to allow translocation of the receptor into the nucleus. The
nuclear localisation signal is bipartate in character and has perhaps been best
described for the progesterone and androgen receptors (Jenster et al., 1993; Ylikomi
et al., 1993). It consists of two basic amino acids separated by 10 amino acid residues
from another set of 4-5 basic amino acid residues. If not already situated in the
nucleus, then following binding of ligand, nuclear receptors need to be transported
into the nucleus to activate transcription. The precise details of nuclear translocation
are unclear, but in yeast the glucocorticoid receptor is actively transported to the
nucleus by a transporter (Kralli et al., 1995) and possibly nuclear transporters exist
for other steroid receptors (Defranco et al, 1995).
1.2.4 DNA binding domain ofsteroid hormone receptors
The DNA binding domain (domain C) is the most highly conserved domain amongst
members of the superfamily. Nuclear magnetic resonance spectroscopy has been
used to characterise the structure of domain C for a number of receptors (Baumann et
al., 1993; Knegtel et al., 1993; Lee et al., 1993; Schwabe et al., 1990). The structure
of the GR DNA binding domain bound to DNA has been determined by x-ray
crystallography (Luisi et al., 1991) (Figure 1.6). The DNA binding domain of GR
has a high basic amino acid content, and contains 9 conserved cystines, 8 of which
form two zinc fingers each containing one molecule of zinc (Luisi et al., 1991). The
zinc is co-ordinated to the sulphur atom of the four cystines. The first zinc finger
contains the amino acids that recognise specifically the steroid response element on
DNA (section 1.2.5) and positions an a-helix to interact with DNA in the major
groove (Green et al., 1988; Luisi et al., 1991). The second zinc finger is involved in
receptor dimerisation and provides phosphate contacts with the DNA backbone
(Luisi et al., 1991); mutations in the second zinc finger reduce efficiency of DNA
binding (Hard et al., 1990; Luisi et al., 1991; Schwabe et al., 1990).
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Figure 1.6 The structure of the glucocorticoid receptor bound to a GRE
Taken from Luisi, et al., 1991.
 
1.2.5 Classes ofnuclear hormone receptors
Members of the nuclear hormone receptor family can be divided into 3 classes on the
basis of their DNA binding activity (Laudet and Adelmant, 1995) (Figure 1.7).
Class I steroid receptors bind to DNA as dimers and recognise inverted repeats with
consensus sequences GGTACAnnnTGTYCT for GR, PR, AR and MR, and
AGGTCAnnnTGACCT for ER (Figure 1.7) (Beato, 1987; Freedman & Luisi, 1993).
The DNA binding specificity primarily results from 3 amino acids in the first zinc
finger which contact exposed edges of base pairs in the major groove, which are
identical in AR, PR, GR and MR, but differ in ER (Green et al., 1988).
Class II nuclear receptors bind as dimers to sequences containing two copies of the
consensus half site, AGGTCA, in various orientations (direct, inverted, everted
repeats), separated by 0-5 nucleotides (depending on the receptor) (Figure 1.7) (Glass
et al., 1991). This group of receptors includes the receptors T3R, RARa, 13, y, RXRa,
8, yand VDR as well as many of the orphan receptors. Direct repeats with different
spacings are selective for different receptors (Naar et al., 1991; Umesono et al.,
1991), with VDR recognising a direct repeat with a 3 base pair spacing (DR+3), T3R
a 4 (DR+4), RAR a 5 or 1 nucleotide spacing (DR+5, DR+1), and RXR a 2 (DR+2)
(Umesono et al., 1991). In addition, RXR forms dimers with, and enhances DNA
binding of RAR, T3R, VDR (Kliewer et al., 1992a; Leid et al., 1992; Marks et al.,
1992; Yu et al., 1991; Zhang et al., 1992) and some orphan receptors including LXR,
RLD-1 and MB67 (Apfel et al., 1994; Baes et al., 1994; Gearing et al., 1993; Kliewer
et al., 1992b; Willy etal., 1995).
Class III nuclear receptors such as NGFI-B and SF-1 bind as monomers to an
element containing the AGGTCA consensus sequence extended by 2-5 nucleotides at
the 5' end (Wilson et al., 1993), with the nucleotides immediately 5' of the half site
important in specifying receptor selectivity (Ueda et al., 1992; Wilson et al., 1993).
1.2.6 Steroid receptor phosphorylation
The glucocorticoid receptor is phosphorylated in its inactive state and rapidly
undergoes hormone induced hyperphosphorylation after binding glucocorticoids
(Orti et al., 1992). There are several phosphorylation sites on the mouse
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AGRACAnnnTGTMCY GRE (IR+3) GR, PR, MR, AR



















Figure 1.7 Classes ofsteroid hormone receptors
Class I, II and III consensus binding sites are shown. (Laudet & Adelmant, 1995).
The inverted repeat (IR), direct repeat (DR) or everted repeat (ER) are indicated by
the arrows. N indicates any nucleotide and x the variable spacing between repeats. R
indicates A/G, M indicates A/C, Y indicates C/T and W indicates A/T. Examples of
the receptors that bind to the different classes of binding sites are listed.
glucocorticoid receptor and most are found in the N-terminal domain (Dalman et al.,
1988; Smith et al., 1989). Hormone-induced hyperphosphorylation increases the
charge at the phosphorylated sites but also increases the overall negative charge
around the region of the N-terminal domain that is involved in transactivation
(Bodwell et al., 1995). Hyperphosphorylation may play a role in regulating
transactivation of GR, or alternatively, may be of relevance to the cell cycle
dependence of GR activity (Hu et al., 1994).
1.2.7 Modulation ofligand availability for nuclear receptors
The hormone ligands for nuclear receptors, including the receptors for
glucocorticoids, oestrogens and T3 are interconverted between active and inactive
forms by enzymes which exhibit tissue-specific distributions. Different isoforms of
an enzyme often exist, with one form activating and the other inactivating hormone,
thereby controlling active intracellular ligand concentration. For example, during
development, the differential expression of deiodinase enzymes (interconverting
active and inactive thyroid hormones) in placenta and foetal tissue is essential for
normal foetal development (Moreno et al., 1994; d'Escobar et al, 1993). Intracellular
levels of active glucocorticoids are governed by the activity of the 1113-
hydroxysteroid dehydrogenase enzymes. The work presented in this thesis is on the
transcriptional regulation of 116-hydroxysteroid dehydrogenase type 1 and in the
next section (Section 1.3) I shall discuss the regulation and actions of the 1113-
hydroxysteroid dehydrogenase enzymes.
1.3 1113-hydroxysteroid dehydrogenase
The enzyme 1113-hydroxysteroid dehydrogenase (1113-HSD) catalyses the
interconversion of B-hydroxy and keto groups at position Cll in glucocorticoids,
thereby regulating the access of glucocorticoids to glucocorticoid receptors. The









Figure 1.8 Modulation ofglucocorticoids by 1lfi-hydroxysteroid dehydrogenase
The figure shows the reaction carried out by 118-HSD in man. In rats, corticosterone
and 11-dehydrocorticosterone are interconverted
In 1953, 118-HSD enzyme activity was first described in rat liver interconverting
steroid 11-hydroxy and 11-keto groups (Amelung et al., 1953). Now, two forms of
118-HSD have been identified, designated type 1 and type 2 (in order of discovery).
118-HSD1 is a lower affinity, NADP(H) dependent enzyme which is widely
expressed, with particularly high levels found in liver (Agarwal et al., 1989) where
its expression in vivo is hormonally regulated (Lax et al., 1978; Low et al., 1993;
Low et al., 1994c). In contrast, 118-HSD2 is a high affinity NAD+ dependent
enzyme expressed predominantly in aldosterone target tissues (e.g. kidney) and in
placenta, which appears to function exclusively as a dehydrogenase, rapidly
inactivating glucocorticoids (Albiston et al., 1994; Brown et al., 1993; Brown et al.,
1996a; Rusvai & Naray-Fejes-Toth, 1993). The main properties of the two enzymes
are summarised in Table 1.2. The biological role of 118-HSD 1 is not clear, although
in general its level of expression correlates with GR expression (Whorwood et al.,
1992), and it may be important for regulating access of glucocorticoids to
glucocorticoid receptors (reviewed in Section 1.3.2.1). 118-HSD2 is found
predominantly in mineralocorticoid target tissues and placenta and its biological
function in kidney has been well described (Section 1.3.2.2.1)
1.3.1 Properties, function and regulation of 11fi-HSDl
1.3.1.1 Properties of 11fi-HSDl
118-HSD 1 was originally identified as a dehydrogenase and on that basis was
purified from liver (Lakshmi & Monder, 1988). It is a 34kDa NADP-dependent
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Properties 11B-HSD1 11B-HSD2
Molecular Weight (kDa) 34 44
Reaction direction (intact cells) 118-reductase 1 lB-dehydrogenase
Reaction direction (cell homogenates) reversible 1 lB-dehydrogenase






Km (nM) (Cortisol) 17000 54
Table 1.2 Comparison of the properties of the type 1 and type 2 1 lfi-hydroxysteroid
dehydrogenases
See text for details (adapted from Seckl, 1993).
glycoprotein (Lakshmi and Monder, 1988) with a Km for Cortisol and corticosterone
in the pM range (Monder & Lakshmi, 1989; Monder et al., 1991). Subsequently, the
corresponding cDNA was isolated from a rat liver cDNA library (Agarwal et al.,
1989), and shown to encode both llB-reductase and 1 lB-dehydrogenase activity in
transfected CHO cells (Agarwal et al., 1989). However, recent evidence suggests
when assayed in intact cells, 11B-HSD1 encoded predominantly reductase activity
with little or no associated dehydrogenase activity, for example, in primary cultures
of human fibroblasts (Hammami & Siiteri, 1991), primary cultures of rat Leydig
cells (C. Leckie, personal communication), primary cultures of rat hepatocytes
(Jamieson et al., 1995) and primary rat neuronal cultures (Rajan et al., 1996).
Reductase activity was also found in cells transfected with 11B-HSD1 cDNA;
transiently transfected COS7 cells (Low et al., 1994a), stably transfected TBM cells
(a toad bladder cell line) (Duperrex et al., 1993) and transiently transfected Y1 cells
(P. Jamieson, personal communication). In vivo, indirect evidence also suggests that
hepatic 11B-HSD1 acts in the reductase direction. In humans given an oral dose of
cortisone, plasma levels of Cortisol increase suggesting that Cortisol is produced from
cortisone by 11B-HSD1 in liver (Walker et al., 1992). 11B-HSD1 cDNAs have now
been isolated from human, monkey, sheep and mouse (Moore et al., 1993; Rajan et
al., 1995; Tannin et al., 1991; Yang et al., 1992) and the corresponding human
(Tannin et al., 1991) and rat (Moisan et al., 1992) genes isolated. There is widespread
expression of a single mRNA species which exists in adult liver, testis, ovary, lung,
vascular tissue and in the brain (Agarwal et al., 1989; Moisan et al., 1990a), but in
kidney at least three mRNAs are present (Krozowski et al., 1990; Moisan et al.,
1992). Transcription starts at a single site in both liver and hippocampus (Moisan et
al., 1992), however, kidney uses two additional transcriptional start sites, together
accounting for about 50% of 11B-HSD1 transcripts in kidney (Moisan et al., 1992).
One of the mRNAs has an extended 5' untranslated region, but does not encode an N-
terminally extended protein (Moison et al., 1992); the other mRNA initiates within
the first intron and is predicted to encode a truncated protein (Moison et al., 1992).
There is however, no evidence to show the truncated RNA is translated in vivo. In
liver, during foetal development, 11B-HSD1 is expressed prior to birth in mouse and
its expression corresponds with the onset of glucocorticoid receptor mediated
functions such as glucose homeostasis (Section 1.1.5.1), 11B-HSD1 may potentiate
glucocorticoid action at this time.
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1.3.1.2 Functions of 11fi-HSDl
11G-HSD1 is widely expressed with highest levels found in liver and lower levels in
other tissues including brain (hypothalamus, cerebellum, hippocampus, and cortex),
kidney, adipose tissue, adrenal and gonads (Agarwal et al., 1989; Moison, et al.,
1990a). The biological role of 11G-HSD1 remains unclear. However, many lines of
evidence point to a role for 11B-HSD1 in modulating glucocorticoid access to
glucocorticoid receptors. The reductase activity of 11B-HSD1 predominates in intact
cells and in perfused liver (Section 1.3.1.1), suggesting that in vivo 11B-HSD1 is
regenerating active glucocorticoid from inert substrates. Furthermore, the relative
levels of expression of glucocorticoid receptor mRNA and 11B-HSD1 mRNA in
various tissues positively correlate, whereas no correlation is seen with mRNA
encoding mineralocorticoid receptors (Whorwood et al., 1992), consistent with a role
for 11B-HSD1 in modulating access of glucocorticoids to glucocorticoid receptors.
11B-HSD1 is not essential for viability or reproduction in mice as mice lacking an
intact 11G-HSD1 gene are healthy and fertile (Kotelevtsev et al., 1996b). Below I
will review the possible biological functions in a limited number of tissues, for which
evidence exists for a role for 11B-HSD1.
1.3.1.2.1 Liver
Increased glucocorticoid levels result in decreased insulin sensitivity and increased
hepatic glucose production (Cryer, 1992). In humans, administration of
carbenoxolone (an inhibitor of 11B-HSD) results in increased insulin sensitivity and
decreased glucose production (Walker et al., 1995). Attenuation of hepatic 11B-
HSD1 expression in rat is associated with decreased levels of mRNA encoding the
key gluconeogenic enzyme, phosphoenolpyruvate carboxykinase (PEPCK)
(Jamieson et al., 1996). Mice homologous for a targeted disruption of the 11B-HSD1
gene, also have reduced fasting glucose levels and decreased expression of G6Pase
compared to wild type animals (Kotelevtsev et al., 1996a; Y. Kotelevtsev personal
communication). All of this data is consistent with a role for 11G-HSD1 in
maintaining glucose homeostasis (Section 1.1.5.1).
1.3.1.2.2 Brain
The function of 11B-HSD1 in the CNS is not clear, but may relate to mood, neuronal
survival and glucocorticoid feedback. It is widely expressed in the brain, with highest
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levels in cerebellum, hippocampus and cortex (Moisan et al., 1990a). It is likely that
as in liver, neuronal 116-HSD1 also predominantly encodes reductase activity e.g. in
primary cultures of rat hippocampal neurones (Rajan et al., 1996), suggesting that it
is the reductase activity of 11B-HSD1 and not dehydrogenase activity which is
modulating glucocorticoid access to corticosteroid receptors. In the hippocampus,
there is no 11G-HSD2 to restrict access of glucocorticoid to hippocampal MR
(Roland & Funder, 1996; Roland et al., 1995), which therefore functions as a high
affinity glucocorticoid receptor, not as an aldosterone receptor. 11B-HSD1 may be
providing glucocorticoid to both receptors, although it is likely that MR is
constitutively occupied at physiological concentrations of glucocorticoids, including
during the diurnal nadir (Rajan et al., 1996).
1.3.1.2.3 Testis
Testosterone production by the rat testis is suppressed by glucocorticoids (Saez et al.,
1977), through glucocorticoid receptor-mediated actions (Bambino & Hseuh, 1981;
Welsh et al., 1982). 11B-HSD1 immunoreactivity was absent from immature rat
testis but became detectable in rats aged 33 days in the Leydig cells of the testis
when oxidative activity appeared to predominate over reductase activity (Phillips et
al., 1989). It was suggested that expression of 11G-HSD1 at puberty led to the
inactivation of glucocorticoids, allowing testosterone production (Gao et al., 1996;
Phillips et al., 1989). In support of this, addition of carbenoxolone to Leydig cells in
culture potentiated the inhibition of testosterone production by corticosterone
(Monder, 1991). However, recent work in our laboratory has shown that primary
cultures of rat Leydig cells contain 11G-HSD1 mRNA and express reductase activity
in intact cells, with little associated dehydrogenase activity (Leckie & Seckl, 1996).
In contrast, 11B-HSD2 mRNA was absent from rat testis. If indeed testicular 11B-
HSD1 is reductive rather than oxidative, then it cannot be responsible, by
inactivating glucocorticoid, for the production of testosterone at puberty. The
function of 11B-HSD1 in the testis therefore remains controversial. It is noteworthy
that mouse testis does not express 11B-HSD1 mRNA (Rajan et al., 1995; C. Leckie,




Glucocorticoid receptors are found in the ovary (Schreiber et al., 1982) and 118-
HSD1 protein and mRNA are located in the oocyte and luteal bodies (Benediktsson
et al., 1992) indicating that 116-HSD1 may be modulating glucocorticoid access to
GR and hence ovarian function. It has been suggested that high intrafollicular
Cortisol is necessary for the complete maturation of the oocyte (Michael et al.,
1993b) and to inhibit the action of luteinising hormone on steroidogenesis in human
granulosa-lutein cells (Michael et al., 1993a).
1.3.1.3 Regulation of 11J3-HSD1
Most studies investigating the regulation of 11B-HSD have measured total activity
and have been unable to distinguish between 116-HSD1 and 116-HSD2 activity,
some do however measure 116-HSD1 mRNA levels which can be used to infer 118-
HSD1 activity. Both 11B-HSD1 and 116-HSD2 are regulated in a tissue specific and
developmentally specific manner, and in adults are hormonally regulated.
There is very little expression of 118-HSD1 mRNA in the developing mouse
embryo. 118-HSD1 mRNA first becomes detectable in mouse foetal liver, at El0.5
with expression in lung, kidney, stomach and liver of newborn mice, increasing to
adult levels by approximately 3 weeks of age (V. Rajan, personal communication),
with highest expression in the liver at all stages.
In the adult rat in vivo 118-HSD1 mRNA is regulated by glucocorticoids in all
tissues examined including hippocampus, liver and kidney (Low et al., 1994c;
Moisan et al., 1990b). Additionally, dexamethasone increases 11B-HSD1 mRNA
expression in vitro in fibroblasts (Hammami and Siiteri, 1991), primary hepatocytes
(Jamieson et al., 1995) and 2S FAZA cells (Voice et al., 1996). In all three cell
systems, expression is also regulated by insulin, with insulin decreasing 11B-HSD1
activity (Hammami and Siiteri, 1991; Jamieson et al., 1995; Voice et al., 1996).
In rats, hepatic 11B-HSD1 activity and mRNA is sexually dimorphic, with males
having approximately 2-fold higher expression than females (Low et al., 1994b); this
hepatic sexual dimorphism of 118-HSD1 expression is not, however, seen in mice
(Rajan et al., 1995). The sexual dimorphism is due to the sex-specific patterns of
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growth hormone secretion, which in turn is determined by sex steroids (Low et al.,
1994b). In addition, administration of oestradiol to rats causes a dramatic decrease in
hepatic 116-HSD1 activity and mRNA to very low or undetectable levels, whilst
leaving hippocampal 11B-HSD1 activity and mRNA unaffected (Low et al., 1994b).
11B-HSD1 is also regulated by thyroid hormone which, attenuates 11B-HSD1
activity and mRNA levels in liver and pituitary (Koerner & Hellman, 1964;
Whorwood et al., 1993).
1.3.2 Properties, function and regulation of 11J.I-HSD2
1.3.2.1 Properties of 11J3-HSD2
11B-HSD2 is an NAD-dependant, exclusive dehydrogenase which has been best
characterised in kidney (Rusvai and Naray-Fejes-Toth, 1993) and placenta (Brown et
al., 1993). It has a molecular size of 44kDa, and high affinity for corticosterone and
Cortisol, with a Km in the nM range (Albiston et al., 1994; Brown et al., 1993; Brown
et al., 1996a; Rusvai and Naray-Fejes-Toth, 1993). 11B-HSD2 cDNA clones have
recently been isolated from human, sheep, rabbit and rat kidney (Albiston et al.,
1994; Agarwal et al, 1994; Naray-Fejes-Toth & Feyes-Toth, 1995; Zhou et al., 1995)
and human placental libraries (Brown et al., 1996a). These cDNAs are very similar
to each other but show only 14% identity with 11B-HSD1 cDNA (Albiston et al.,
1994). 11B-HSD2 mRNA is highly expressed in kidney, colon, pancreas and
placenta. The human gene encoding 11B-HSD2 has recently been cloned (Agarwal et
al., 1995) as well as the mouse gene encoding 11B-HSD2 (Cole, 1995). Patients with
the syndrome of Apparent Mineralocorticoid Excess (AME) (Section 1.3.2.2.1) have
mutations which disrupt the 11B-HSD2 gene (Mune et al., 1995; Wilson et al.,
1995a; Wilson et al., 1995b), suggesting that a lack of active 11B-HSD2 is
responsible for the disorder (Section 1.3.2.2.1).
1.3.2.2 Function of 11J3-HSD2
The function of 11B-HSD2 appears to be protective. In adults it plays a crucial role in
protecting MR from occupation by glucocorticoids (Section 1.3.2.2.1) and during
development 116-HSD2 protects the foetus and foetal tissues from inappropriate
exposure to glucocorticoids. The presence of 11B-HSD2 by inactivating
glucocorticoid allows selective access of aldosterone to MR in cells which co-
express 11B-HSD1 and MR.
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1.3.2.2.1 Mineralocorticoid target tissues and the syndrome ofAME
11G-HSD2 in the distal nephron inactivates glucocorticoids, permitting only
aldosterone present at approximately one hundredth the level of glucocorticoids to
gain access to the otherwise non-selective MR (Figure 1.9). The function of 116-
HSD2 has become apparent from studying patients who have defective 116-HSD2
activity and suffer from the syndrome of Apparent Mineralocorticoid Excess (AME)
which results in glucocorticoid occupation of MR, thereby mimicking the effects of
mineralocorticoids resulting in salt retention and hypokalaemia and hence high blood
pressure (Stewart et al., 1988; Ulick et al., 1979). They have an increased ratio of
Cortisol:cortisone metabolites in urine, and 1 la3H-cortisol when administered
exhibits a prolonged half life, confirming the impaired inactivation of Cortisol
(Stewart et al., 1988). This is now known as AME Typel, having a defect in the 116-
dehydrogenase, but not 11-oxidase activities of 116-hydroxysteroid dehydrogenase.
Type 2 AME has also been described. This is identical to Type-1 AME except that
there is a normal cortisokcortisone metabolite ratio. Proof of abnormal 116-
dehydrogenation was obtained as 11 a H-cortisol had a prolonged half life (Mantero
et ah, 1994).
1.3.2.2.2 Function of 11J1-HSD2 in placenta and during development
116-HSD2 is widely expressed in developing foetus which is consistent with a role in
ensuring a glucocorticoid-free environment in early development (Brown et ah,
1996b) which would otherwise result in detrimental effects on development (Brown
et ah, 1996b). 116-HSD2 mRNA disappears during mid-late gestation, permitting
active glucocorticoid to rise in tissues. 11G-HSD2 plays a similar role in placentas,
restricting access of glucocorticoids across placenta during development of the
foetus. It seems to be especially important during early foetal stages as expression in
mouse placenta is high until El5.5, after which time it rapidly disappears. In addition
exposure to high levels of maternal glucocorticoids results in low birth weight and an
increased risk in adult life of hypertension (Benediktsson et ah, 1993).
1.3.2.3 Regulation of 11J1-HSD2
Very few studies describe the regulation of 116-HSD2 in adults. Oestrogen probably
increases 11G-HSD2 activity in kidney (Low et ah, 1993) and 11G-HSD2 activity in
the baboon placenta is increased by oestrogen treatment (Baggia et ah, 1990). Rats
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Figure 1.9 The role of 11J3-HSD2 in the human distal nephron
Both aldosterone and Cortisol can enter the renal cortical collecting cells, however
1113-HSD2 acts to protect mineralocorticoid receptor (MR). The active
glucocorticoid Cortisol (F) is inactivated to form cortisone (E), thus allowing
aldosterone to bind and activate MR causing MR to enter the nucleus and activate
transcription (adapted from Seckl, 1993).
 
treated with dexamethasone, deoxycorticosterone and 9a-fluorocortisol show
increased renal 1113-HSD2 activity (Li et al., 1996) and activity in JEG3 cells, a
human cytotrophoblastic cell line, was increased by treatment with forskolin or
dibutyryl cAMP suggesting that hormones that activate protein kinase A may
increase expression of 11B-HSD2 (Pasquarette et al., 1996).
The bulk of this thesis is concerned with transcriptional regulation of hepatic 1113-
HSD1. In the next sections I shall briefly review what is known of the processes
involved in initiation of transcription in eukaryotes and of the transcription factors
involved in gene expression in mammalian liver.
1.4 Transcription in eukaryotes
1.4.1 The assembly of the basal transcription initiation complex
In eukaryotes, three types of RNA polymerase exist which transcribe different types
of RNA. Type I RNA polymerase transcribes the genes encoding 18S, 5.8S and 28S
ribosomal RNA's; 5S ribosomal RNA and transfer RNA are transcribed by RNA
polymerase III; RNA polymerase II transcribes mRNA, RNA that will be translated
into proteins.
The basal promoter in most cases consists of the initiator element, a weakly
conserved element encompassing the transcription start, first described in the TATA-
less terminal deoxynucleotidyl transferase gene (Smale & Baltimore, 1989), and in
many genes but by no means all, the TATA box, located 25 to 30 base pairs
upstream of the transcription start (Conaway & Conaway, 1993). Initiation of
eukaryotic mRNA synthesis is controlled by the action of multiple transcription
factors that regulate the ordered assembly and activity of the transcription complex
containing RNA polymerase II and the general transcription factors (some of which
include TFIIA, IIB, IID, HE, IIF and IIH) on the basal promoter (Hernandez, 1993).
Transcription factors, chromatin structure, and the methylation state of promoter
DNA all provide additional levels of control on the activity of the RNA polymerase
II transcription complex (Sections 1.4.4). The exact order (and even involvement) of
assembly of the basal transcription factors remains controversial, and may differ
according to the promoter, but the generally accepted view is outlined in Figure 1.10
and summarised below.
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Figure 1.10 Assembly of the basal transcription complex
Schematic model of stepwise basal transcription complex assembly on a TATA
containing promoter. The bent arrow indicates the site of transcription initiation.
General transcription factors are indicated by bold letters.
 
The first step in assembly is probably binding of TFIID to the basal promoter; to both
TATA-less and TATA containing promoters (Kaufmann & Smale, 1994; Purnell &
Gilmore, 1993). Mammalian TFIID consists of the TATA binding protein (TBP)
together with at least 8 TBP associated factors (TAF's) (Dynlacht et al., 1991; Tanese
et al., 1991; Goodrich & Tjian, 1994a). Although, TBP alone can bind to the TATA
element and is sufficient for basal transcription, some, or all of the TAFs are required
for the activity of transcriptional activator proteins (Dynlacht et al., 1991; Hoey et
al., 1993; Tanese et al., 1991; Zhou et al., 1992; Zhou et al., 1993), and some may be
involved in the formation of nucleoprotein complexes at the transcription start. For
example, TAF complexes resembling histone tetramers or octamers have been
described (Xie et al., 1996; Hoffmann et al., 1996), and it has been suggested that
one role of these TAFs is to induce a partial bend in DNA which may contribute to
the stability of the initiation complex (Hoffmann et al., 1996).
The next step in the formation of the transcription initiation complex is the
association of TFIIA. The requirement for TFIIA is controversial and it may play a
stimulatory though not essential role in assembly of the basal transcription complex,
possibly through interacting with one of the TAFs (Yokomori et al., 1993). In
addition, TFIIA has been implicated as a target for certain transcriptional activator
protiens (Kobayashi et al., 1995).
The next component of the transcription complex to join the initiation complex is
likely to be TFIIB which binds directly via its C-terminal domain to DNA-bound
TBP (Nikolov et al., 1995) (Figure 1.10), and makes weak contacts with the DNA
phosphate backbone (Lee & Hahn, 1995; Nikolov et al., 1995). TFIIB and RNA
polymerase II may be preassociated and enter the initiation complex together
(Conaway & Conaway, 1993); N-terminus is a zinc finger domain that is essential to
recruit RNA polymerase II to the initiation complex, possibly via an interaction with
TFIIF (Buratowski, 1994), the factor that delivers RNA polymerase II to the
initiation complex (Ha et al., 1993) (Figure 1.10). Transcriptional activators can bind
TFIIB (Lin et al., 1991) and may be necessary for the stable interaction of TFIIB
with TFIID (Choy & Green, 1993).
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Therefore, through the combined activities of TFIID, TFIIB and TFIIF, RNA
polymerase II is stably recruited into the preinitiation complex (Buratowski, 1994)
(Figure 1.10). The carboxy terminal domain of RNA polymerase II is implicated in
contacting DNA (Suzuki, 1990) and TBP (Usheva et al., 1992). It contains a seven
peptide repeat (YSPTSPS) which is phosphorylated in vivo, and the polymerase
exists in at least two distinguishable forms that differ in the extent of this
phosphorylation (Conaway and Conaway, 1993). The hypophosphorylated form of
the polymerase is preferentially recruited into the preinitiation complex, whilst the
transcribing enzyme is hyperphosphorylated (reviewed in Buratowski, 1994). TFIIH
which can phosphorylate the carboxy terminal domain, has been implicated in the
conversion of the initiation complex into an elongation complex (Goodrich & Tjian,
1994b).
TFIIE and TFIIH are in general required to form the preinitiation complex (Wang et
al., 1992a). TFIIE is a 34/56kDa heterodimer (Inostroza et al., 1991), whereas TFIIH
is a multisubunit complex made up of at least eight polypeptides (Schaeffer et al.,
1994). It is associated with several activities, including a DNA dependent and a Cdk
dependent protein kinase activity capable of phosphorylating the carboxy terminal
domain of RNA polymerase II (Lu et al., 1992; Serizawa et al., 1992; Serizawa et al.,
1995; Shiekhatter et al., 1995; Liao et al., 1995), a DNA-dependent ATPase activity
and an ATP-dependent DNA helicase activity (Drapkin et al., 1994; Roy et al.,
1994). Evidence suggests that TFIIE may regulate the activities of TFIIH (Drapkin et
al., 1994; Ohkuma and Roeder, 1994). TFIIH has been implicated as a target for the
transcriptional activators VP16 and p53 which interact in vitro with TFIIH (Xiao et
al., 1994). TFIIH also has an essential role in excision repair of DNA (Drapkin et al.,
1994; van Vuuren et al., 1994; Mu et al., 1995).
It should be emphisised that the above scheme outlined in Figure 1.10 is based on
experiments carried out in vitro and it is possible that in vivo active transcription
complexes may be formed in pre-assembled manner rather than by stepwise
recruitment of individual complexes (Koleske & Young, 1994; Ossipow et al., 1995).
The assembly of the basal transcription complex and the conversion into an actively




The structure of transcription factors is modular. In general, transcription factors
have a domain required for tethering close to the promoter, either a DNA binding
domain or a domain required to bind to a DNA-bound protein, and a domain
involved in transcriptional control, the 'activation' domain (Ptashne M & Gann AF,
1990). Transcriptional activation domains have been much less well characterised
than those involved in DNA binding and may be much more diverse. However, some
activation domains appear to fall into particular classes; the acidic activation domains
e.g. VP 16, the glutamine-rich activation domains e.g. Sp-1 and the proline rich
activation domains (Tjian & Maniatis, 1994). These activation domains interact with
the basal transcription machinery to alter the rate of transcription initiation (Section
1.4.3).
The DNA binding domain of transcription factors have been much better
characterised. The majority of proteins which bind directly to DNA use one of two
structures in DNA binding; an a-helix or a 13-sheet. The 13-sheet has so far only been
described in a limited number of prokaryotic DNA binding proteins (Breg et al.,
1990; Phillips, 1991; Raumann et al., 1994) and so will not be further discussed in
this thesis. Below I will briefly describe eukaryotic DNA binding motifs containing
an a-helix.
1.4.2.1 a-helix-containing DNA binding domains
An a-helix is the most common mode of DNA binding and occurs in several 'motifs'
including the helix-turn-helix (HTH) / homeodomain motif, (Cys)4 and (Cys)2(His)2
zinc fingers, the leucine zipper motif and the helix-loop-helix (HLH) motif.
1.4.2.1.1 Helix-turn-helix and homeodomains
The HTH DNA binding motif was first described in prokaryotic DNA binding
proteins and was later found to occur in a related eukaryotic motif, (reviewed in
Burley, 1994). Structural studies (2D NMR and X-ray crystallography) have shown
that the overall fold of the homeodomain shows strong similarity to the prokaryotic
HTH motif (Anderson et al., 1981; Klemm et al., 1994; Ohlendorf et al., 1982). Both
use an a-helix (the 'recognition' helix) to specifically recognise the exposed edges of
the base pairs in the major groove (Figure 1.11a).
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The amino acid 60 residue homeodomain forms a stably folded structure containing
3 a-helices, and can bind DNA by itself as a monomer (Affolter et al., 1990; Qian et
al., 1989; Sauer et al., 1988) in contrast to the prokaryotic HTH proteins which all
bind DNA as dimers (Anderson et al., 1981; Ohlendorf et al., 1982). The main DNA
contacts are made by helix 3 of the homeodomain which fits into the major groove
(as in the prokaryotic HTH protein (Wharton et al., 1984)). In addition, the N-
terminal arm of the homeodomain (Kissinger et al., 1990) makes contacts in the
minor groove of the DNA. The homeodomain therefore contacts both faces of DNA
(major and minor groove interactions) giving a stable monomer interaction (Garcia-
Blanco et al., 1989).
1.4.2.1.2 The leucine zippers and helix-loop-helix proteins
The leucine zipper family of transcription factors is a large group of proteins, which
bind to DNA as either homo- or heterodimers. This family includes the liver-
enriched transcription factor C/EBP (reviewed in Section 1.5), which is the subject of
a large part of the work contained in this thesis. Like the leucine zipper proteins,
HLH transcription factors all bind to DNA as homo- and heterodimers and are
typified by the prototype HLH dimer myc/max. Both contain an N-terminal region
rich in basic amino acids which bind to DNA, and an a-helical segment (the leucine
zipper or the HLH region) involved in dimerisation.
Crystal structures of the DNA binding domains of several leucine zipper containing
transcription factors and HLH proteins have been determined (O'Shea et al., 1991;
Ferre-D'Amare et al., 1993) and show some similarities; representations of the DNA
binding domains are shown in Figure 1.1 lb and Figure 1.11c respectively.
The structure of the basic leucine zipper of GCN4 (a yeast leucine zipper
transcription factor) complexed to either a CRE or an AP-1 binding site (Ellenberger
et al., 1992; Konig & Richmond, 1993) showed that the basic region forms an a-
helix which contacts the major groove of a half site, contacting both the phosphate
back bone and the edges of the base pairs (Ellenberger et al., 1992; Konig &
Richmond, 1993). The 30-40 amino acid C-terminal 'leucine zipper' region contains
an a-helix with a heptad repeat of leucines ((leuX6)N, where X is any amino acid)
which forms the dimerisation interface, with two parallel a-helices in a coiled-coil
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Figure 1.11 Transcription factor DNA binding domains
Models of the DNA binding domains of (a) The Drosophila homeodomain protein
engrailed, (b) a dimer of the yeast leucine zipper protein GCN4, (c) a homodimer of
the mammalian helix-loop-helix protein, MAX, (d) the mammalian steroid receptor
protein and (e) the mammalian zinc finger protein zif 268. Engrailed, GCN4, MAX
and zif 268 are shown bound to DNA. Taken from Pabo & Sauer, 1992; Ellenberger,
1994; Schmiedeskamp & Klevit, 1994.
 
arrangement and one a-helix contributed from each subunit of the dimer (O'Shea et
al., 1989).
The crystal structure of the Max homodimer/DNA complex shows that the DNA
binding surface of Max is formed by a straight a-helix oriented parallel to the major
groove. The HLH region is involved in dimerisation and forms a left handed parallel
four helix bundle with a loop connecting helices 1 and 2 of each subunit of the dimer
(Ferre-D'Amare et al., 1993).
1.4.2.1.3 Zinc fingers
At least 10 zinc-containing DNA-binding motifs exist and include the classical zinc
finger (Cys2His2 type), nuclear hormone receptor zinc fingers (Cys4 type), GAL4,
Ring Finger and MetRS (reviewed in Klug & Schwabe, 1995). All contain zinc
coordinated to Cys/His which holds together the structure in a form able to recognise
and bind specifically to DNA. The Cys4 type of zinc finger, formed in nuclear
receptors is described in Section 1.2.1 and is depicted schematically in Figure 1.1 Id,
and will not be further discussed here. In this section I limit the discussion to the
classical zinc finger motif.
'Classical' zinc were first described in the Xenopus transcription factor IIIA and
contain tandem repeats of the 30 amino acid zinc finger motif containing cysteine
and histidine (0-X-Cys-X2.5-Cys-X3-0-X5-0-X2-His-X2.5-His); where O is a
hydrophobic amino acid and X is variable in character (Miller et al., 1985). The first
structural data on Cys2His2 zinc finger came from the crystal structure of Zif268 (a
mammalian transcription factor) bound to DNA (Pavletich and Pabo, 1991). The
structure revealed that zinc fingers are modular structures with each finger
recognising a 3 bp unit in the DNA recognition sequence (Pavletich and Pabo, 1991).
Each zinc finger contains an a-helix which sits in the major groove, held in place by
an antiparallel 8-sheet (Pavletich and Pabo, 1991).
1.4.3 Activation of transcription
Increased transcription occurs when RNA production is stimulated in response to
activators binding to the promoter DNA or components of the basal transcription
machinery (Emili et al., 1994; Kerr et al., 1993; Lee et al., 1991; Lieberman & Berk,
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1991; Lin et al., 1991; Xiao et al., 1994). Transcription factors can alter transcription
initiation, either by increasing recruitment of basal transcription factors to the
promoter, for example, TFIID, TFIID/A or TFIIB (Klein & Struhl, 1994; Lieberman
& Berk, 1994; Lin & Green, 1991; Sauer et al., 1995; Wang et al., 1992b), thereby
increasing formation of the preinitiation complex, or by interacting with the
preinitiation complex to cause conformational changes resulting in conversion of the
preinitiation complex into an initiated complex (Roeder, 1991).
The precise mechanisms by which activators increase the rate of transcription are not
clear and are likely to be diverse. Interactions between 'acidic' activators (VP 16 in
particular) and TBP (Ingles et al., 1991; Stringer et al., 1990), TFIIB (Lin et al.,
1991; Roberts et al., 1993) and TFIIH (Xiao et al., 1994) have been described.
However, many of these results were obtained in vitro, with partially purified
preparations of proteins and it remains open to question the extent to which these
interactions may occur in vivo.
Coactivators, or mediators e.g. PC4 transduce the activation signal from the DNA
bound transcriptional activator to the basal transcription machinery, they do not
themselves activate transcription (Ge and Roeder, 1994). Coactivators have also been
identified for steroid receptors; the nuclear factor RIP140 interacts only with ligand-
occupied ER; mutations within the ligand binding domain of ER which abolish
transactivation function also eliminate the interaction with RIP 140 (Cavailles et al.,
1995).
1.4.4 Repression of transcription
Selective repression of gene transcription is of importance in generating the required
pattern of tissue specific gene expression. Various mechanisms of repression exist,
ranging from interference with transcriptional activation via activators, co-activators
or the basal transcription machinery, active repression by 'co-repressors' to
modification of chromatin structure or methylation of promoter DNA. Only the last 3
will be described here in any detail as evidence suggests they are likely to be
important in vivo in tissue-specific control of gene expression.
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1.4.4.1 Co-repressors of transcription
Co-repressors are proteins that interact with the repressor and the target of the
repressor, probably the transcription initiation complex, and have recently been
described for members of the nuclear receptor superfamily. In the absence of ligand,
T3R is a repressor of transcription. Two recent studies have shown that T3R and
RARa in the absence of ligand interact with a 'co-repressor' protein, called thyroid-
retinoic-acid-receptor associated co-repressors (TRACs) (Chen & Evans, 1995;
Horlein et al., 1995; Kurokawa et al., 1995), or silencing mediator for retinoic and
thyroid hormone receptors (SMRT) (Chen & Evans, 1995). Comparison of protein
sequences show homology between these factors in their receptor interacting
domains, implying the existance of a family of co-repressor molecules (Perlmann &
Vennstrom, 1995).
1.4.4.2 The role ofchromatin in transcriptional regulation
Nucleosomes play a central role in repressing basal transcription in vivo and
disruption of chromatin structure is needed for activation of transcription in vivo.
Perhaps the best studied example is the activation of the MMTV promoter by GR,
where positioned nucleosomes on the MMTV promoter prevent access of ubiquitous
and general transcription factors to the promoter DNA (Beato et al., 1996). Binding
of GR to MMTV DNA results in the displacement of a nucleosome on the MMTV
promoter, allowing access of transcription factors to the promoter and leads to
transcription initiation (Beato et al., 1996). Many other studies are demonstrating the
importance of chromatin structure in gene activation and repression in vivo, for
example, the action of steroid receptors in yeast requires SW1 (Yoshinga et al.,
1992) and recent evidence shows the SWI/SNF complex, a component of the yeast
RNA polymerase II holoenzyme, has ATP-dependent chromatin disruption
capabilities which allows RNA polymerase II access to DNA encoding genes to be
transcribed (Wilson et al., 1996). Histone acetylation plays a role in
repression/activation of genes embedded in chromatin (Hebbes et al., 1994;
Braunstein et al., 1993); acetylation of histones results in a change in nucleosome
conformation, rendering nucleosomal DNA more accessible to transcription factors
(Garcia-Ramirez et al., 1995). It is becoming increasingly clear that some generally
acting transcription factors may act by acetylating histones, an example is the yeast
GCN5 protein (Brownell et al., 1996). The importance of chromatin structure in
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regulating transcription is also illustrated by the recently described conservation of
structure between histones and certain basal transcription factors (Hoffmann et al.,
1996; Xie et al., 1996); and the demonstration that TAFs probably form a
nucleosome-like structure at the promoter in the pre-initiation complex at the
transcription start (Hoffmann et al., 1996; Xie et al., 1996).
1.4.4.3 The role ofmethylation in gene repression
Vertebrate genomic DNA is methylated, at CpG dinucleotides, on the 5' position of
cytosine (Bird, 1986). CpG dinucleotides are under-represented in the bulk of
vertebrate DNA and occur in clusters, 'CpG islands', generally at the 5' end of genes
(Bird, 1995). Methylation is essential for viability as a targeted disruption of the
MeCP2 gene encoding a CpG methylase is lethal in early mouse embryogenesis
(Tate et al., 1996). It has been suggested that methylation of DNA acts as a global
repressor of transcription, reducing noise background, thereby allowing transcription
of important genes (Bird, 1995). The effect of methylation appears to be modulated
at any one site by the number of methylated sites; high densities of methyl-CpG
repress even strong promoters, low densities of methyl-CpG only repress weak
promoters (Bird, 1992; Boyes & Bird, 1992).
1.5 CCAAT/enhancer binding protein
11B-HSD1 expression in liver is a major focus of the work I have carried out towards
this thesis. I have explored the role of C/EBP in binding to the 11B-HSD1 promoter
and here I review the properties and functions of the C/EBP family of transcription
factors.
1.5.1 Structure and characterisation of the CCAAT/enhancer binding protein
The CCAAT/Enhancer Binding Protein (C/EBP) was first identified in crude rat liver
nuclear extract by virtue of its ability to bind to a CCAAT motif located
approximately 80bp upstream of the transcription start of the herpes simplex virus
thymidine kinase gene (HSV-TK), and to the enhancer of the Moloney murine
sarcoma virus (MSV) located in the MSV long terminal repeat (LTR) (Graves et al.,
1986; Johnson et al., 1987). C/EBP was purified from rat liver, and the encoding
cDNA cloned (Landschultz et al., 1988). C/EBP was found to show homology to
other transcription factors e.g. GCN4 and was one of the first leucine zipper
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containing transcription factors (Section 1.4.2.1.2) to be identified. With the
subsequent discovery of other related proteins (Table 1.3), the original C/EBP cDNA
clone from rat liver was designated C/EBPa. C/EBPa encodes a 42kDa protein
which is susceptible to proteolytic cleavage (Landschultz, 1988). Proteolytic
cleavage of C/EBPa results in a 14kDa fragment consisting of the C-terminal 106
amino acids, including the basic leucine zipper region (Section 1.4.2.1.2), which
retains DNA binding activity (Landschultz et al., 1988).
1.5.2 C/EBP related proteins
C/EBP related proteins (summarised in Table 1.3) all form homo- and heterodimers
with other members of the family, but do not hetero-dimerise with other leucine
zipper proteins such as Fos or Jun. All share very similar DNA binding domains and
hence sequence specificity (the structure the DNA binding domain of leucine zipper
proteins is reviewed in section 1.4.2.1.2 and the structure of C/EBP is shown in
Figure 1.12). C/EBP related proteins can bind to a wide range of related DNA
sequences which diverge considerably from the consensus binding site
T(T/G)NNG(T/C)AA(T/G) (Locker, 1993) including ATF and CREB binding sites
(Bakker & Parker, 1991) and binding sites for the PAR subgroup of leucine zipper
transcription factors (VBP/TEF, DBP and HLF) (Mueller et al., 1990).
non-conserved conserved
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Figure 1.12 Diagrammatic view of the structure of C/EBPs
Domain structure of C/EBP and related factors. The basic/leucine zipper region is
conserved and the N-terminal domain is non-conserved.
1.5.3 Inhibitors of C/EBP action
Shorter translation products of C/EBPa and C/EBPB (termed C/EBPa (30kDa) and
LIP respectively) exist which are truncated at the N-terminal domain and lack part of
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Protein Synonyms MWt (kDa) Source Reference
C/EBPa C/EBP 42 rat
human
(Landschultz et al., 1988a)
(Antonson et al., 1995)
C/EBP15 NF-IL6, 38 human (Haas et al., 1995; Akira et al., 1990)
IL-6DBP, LAP,
CRP2,
32 rat (Poli et al., 1990; Descombes et al., 1990;
Williams et al., 1991)
GPE-BP, AGP/EBP, 35 mouse (Cao et al., 1991; Nishizawa et al., 1992;
Chang et al., 1990)
NF-M 45 chicken (Katz et al., 1993)
C/EBP8 NF-IL6B 28 human (Kinoshita et al., 1992)
CRP3 29 mouse (Cao et al., 1991; Williams et al., 1991)
C/EBPy rat (Thomassin et al., 1992)
Ig/EBP-1 45 mouse (Roman et al., 1990)
al/EGP chicken
human
(Bowers et al., 1992)
(Davydov et al., 1995)
crpl 27 rat (Williams et al., 1991)
d/C/EBP 49 drosophila (Montell et al., 1992)
CHOPIO GADD153 29 mouse (Ron et al., 1992)
Table 1.3 Cloned cDNAs encoding members of the C/EBP family
the transactivation domains (and therefore do not activate transcription), but are still
capable of dimerisation and DNA binding (Calkhoven et al., 1994; Descombes &
Schibler, 1991; Lin et al., 1993; Ossipow et al., 1993). It is possible that these factors
form heterodimers with full length C/EBPs therefore sequestering the
transcriptionally active subunits in inactive heterodimeric complexes. Another
C/EBP related factor is CHOP-10 (C/EBP homologous protein), which dimerises
with C/EBP's, but is unable to bind C/EBP consensus binding sites (Ron & Habener,
1992), and thus acts as a dominant negative regulator of C/EBP. CHOP is induced by
a variety of cellular stresses including exposure to toxins, nutrient deprivation and
the acute phase response (Carlson et al., 1993; Fornace et al., 1989; Ron and
Habener, 1992; Sylvester et al., 1994; Ubeda et al., 1996).
1.5.4 Distribution of C/EBPa and C/EBPfi mRNAs
C/EBPa and C/EBP13 mRNA's show similar distributions, with highest levels in
liver, fat and lung (Williams et al., 1991). The tissue distributions of C/EBPa and
C/EBP13 mRNA in rat are summarised in Table 1.4.
Tissue Distribution C/EBPa mRNA C/EBP6 mRNA
Liver +++ +++
Brown fat +++ +






Table 1.4 Summary of the tissue specific distribution of C/EBPa and C/EBP13 in rats.
+++, highly expressed; ++, moderately expressed; +, weakly expressed; -/+ very
weakly expressed (Birkenmeier et al., 1989; Descombes et al., 1990; Williams et al.,
1991).
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In liver, C/EBPa and C/EBPB expression is dependent on differentiation of
hepatocytes. No expression of C/EBPa or C/EBPG mRNA is seen in liver before E12
and E14 respectively (Van den Hoff et al., 1994). Between E14 and birth, mRNA
levels rise to reach adult levels by birth (Van den Hoff et al., 1994). However, no
C/EBPa protein is detectable before birth despite the expression of C/EBPa mRNA
in foetal liver, but C/EBPB protein is expressed (Diehl et al., 1994a). The
regeneration of liver after partial hepatectomy has been used to examine the
developmental regulation of C/EBPa and C/EBPB. Partial hepatectomy of adult liver
in rodents induces the remaining liver cells to divide in a synchronised manner
(Johansson & Andersson, 1990) while retaining almost all metabolic and hepatic
functions (Friedman et al., 1984; Michalopoulos, 1990). A complex pattern of C/EBP
related protein expression occurs after partial hepatectomy, with reduced C/EBPa
and increased C/EBPB and C/EBP8 expression (Flodby et al., 1993), consistent with
a role for C/EBPa only in fully differentiated post-mitotic cells.
Other C/EBP mRNA are widely distributed. C/EBP8 is found in liver, lung, kidney,
adipose, brain, heart, testes, uterus and submaxillary gland (Williams et al., 1991).
C/EBPy mRNA is ubiquitously expressed with high levels found in early B cells
(Roman et al., 1990).
1.5.5 Roles of C/EBP related proteins
Members of the C/EBP family of transcription factors are reported to have many
roles and regulate networks of genes involved in terminal cell differentiation, arrest
of mitotic growth, energy metabolism and the immune response (Darlington et al.,
1995; Yeh & Mcknight, 1995; McKnight, 1993; Tanaka et al., 1995; Screpanti et al.,
1995). An insight into some of the major roles of C/EBPa and C/EBPB have been
provided by mice lacking either C/EBPa or C/EBPB.
1.5.5.1 The role of C/EBPa in the regulation ofenergy metabolism
C/EBPa was suggested to be a central regulator of energy metabolism (McKnight et
al., 1989) and several lines of evidence support this hypothesis. C/EBPa is expressed
in tissues that are involved in fuel metabolism (Section 1.5.4). Key enzymes involved
in energy homeostasis such as PEPCK, acetyl CoA carboxylase, GLUT4, the insulin
receptor and SCD1 all have C/EBP binding sites within their promoters (Park et al.,
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1993; Tae et al., 1994; Kaestner et al., 1990; Kaestner et al., 1989; McKeon & Pham,
1991; Christy et al., 1989). Most recently, mice which lack C/EBPa have been
described; the phenotype of these mice strongly supports the involvement of C/EBPa
in the regulation of energy metabolism (Wang et al., 1995). Homozygous mice
lacking the C/EBPa gene develop normally and are born in similar numbers to their
wild type litter mates, demonstrating that C/EBPa does not play an essential role
during development. However, they become profoundly hypoglycaemic and die
several hours after birth (Wang et al., 1995). Injecting glucose into these mice
enables them to survive for up to 40 hours after birth (Wang et al., 1995). Mutant
animals showed many metabolic defects (Wang et al., 1995). They lacked hepatic
glycogen at birth and glycogen synthase mRNA was undetectable. Also at birth
mRNA's encoding the key gluconeogenic enzymes PEPCK, G6Pase and tyrosine
amino transferase were undetectable in liver. However, the levels of PEPCK and
G6Pase mRNA returned to normal 7 hours after birth, suggesting that expression of
these enzymes relies on C/EBPa expression at a specific time during development,
and that 7 hours after birth either compensatory mechanisms come into effect or
other transcription factors are normally expressed which regulate the expression of
these gluconeogenic enzymes. In addition to defects in liver metabolism these mice
failed to accumulate lipid in brown and white adipose tissue (Darlington et al., 1995;
Wang et al., 1995). C/EBPa gene knock-out mice also have defects in their immune
response with a component of complement, C3, and y-fibrinogen levels being
reduced compared to wild type mice (Burgess-Beusse & Darlington, 1996).
1.5.5.2 The role of C/EBPfi, C/EBPyand C/EBP8in the acute phase response
C/EBPB was first described as part of the interleukin-6 (IL-6) signalling pathway in
liver (Akira et al., 1990). Roles for C/EBPa, C/EBPyand C/EBP8 have also been
proposed in the immune system (Burgess-Beusse and Darlington, 1996; Chang et al.,
1990; Roman et al., 1990). Binding sites for these factors are found in the promoters
of genes expressed in monocytes and macrophages including TNF-a (Pope et al.,
1994), IL-6 (Bretz et al., 1994; Matsusaka et al., 1993; Tanaka et al., 1995), and
lysozyme (Ness et al., 1993). C/EBPB and C/EBP8 are themselves induced by
lipopolysaccaride (LPS), an inducer of the acute phase response (Section 1.6.5)
(Kinoshita et al., 1992; Natsuka et al., 1992), and in peripheral blood monocytes
C/EBPB is translocated to the nucleus upon LPS stimulation (Bretz et al., 1994).
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C/EBPy is found in early B cells and both C/EBPB and C/EBPy are expressed in
mature B cells (Cooper et al., 1992; Roman et al., 1990). C/EBPs bind to the
promoter of immunoglobin genes, and C/EBPB and C/EBPy mediate LPS and IL-4
responsiveness of the unrearranged VH genes (Cooper et al., 1992; Lundgren et al.,
1994).
A role for C/EBPB in the immune response is supported by the phenotype of mice
lacking the C/EBPB gene. Two studies have described the construction of lines of
C/EBPB knock-out mice (Screpanti et al., 1995; Tanaka et al., 1995). One study
(Tanaka et al., 1995) reports that elimination of C/EBPB compromised viability, with
fewer homozygous 'knock-out' mice reaching the weaning stage than predicted
(Tanaka et al., 1995). Both lines of C/EBPB 'knock-out' mice are highly susceptible
to yeast or bacterial infection (Screpanti et al., 1995; Tanaka et al., 1995) having
defective activation of the immune response and mice lacking C/EBPB showed
impaired induction of G-CSF, a cytokine involved in the immune response (Tanaka
et al., 1995). Unexpectedly, C/EBPB 'knock-out' mice had increased interleukin 6
(IL-6) levels, which contradicted earlier reports that C/EBPB acts as a positive
regulator of IL-6 production (Akira et al., 1990).
1.5.5.3 A role for C/EBPs in controlling cell proliferation
Additional roles of C/EBP's not addressed by the 'knock-out' mice are their
developmental and antiproliferative activities which have been studied in adipocytes
and liver. Mice lacking either the C/EBPa or C/EBPB have normal livers and have
adipose tissue (Wang et al., 1995; Screpanti et al., 1995; Tanaka et al., 1995).,
therefore C/EBPa and C/EBPB may not be essential for cell differentiation.
However, the long term effects of loss of C/EBPB have not been studied (the long
term effects on C/EBPa 'knock-out' mice cannot be studies because of perinatal
lethality). Evidence for a role in proliferation came from studies on certain fibroblast
cell lines which can be induced, in vitro, to differentiate into adipocytes all of which
were cloned from mouse 3T3 cells (Green & Kehinde, 1974; Green & Kehinde,
1975). Much of the biology of C/EBPs involvement in adipose differentiation and
gene expression has been elucidated in the model cell line 3T3-L1. This cell line (and
the related cell line 3T3-F442A) can be induced to differentiated in vitro, from
fibroblast-like cells into cells exhibiting many of the properties of post mitotic
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adipocytes including expression of differentiated adipocyte genes and lipid
accumulation (MacDougald & Lane, 1995). Constitutive expression of antisense
C/EBPa RNA blocked expression of C/EBPa, the differentiation of preadipocytes
into adipocytes and the expression of adipocyte specific genes e.g. 422(aP2), SCD1
and GLUT4 (Lin & Lane, 1992). The adipocyte phenotype could be rescued by
expressing a 'sense' C/EBPa RNA (Lin and Lane, 1992). C/EBPa therefore appears
to be sufficient to induce differentiation of 3T3-L1 adipocytes. Inappropriate
expression of C/EBPa in 3T3-L1 preadipocytes, however inhibited mitosis in the
cells, demonstrating the antimitotic activity of C/EBPa (Freytag & Geddes, 1992).
As discussed earlier (Section 1.5.3) there are two translation products of C/EBPa
mRNA; a 42kDa and a 30kDa protein. The 42kDa product is anti-mitotic but the 30
kDa product is not. Constitutive expression of the 30kDa translation product of
C/EBPa in transfected preadipocytes is insufficient to trigger differentiation, but
when hormonal stimuli are used differentiation occurs (Lin et al., 1993). C/EBPB and
C/EBP8 are also involved in adipocyte differentiation (Cao et ah, 1991). These are
expressed at high levels in proliferating cells but the level of expression decreases
when cells stop dividing as they reach confluence and differentiate (Cao et ah, 1991).
1.5.6 Regulation of C/EBPa and related proteins
C/EBPa is most highly expressed in fully differentiated liver and adipose cells
(Williams et ah, 1991). Several lines of evidence suggest that C/EBPa is
autoregulatory, stimulating expression of its own gene. In 3T3-L1 cells C/EBPa
antisense RNA blocks transcription of the C/EBPa gene (Lin and Lane, 1992). This
effect may be indirect; C/EBPa does not bind to the promoter of the human gene
encoding C/EBPa but induces the ubiquitously expressed transcription factor USF
which in turn regulates the C/EBPa promoter (Timchenko et ah, 1995). Another
factor which regulates C/EBPa expression is C/EBPa undifferentiated protein (CUP)
which may repress transcription in cells in which C/EBPa is not expressed including
a cell line derived from mouse 3T3 cells 3T3-C2, which does not differentiate into
adipocytes (Vasseur-Cognet & Lane, 1993). CUP binds to the C/EBPa promoter in
preadipocytes and its expression decreases as preadipocytes differentiate into
adipocytes and C/EBPa expression increases (Vasseur-Cognet and Lane, 1993).
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1.5.6.1 Regulation of C/EBPaand C/EBPfi in liver
In hepatocytes C/EBPa gene expression is down regulated by epidermal growth
factor (EGF) at both the transcriptional and postranslational levels (Mischoulon et
al., 1992) Insulin and growth hormone do not affect C/EBPa expression (Bosch et
al., 1995; Potter et ah, 1993), however, C/EBPB mRNA is altered by these hormones;
insulin inhibits (Bosch et ah, 1995) and growth hormone increases (Potter et ah,
1993) the expression of C/EBPB mRNA. Glucagon and dexamethasone induce
C/EBPB gene expression in primary cultures of rat hepatocytes (Matsuno et ah,
1996).
1.5.6.2 Regulation of C/EBPa and C/EBPfi in adipocytes
There is not much data on C/EBPa gene regulation in adipocytes as it is only
expressed in fully differentiated post mitotic cells. As expected, in its role as a global
regulator of energy homeostasis, the C/EBPa gene is hormonally regulated by
glucocorticoids, which decrease expression (MacDougald et ah, 1994), by insulin
and cAMP which both increase expression (Guerra et ah, 1994; Tae et ah, 1995).
C/EBPB expression in adipocytes is controlled by similar factors to C/EBPa. It is
regulated by cytokines and agents which induce the acute phase response e.g. TNFa
and LPS administration to adipocyte cells is associated with increased C/EBPB levels
(Alam et ah, 1992; Ron et ah, 1992). Hormonal manipulations also alter C/EBPB
expression, with growth hormone and cAMP increasing expression (Clarkson et ah,
1995; Tae et ah, 1995).
1.5.6.3 Postranslational regulation
In chicken C/EBPB (NF-M), the N-terminally located transactivation domain
interacts with an inhibitory domain within the protein. Phosphorylation of the
inhibitory domain liberates the transactivating domain allowing activation of
transcription (Kowenz-Leutz et ah, 1994). One of the signal pathways leading to
derepression of the C/EBPB includes MAP kinases that phosphorylate MAP-kinase
site in the C/EBPB protein (Nakajima et ah, 1993). Other phosphorylation sites
include a serine in the leucine zipper dimerisation region of C/EBPB that can be
phosphorylated by Ca2+-calmodulin-dependent protein kinase II (CaMKII),
conferring calcium regulated stimulation of transcriptional activity (Wegner et ah,
1992), and a serine in the DNA-binding region of all C/EBP family members which
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when phosphorylated by protein kinase C attenuates DNA-binding of C/EBPa in
vitro (Mahoney et al., 1992). C/EBP8 is also activated by phosphorylation and this
modification is required for its DNA binding activity (Ray & Ray, 1994). Regulation
of transcriptional activity by phosphorylation provides a mechanism by which
hormonal signals can alter expression of C/EBP-regulated genes.
1.5.6.4 Synergistic transcriptional activation ofby C/EBP and otherfactors
Synergistic activation of genes by C/EBP-related and non-related transcription
factors can occur as well as synergy between members of the C/EBP family.
Members of the C/EBP family synergistically activate transcription, for example,
C/EBP8-C/EBPG heterodimers are more potent in activating transcription than
homodimers of C/EBPB (Kinoshita et al., 1992). Several groups have reported an
interaction between the Rel protein NFkB, and C/EBP family members.
Heterodimers of NFkB and C/EBP bind to C/EBP but not to Rel consensus sites
(Diehl & Hannink, 1994b). Another group found that activation from both the NFkB
and C/EBP binding sites in the serum ameloid A gene (Ray et al., 1995). NFkB, like
C/EBPB, is a global regulator of cytokine encoding genes and genes regulated by
cytokines. The interaction between these two factors probably modulates cytokine
gene expression. A three way interaction of transcription factors involving NFkB,
C/EBPB and ER represses the IL-6 promoter (Stein & Yang, 1995). Inhibition of IL-
6 by oestrogens was shown to be mediated by binding sites on the IL-6 promoter for
NFkB and C/EBP, and may involve the formation of heteromeric ER-NFkB and ER-
C/EBPG complexes which reduces the amount of NFkB and C/EBP heterodimers and
therefore transcription (Stein and Yang, 1995).
C/EBPB and GR synergistically activate transcription of the acute phase response
protein o^-acid glycoprotein (Nishio et al., 1993) and interact during chick neural
retina development (Ben-Or & Okret, 1993). Other examples of synergistic
activation involving C/EBP related proteins and non-related proteins include
C/EBPa with HNF1 (Wu et al., 1994; Yanuka-Kashles et al., 1994) and HNF4
(Metzger et al., 1993); C/EBPB interacting with API (Hsu et al., 1994), CREB
(Vallejo et al., 1995) and SP1 (Lee et al., 1994) and T3 binding to a response element
in the PEPCK gene which is dependent upon binding of C/EBP (Park et al., 1995).
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1.6 Regulation of hepatic gene expression
1.6.1 Liverfunction
The liver has many functions that can be broadly classified into three groups. Firstly,
a major role of liver is maintaining blood glucose homeostasis, through the
metabolism of carbohydrates, proteins and lipids. It is also the major site of
detoxification in the body, and is the main organ responsible the synthesis of plasma
proteins (Guyton, 1986).
In liver, many metabolic pathways operate to maintain glucose homeostasis. These
pathways include glycogenesis (the synthesis of glycogen from glucose),
glycogenolysis (the conversion of glycogen to glucose), glycolysis, (the oxidation of
glucose or glycogen to pyruvate and lactate), and gluconeogenesis (the formation of
glucose from non-carbohydrate sources). Metabolism of fat occurs throughout the
body, but liver performs some specific metabolic functions such as B-oxidation of
lipid, formation of lipoproteins, synthesis of cholesterol and conversion of
carbohydrate and proteins into fat. Liver performs many functions required for
protein metabolism, including deamination of amino acids, formation of urea for
removal of ammonia, formation of plasma proteins and interconversion among
different amino acids (Guyton, 1986).
Detoxification occurs to render toxic substances more polar so that they can be
removed from the body and includes processes such as conjugation or oxidation.
Conjugation is a process by which potentially harmful substances are removed from
the body. The unwanted substance is rendered more hydrophilic by complexing with
another molecule or chemical group such as sulphate, glycine, glucuronic acid or
acetic acid eventually resulting in excretion in the urine. Many substances are
destroyed by the liver by complete oxidation e.g. nicotine and the short acting
barbiturates with partial oxidation often precedes conjugation (Guyton, 1986).
Liver forms part of the reticulo-endothelial system which includes bone marrow,
lymph nodes and spleen and has a role in regulating the formation and destruction of
red blood cells, is a major site of blood storage in the body and synthesises plasma
proteins such as albumin, fibrinogen and prothrombin (Guyton, 1986).
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1.6.2 Hormonal control ofhepatic gene expression
Networks of genes are involved in metabolism, detoxification and haematopoiesis
which are coordinately regulated by extracellular signals, namely hormones and
cytokines. Networks of genes involved in metabolism of lipids, carbohydrates and
proteins are regulated chiefly by insulin, glucagon and glucocorticoids.
If blood glucose levels increase then the rate of insulin secretion from the pancreas
increases to promote uptake of glucose into the liver, glycogen synthesis and storage,
and if in excess storage in adipose tissue. Insulin binds to cell surface receptors,
initiating a cascade of events culminating in the phosphorylation or
dephosphorylation of transcription factors and hence regulation of insulin target
genes. Glucagon is secreted when blood glucose levels fall and its functions oppose
those of insulin. It promotes the breakdown of glycogen stores in liver and lipids in
adipose tissue for glucose production and gluconeogenesis. Glucagon binds to cell
surface receptors resulting in increased adenylate cyclase activity, increased cAMP
production and hence regulates metabolic gene transcription by phosphorylation of
transcription factors. Cortisol is secreted in response to hypoglycaemia promoting
breakdown of fat and gluconeogenesis. Glucocorticoid activation of genes is
described in Section 1.2 and its effects on liver metabolism in Section 1.1.5.1.
1.6.3 Transcriptional control ofhepatic gene expression
There are four main transcription factor sub-families which have been identified as
regulating liver specific genes, these do not include all liver transcriptional regulators
but are representative of factors controlling liver specific gene expression and
include hepatocyte nuclear factor 1 (HNF1) (Derman et al., 1981), C/EBP, HNF3
and members of the nuclear hormone receptor family including HNF4 and COUP-TF
(Cereghini, 1996).
HNF1 binds to the promoters of the 8-fibrinogen, albumin and arantitrypsin genes,
and was one of the first liver-enriched transcription factors to be identified
(Cereghini et al., 1988; Courtios et al., 1987; Hardon et al., 1988). The genes
regulated by HNF1 generally encode proteins involved in a wide range of metabolic
functions, including carbohydrate metabolism and detoxification including PEPCK
and C-reactive protein (Cereghini, 1996). HNF1 is dispensable for normal
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development but it does seem to be required for the maintenance of metabolic
functions. Mice which lack HNF1 die after 1 month from an acute wasting syndrome
(Pontoglio et al., 1996). These animals lack phenylalanine hydroxylase (metabolises
phenylalanine to tyrosine), and develop phenylketonuria, although expression of
other genes is not significantly altered (Pontoglio et al., 1996).
HNF3 related proteins were originally identified as binding to the promoter of the
transthyretin and a 1-antitrypsin genes (Costa et al., 1989). Three HNF3 transcription
factors exist; a, B and y (Lai et al., 1991). All three are essential for normal
development (Cereghini, 1996).
The orphan receptors HNF4 and COUP-TF also regulate liver gene expression. Like
HNF3, HNF4 was first identified as binding to the promoter of the transthyretin and
a 1-antitrypsin genes (Costa et al., 1989) and is essential for development as
disruption of HNF4 leads to early embryonic death (Chen et al., 1994). HNF4
interacts with the promoter of genes involved in a variety of functions, including
cholesterol and amino acid metabolism, gluconeogenesis and blood coagulation
(Cereghini, 1996). The regulatory functions of HNF4 usually depend upon its
synergistic interaction with other transcription factors (Cereghini, 1996). COUP-TF
acts as a negative regulator of transactivation by HNF4.
Members of the C/EBP transcription factor family (see Section 1.5) activate many
liver specific genes including albumin (Friedmann et al., 1989), PEPCK (Park et al.,
1990), transferrin (Theisen et al., 1993) and factor IX (Crossley & Brownlee, 1990),
and the role of C/EBP related proteins in hepatic gene expression is described in
Section 1.5.5. C/EBPa 'knock-out' mice have defects in glucose metabolism and do
not survive for long after birth (Wang et al., 1995) and mice lacking C/EBPB have
defects in their immune systems (Screpanti et al., 1995; Tanaka et al., 1995).
These transcription factors seem to affect a wide range of genes with different
functions, but they also regulate genes with related functions with some affecting
primarily development (HNF3 and HNF4), others metabolism (HNF1, HNF4,
COUP-TF and C/EBPa) and others the immune response (C/EBPB).
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1.6.4 Regulation ofphosphoenolpyruvate carboxykinase
The enzymes involved in glucose homeostasis are all regulated by a similar array of
transcription factors. As an example of gene regulation in liver I will focus on the
regulation of the gluconeogenic enzyme PEPCK, which synthesises
phosphoenolpyruvate from oxaloacetate (Cryer, 1992).
PEPCK is expressed predominantly in liver, kidney and adipose tissue and at lower
levels in other tissues including mammary gland, colon, heart and lung (Lemaigre &
Rousseau, 1994). Liver extracts produce 8 DNase I footprints on the promoter
between -500 and +1, termed cyclic AMP response element (CRE)l, CRE2 and PI to
P6 (Quinn et al., 1988; Roesler et ah, 1989). The proteins in liver which bind to these
sites include C/EBPa (Park et ah, 1990; Roesler et ah, 1992), C/EBP6 (Park et ah,
1993), DBP (Roesler et ah, 1992), HNF-1 (Roesler et ah, 1989), HNF-4 (Hall et ah,
1992) and the ubiquitous transcription factors CREB (Quinn et ah, 1988) and AP-1
(Gurney et ah, 1992). C/EBPa, C/EBPG and DBP bind to several promoter binding
sites including CRE1, although C/EBPG binds with highest affinity to the CRE1 site
(Park et ah, 1993). CREB, a mediator of cAMP action, and AP-1 also binds to the
CRE1 site (Gurney et ah, 1992).
PEPCK gene expression is regulated by carbohydrate intake; fasting increases
PEPCK expression (Lemaigre & Rousseau, 1994). It is hormonally regulated by the
factors controlling blood glucose; insulin, glucagon and glucocorticoids (Lemaigre &
Rousseau, 1994). Insulin decreases the transcription rate of the PEPCK gene
(Granner et ah, 1983) and inhibits cAMP and glucocorticoid induction of PEPCK
(Magnuson et ah, 1987; Sasaki et ah, 1984). Two insulin responsive sites exist on the
promoter; one of these binds AF-2 (an accessory factor involved in glucocorticoid
gene regulation (Imai et ah, 1990). However, expression of AF2 is not affected by
insulin (Iami et ah, 1990), and it has been suggested that insulin could block
glucocorticoid activity by disabling the function of AF-2 (O'Brian et ah, 1990).
Glucagon acting through cAMP stimulates PEPCK gene expression. Several cis-
acting sequences in the promoter mediate the effect of cAMP including CRE1, (but
not CRE2) (Short et ah, 1986). CRE1 is a target for CREB, C/EBPa, C/EBPG and
DBP (Park et ah, 1990; Park et ah, 1993; Roesler et ah, 1993). CREB and potentially
C/EBPa (Mahoney et ah, 1992; Quinn et ah, 1988), but not C/EBPG or DBP
41
(Roesler et al., 1993), are phosphorylated by cAMP-dependent protein kinase, and
potentially mediate the effects of glucagon on PEPCK gene transcription (Mahoney
et al., 1992; Quinn et al., 1988). Glucocorticoids stimulate PEPCK gene transcription
in liver and repress it in adipocytes (Nechushtan & al, 1987; Sasaki et al., 1984). The
mechanism of glucocorticoid activation of the PEPCK gene in liver requires
accessory factors AF1 and AF2, in addition to GR which are individually unable to
stimulate transcription in response to glucocorticoids (Lemaigre & Rousseau, 1994).
I.6.5 Regulation of the acute phase response
An early reaction occurs in liver in response to injury, trauma or infection, during the
process of 'inflammation', - the Acute Phase Response (APR).
Macrophages and monocytes are activated by trauma, injury or infection and are the
primary initiators of the APR cascade (Baumann & Gauldie, 1994). Activated
macrophages release cytokines belonging to the interleukin and tumour necrosis
factor families. These factors act locally to release additional cytokines which then
initiates a 'second wave' of cellular and cytokine cascades involved in the APR. The
mediators of the APR can be classified into 4 groups; IL-6-type cytokines (e.g. IL-
II, IL-6), IL-l-type (IL-la, IL-16, TNF-a and TNF13), glucocorticoids and growth
factors (e.g. insulin, hepatocyte growth factor) (Baumann and Gauldie, 1994). IL-6,
is the major regulator of APR genes and in general synergistically enhances genes
induced by IL-1 type cytokines such as serum amyloid A and C-reactive protein (a
component of complement C3) (Baumann & Gauldie, 1990). Glucocorticoids can
stimulate expression of some APR proteins directly although its main action is to
synergistically enhance IL-1 and IL-6 type actions (Baumann & Gauldie, 1990). The
fourth group of mediators modulates the response of liver to the IL-1 and IL-6 type
cytokines, for example, insulin attenuates the effects of IL-1 and IL-6 type cytokines
on gene expression (Baumann & Gauldie, 1990). The cytokines bind to cell surface
receptors activating intracellular pathways resulting in regulation of transcription
factor activity, for example, IL-1 and IL-6 activate the JAK2 and mitogen-activated
kinase pathway (MAPK), to mediate phosphorylation of transcription factors
(Baumann & Gauldie, 1990). The cooperative interaction between transcription
factors is required to achieve the expression of genes for the APR e.g. IL-6, is
regulated by C/EBPB and an NF-KB-like proteins. The promoter for IL-6 also
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contains binding sites for other factors including GR and AP-1, but these do not
directly regulate the IL-6 gene although they may regulate other secondary cytokines





2.1.1 Chemicals and solvents
All chemicals and solvents were of analytical grade and were obtained from either
BDH Chemicals Ltd, Poole, UK or Sigma Chemicals Ltd, Poole, UK with the
following exceptions:
Aprotinin Bayer UK Ltd, Pharmaceutical Business Group,
Bayer House, Strawberry Hill, Newbury,
Berkshire. RG13 1JN. UK.
Ethanol Hayman Ltd, 70, Eastways Industrial Park,
Witham, Essex CM8 3YE. UK.
Agarose Gibco BRL, (Life Technologies Ltd), Trident
House, Renfrew Road, Paisley. PA3 4EF. UK.
SeaPlaque agarose
NuSieve agarose
FMC Bioproducts, Flowgen Instruments Ltd,
Broad Oak Enterprise Village, Broad Oak Road,
Sittingbourne, Kent. ME9 8AQ. UK.
Nucleotide triphosphates
O-methyl-GTP
Pharmacia Biosystems Ltd, Davy Avenue,
Knowlhill, Milton Keynes. MK5 8PH. UK.
Pharmacia Biosystems Ltd, Davy Avenue,
Knowlhill, Milton Keynes. MK5 8PH. UK.
Proteinase K Boehringer Mannheim UK (Diagnostics/
Biochemicals) Ltd, Bell Lane, Lewes. BNY 1LG.
UK.
Yeast tRNA Gibco BRL, (Life Technologies Ltd), Trident
House, Renfrew Road, Paisley. PA3 4EF. UK.
Poly (dl-dC).(dl-dC) Pharmacia Biosystems Ltd, Davy Avenue,
Knowlhill, Milton Keynes. MK5 8PH. UK.
Caesium chloride Boehringer Mannheim UK (Diagnostics/
Biochemicals) Ltd, Bell Lane, Lewes. BNY 1LG.
UK.
Dimethyl sulphate (DMS) Aldrich Chemical Company Ltd, The Old Brick
Yard, New Road, Gillingham. SP5 4BR. UK.
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2.1.2 Radiochemicals







[a32P]-UTP 800 Ci/mmol, 20mCi/ml
2.1.3 Enzymes
Restriction enzymes, DNase I (RNase free) and the Klenow fragment of DNA
polymerase I were routinely supplied by Promega Ltd, Delta House, Chilworth
Research Centre, Southampton. SOI6 7NS. UK.
RNase A (20|ig/ml) was freshly prepared by dilution in TE buffer a
stock (lOmg/ml), made by dissolving RNase A
(Sigma Chemicals Ltd, Poole, UK) in water,
and boiling for lOmin (to inactivate DNase I).
2.1.4 Miscellaneous
DNA size markers Routinely used lkb DNA ladder.
Gibco BRL, (Life Technologies Ltd), Trident
House, Renfrew Road, Paisley. PA3 4EF. UK.
Dried skimmed milk powder Marvel, Premier Beverages, Knighton, Adbaston,
Stafford. ST20 0QJ. UK.
Film (DuPont NEF485) DuPont UK Ltd, Wedgwood Way, Stevenage.
SG14QN.UK.
Oligonucleotides Synthesised by Oswell DNA Service,
Southampton. UK.
Bovine gamma globulin BioRad Laboratories Ltd, May lands Avenue,
Hemel Hampstead. HP2 7TD. UK.
BioRad protein assay solution BioRad Laboratories Ltd, Maylands Avenue,




The following plasmids were used for the preparation of DNA fragments (Figure
2.1) containing regions of the rat 118-HSD1 gene promoter. The plasmids pKC 302,
pKC 303, pKC 304, pKC 305 and pKC 306 have 116-HSD1 promoter DNA inserted
into the vector pGem 3 (Promega Ltd). pDelta 10 and pDelta 47 were from a 5'
deletion series produced by exonucleaselll/mung bean nuclease digestion of
pVL116, containing a PstI fragment (-966/+47) from the rat 11B-HSD1 gene (the
deletion series was made by Val Lyons; unpublished data) (Figure 2.1). A 185 base
pair EcoRI/EcoRV pBR 322 fragment was used as non-specific competitor in gel
mobility shift analyses.
2.1.5.2 Oligonucleotides
Sequences of oligonucleotides used in investigations of protein interaction with the
rat 11B-HSD1 gene are shown in Table 2.1.
2.1.5.3 Plasmids usedfor in vitro transcription reactions
A plasmid in which the adenovirus major late promoter is linked to a 370bp G-free
cassette, pML(C2AT) (Sawadogo & Roeder, 1985) was a gift from R. Roeder.
Plasmids in which the adenovirus major late promoter is linked to a 270bp G-free
cassette, pAdM(270) or a 170bp G-free cassette, pAdM(170) (Vaulont et al., 1989)
were a gift from S. Vaulont. pll81(-599)-(C2AT)i9 and pi lBl(-88)-(C2AT)19, were
constructed by Dr. K. Chapman as follows. To construct pi lBl(-599)-(C2AT)19 an
SstI fragment encoding -599 to +76 of the rat 11B-HSD1 gene was subcloned into
the unique SstI site of the G-free cassette vector, p(C2AT)19 (Sawadogo & Roeder,
1985). An EcoRI-Hindlll fragment containing the 116-HSD1 sequence and the G-
free cassette was subcloned between the EcoRI and Hindlll sites of M13mpl8.
Oligonucleotide-directed mutagenesis was carried out to remove 116-HSD1 DNA
between +9 and +76 (which contained G residues) using an oligonucleotide
corresponding to sequences between -22 of 11B-HSD1 and the first 12 nucleotides of
p(C2AT)]9 immediately following the second G of the SstI site (5'-AGCCTCCC
CCGTCCCTGATGTCACAATTCACTCCATACCCTT-3'; the transcriptional start
is underlined). The altered sequence was verified by DNA sequencing and the
EcoRI-Hindlll fragment recloned into p(C2AT)19 to create pi lBl(-599)-(C2AT)19.
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Table 2.1 Sequences ofsynthetic double stranded oligonucleotides
Oligonucleotides encoding parts of the 11B-HSD1 gene are designated 11B-HSD1
with the nucleotide numbers of the 5' and 3' ends of the oligonucleotides shown in
brackets. The 11B-HSD1 transcription start site nucleotide is in bold type in the
oligonucleotides 0A, Og, Oh, all of which span the transcription start. 11B-HSD1
promoter oligonucleotides Og and Oh encode -14 to +15 of the rat 11B-HSD1 gene
with mutations introduced at +2 (0G) and +2, -1 (Oh) (underlined in Table 2.1). Od
encodes the P3(I) site from the PEPCK promoter shown to bind C/EBP (Park et al.,
1993) and 0E encodes an optimal C/EBP site (Nye & Graves, 1990).
Oligonucleotides Oj, Oj, Ok, Ol, Om and On were a gift from Dr John Quinn,
University of Edinburgh, Ch encodes the cAMP response element (CRE) of the
somatostatin gene (Montminy et al., 1986); Oj encodes a functional CRE from the
bovine preprotachykinin gene (Kageyama et al., 1991) which does not bind Fos/Jun
or CREB (J. Quinn, personal communication); Ok encodes an AP-1 site which binds
Fos/Jun (J. Quinn, personal communication); Ol encodes a Fos/Jun binding site from
the arginine vasopressin gene (J. Quinn, personal communication); Om encodes a
putative E-box but doesn't bind anything (J. Quinn, personal communication); On is
an E-box-like oligonucleotide, and has an AP-1 and CRE site (J. Quinn, personal
communication). Ot encodes the TdT initiator element (Smale & Baltimore, 1989).
0Ns encodes the oestrogen response element from the rat prolactin gene (Maurer &
Notides, 1987) which was used as a non-specific competitor.
References: 1, this work; 2, (Park et al., 1993); 3, (Nye & Graves, 1990), 4, Dr. John
Quinn, personal communication; 5, (Smale & Baltimore, 1989); 6, (Maurer &
Notides, 1987).
















PEPCK P3(I) site 2
oE GATCCCAATTGCCCAATCAG
GGTTAACGGGTTAGTCCTAG

















































Figure 2.1 Plasmids containing llfi-HSDl gene promoter DNA
W and 1 indicate regions of polylinker derived from pGem3.
PLASMID FRAGMENT
pKC 302 Fa (-88/+47)





pDelta 10 Fb (-812/-599)
pDelta 47 110(-322/+47)
PstI SstI Haelll Haelll BarnHI J'stl SstI
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To create pi lGl(-88)-(C2AT)19, pi 161(-599)-(C2AT)19 was restricted with BamHI,
and blunt-ended using the Klenow fragment of DNA polymerase I, before restricting
with Smal. The resulting fragment containing -88 to +8 of the 1113-HSD1 gene
linked to the G-free cassette was subcloned into p(C2AT)19, which had been
restricted with EcoRI and Smal and blunt-ended using the Klenow fragment of DNA
polymerase I.
2.1.6 Antibodies
Polyclonal C/EBPa antibody Autogen Bioclear Ltd, Butts Farm, Pottern, Nr
Devizes, Wiltshire. SN10 5LR. UK or a gift from
Dr Steven L. McKnight, Tularic Inc. USA.
Polyclonal C/EBP6 antibody Autogen Bioclear Ltd, Butts Farm, Pottern, Nr
Devizes, Wiltshire. SN10 5LR. UK.
Polyclonal COUP-TF antibody Gift from Dr M. Parker, ICRF, Lincoln Inns
Field, London. UK.
2.1.7 Buffers
2.1.7.1 General buffers and solutions
All solutions were prepared using distilled water and stored at room temperature
unless otherwise stated.
DNA loading buffer 0.25%(w/v) bromophenol blue, 0.25%(w/v)
xylene cyanol, 30% glycerol
Gel mobility shift assay
buffer (5x)
20mM Tris-HCl (pH 7.5), 500mM KC1, 25mM




50% glycerol, 50mM Tris-HCl (pH 7.5), 12.5mM
MgCl2, 5mM CaCl2, 0.5mM EDTA, 375mM KC1,
20mM spermidine, 2.5mM DTT
Tris-saturated phenol (pH 8.0) Frozen phenol was thawed by heating to 60°C.
Phenol was then extracted 2-3 times with 0.2M
Tris-HCl (pH 8.0) until buffer pH was >7.0.
Phenol was extracted twice further with 0.1M
Tris-HCl (pH 8.0) and finally stored at 4°C under




Poly (dl-dC).(dl-dC) Resuspended at 3|ig/|il in water
GTE 50mM glucose, 25mM Tris-HCl (pH 8.0),
lOmM EDTA
Alkaline SDS solution 0.2M NaOH, 1 % SDS
Potassium acetate Prepared by combining 60ml 5M potassium
acetate, 11.5ml glacial acetic acid, 28.5ml water.
The final solution is 3M with respect to potassium,
5M with respect to acetate
Formamide gel loading
buffer
Deionised formamide to which 0.03% xylene
cyanol, 0.03% bromophenol blue, 20mM EDTA
has been added
SpinBind DNA binding buffer 9 parts 8M Nal, 22mM DTT; 1 part 1M sodium
phosphate buffer (pH 6.0).
8M Nal, 22mM DTT was made by dissolving
34mg DTT and 11.9g Nal at 50°C with stirring
into a final volume of 10ml dH20.
Sodium phosphate buffer was prepared by adding
1M Na2HP04 to 10ml of 1M NaH2P04 while
stirring until the pH reaches 6.0
SpinBind high ethanol
wash buffer
80ml ethanol, 1.0ml 1M Tris-HCl (pH 8.0), 40pl
0.5M EDTA (pH 8.0) made up to 100ml with
dH2Q
DMS stop 1.5M sodium acetate (pH 7.0), 200|ig/ml yeast
tRNA, 7%(v/v) 2-mercaptoethanol
Maxam and Gilbert (G+A) stop
Maxam and Gilbert (G) stop
0.3M Sodium Acetate (pH 7.0), O.lmM EDTA,
25|ig/ml yeast tRNA
1.5M Sodium acetate (pH 7.0), 200|ag/ml yeast
tRNA, 7%(v/v) mercaptoethanol
TBE(lOx) 108.9g Tris base, 55.7g boric acid, 4.7g EDTA
made up to 1000ml
TE (lx) lOmM Tris-HCl (pH 8.0), ImM EDTA
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2.1.7.2 Buffersfor making nuclei and nuclear extracts
Homogenisation buffer lOmM Hepes-KOH (pH 7.6), 15mM KC1,
0.15mM spermine, 0.5mM spermidine,
ImM EDTA, 2.1M sucrose, 1% low fat milk
(MARVEL), 1% protease inhibitor mixture,
0.5mM DTT, 0.5mM PMSF
100% protease inhibitor Made by mixing 5ml 100% aprotinin, 2ml mixture
pepstatin (250(Xg/ml) and 50|il leupeptin
(10mg/ml). Stored at -20°C in 1ml aliquots.
Nuclear lysis buffer (nuclear
extracts used for in vitro
transcription reactions (IVT)
lOmM Hepes-KOH (pH 7.6), 0.1M KC1, O.lmM
EDTA, 10% glycerol, 3mM MgCl2,
ImM DTT, O.lmM PMSF, 1% aprotinin
Nuclear dialysis buffer (IVT) 25mM Hepes-KOH (pH 7.6), O.lmM EDTA,





52.85g (NH4)2S04was dissolved in 100ml
dH20, pH was adjusted to 7.9 with NaOH and
stored at 4°C
400mM NaCl, lOmM Hepes-KOH (pH 7.9),
1.5mM MgCl2 O.lmM EGTA, 0.5mM




20mM HEPES-KOH (pH 7.9), 75mM NaCl,
O.lmM EDTA, 0.5mM DTT, 20% glycerol,
0.5mM PMSF
2.1.7.3 Buffers usedfor in vitro transcription
5x In vitro transcription 100pl 1.0M Hepes-KOH (pH 7.6), 350|LLl 87%
reaction buffer glycerol, 85pl 3.0M KC1, 60|il 1.0M MgCl2,
250|il 25mM CTP, 250pl 25mM ATP, 35|xl
lOmM UTP, 200ml lOmM O-methyl-GTP,
670|il dH20




DNA elution buffer lOmM Tris-HCl (pH8.0), 20mM acetic acid, ImM
EDTA (pH 8.0), 0.1% SDS
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2.1.7.4 Restriction enzyme buffers
EcoRI, PstI restriction 90mM Tris-HCl (pH 7.5), lOmM MgCl2, 50mM
buffer (lx) NaCl
Hindlll restriction buffer (lx) 6mM Tris-HCl (pH 7.5), 6mM MgCl2, 60mM
NaCl, ImMDTT
Smal restriction buffer (lx) lOmM Tris-HCl (pH 7.5), 7mM MgCl2 50mM
KC1, ImM DTT. DNA cleaved at 25°C
Multicore restriction buffer (lx) 25mM Tris-Acetate (pH 7.8), lOOmM potassium
acetate, lOmM magnesium acetate, ImM DTT
Klenow buffer (lOx) 500mM Tris-HCl (pH 7.2), lOOmM MgS04, ImM
DTT
2.1.8 Bacterial media and agar
Bacto tryptone, yeast extract and bacto agar were supplied by Difco Laboratories,
Michigan, USA. All media were made in dH2Q and autoclaved prior to use.




As for L-broth except with 1.5% (w/v) bacto agar
LB-agar was melted in the microwave, allowed to
cool until warm, and if required, ampicillin
(lOOmg/ml) was added prior to pouring plates in
sterile plastic 100mm petri dishes.
M9 (5x) 64g Na2HP04.7H20, 15g KH2P04, 2.5g NaCl, 5g
NH4C1 to 1 litre with dH2Q
M9 Minimal medium lxM9, 0.3% casamino acids, 0.5% glucose,




2.2.1.1 Agarose gel electrophoresis
Agarose gels were prepared by adding agarose at 0.8-2% (w/v) to 0.5xTBE followed
by boiling in a microwave oven. l|0,g/ml of ethidium bromide was added to the
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dissolved agarose and the solution was poured into a gel mould. Once set, the gel
was submerged in 0.5xTBE in a gel tank and DNA samples, containing agarose
loading buffer, were loaded into the wells. Samples were electrophoresed at 100-
200V until the DNA fragments were resolved. DNA was visualised on a UV
transilluminator and photographed. The sizes of DNA fragments were estimated by
comparison of their mobility to that of DNA size markers.
2.2.1.2 Vertical polyacrylamide gel electrophoresis
2.2.1.2.1 Gel plates
Gel plates used in polyacrylamide gel electrophoresis were scrubbed in detergent,
rinsed with dt^O and wiped with ethanol before use.
2.2.1.2.2 Non-denaturing polyacrylamide gel electrophoresis
Non-denaturing polyacrylamide gel electrophoresis was used in gel mobility shift
analysis (Section 2.2.5.1) and methylation interference analysis (Section 2.2.5.3).
DNA fragments were electrophoresed on 4% polyacrylamide gels and
oligonucleotides on 5% polyacrylamide gels.
The gel mix contained 2.5ml of lOxTBE, 300p,l 10% ammonium persulphate and
either 5ml of 40% acrylamide:bis-acrylamide (19:1) (for 4% gels) or 6.25ml of 40%
acrylamide:bis-acrylamide (19:1) (for 5% gels), in a final volume of 50ml.
Polymerisation was initiated by addition of 40|il TEMED and the gel was poured
into the gel cast. The gel cast for gel mobility shift analysis consisted of 15cm x
17cm glass plates sandwiching spacers 1.5mm thick, which was sealed by 1%
agarose (w/v). The gel cast for methylation interference non-denaturing gel consisted
of 16.5cm x 28cm plates which sandwiched 1.5mm spacers. Once the gel was
poured, a 20 tooth comb was inserted into the gel cast to form wells for use in gel
mobility shift assays and a 6 tooth comb inserted for the methylation interference gel.
The gel was allowed to set for at least 2h prior to electrophoresis on a Gibco BRL
Model VI6 apparatus for gel mobility shift analysis, or a Sigma Model E5514
apparatus for methylation interference. Gels were pre-run at 100V in 0.5xTBE for at
least 30min before samples were loaded. Gels were run at 200V for approximately
90min. After electrophoresis the gel was transferred to Whatman 3MM paper,
covered with Saranwrap and dried under vacuum at 80°C in a gel drier (BioRad 583
51
Gel Drier). Protein-DNA complexes were visualised by exposing the dried gel for
24h to autoradiographic film (2.2.2).
2.2.1.2.3 Denaturing polyacrylamide gel electrophoresis
An 8% or 10% denaturing polyacrylamide gel was used in DNase I protection
analysis and methylation interference analysis, depending on the size of fragment
under investigation, and a 4% denaturing gel was used in in vitro transcription
analysis. For a 10% denaturing gel, 42g of urea was dissolved in 25ml 40%
acrylamide:bis-acrylamide (19:1), 10ml lOxTBE, 600|il ammonium persulphate,
made up to 100ml with df^O and filtered through Whatman #1 filter paper. The
solution was degassed, and polymerisation started by the addition of 40p.l TEMED,
and then poured into the gel cast. The gel cast was made using 0.3mm spacers
sandwiched between glass plates (45cm x 35cm) and sealed with 1 % agarose (w/v).
Once the gel was poured the comb was inserted, and the gel allowed to polymerise
for at least 2h before assembly into the electrophoresis apparatus (IBI model
STS45i). The gel was pre-run at 1800V for 30min, samples in formamide loading
buffer were heated to 90°C for 3min, centrifuged and loaded onto the gel. Gels were
run at 1800V until the bromophenol blue had reached the bottom of the gel. For
single nucleotide resolution of DNA fragments greater than 100 nucleotides, a
second loading of sample was applied to the gel and electrophoresed until the
bromophenol blue had reached the bottom, at which time the xylene cyanol had
electrophoresed approximately 3/4 of the way down the gel. After electrophoresis the
gel was transferred to Whatman 3MM paper and dried under vacuum at 80°C on a
BioRad 583 Gel Drier. The gel was exposed to autoradiographic film overnight at -
80°C to visualise the DNA.
For a 4% denaturing gel, 21 g of urea was dissolved in 5ml 40% acrylamide:bis-
acrylamide (19:1), 5ml lOxTBE, 300|il ammonium persulphate, made up to 50ml
with dH20 and filtered through Whatman #1 filter paper. The solution was degassed,
polymerisation started by addition of 20|il TEMED and then poured in the gel cast.
To make the gel cast, glass plates (15cm x 17cm) were put together using 0.8mm
spacers and sealed with 1% agarose (w/v). Once the gel was poured, a 20 tooth comb
was inserted and the gel allowed to polymerise for at least 2h before assembly into
the electrophoresis apparatus (Gibco BRL Model VI6). The gel was pre-run at 150V
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for 30min, samples (in formamide loading buffer) were heated to 90°C for 3min,
centrifuged and loaded onto the gel. After electrophoresis at 200V for 1.5h the gel
was fixed in 20% methanol, 10% acetic acid for 20min and transferred to Whatman
3MM paper and dried under vacuum at 80°C on a BioRad 583 Gel Drier. The gel
was visualised by exposure to autoradiographic film overnight at -80°C.
2.2.2 Autoradiography
Dried gels were exposed to autoradiographic film (DuPont NEF 485) at -80°C inside
cassettes containing a single intensifying screen (DuPont). Film was exposed for an
appropriate length of time then developed for 3mins in D19 developer (Kodak) and
fixed in Amfix fixative (1 in 5 dilution) (Champion), rinsed in tap water and left to
dry before analysis.
2.2.3 DNA techniques
2.2.3.1 Propagation ofDNA in E. coli
2.2.3.1.1 Preparation ofcompetent bacteria
A single colony of Escherichia coli (HB101 or JM109) was routinely used for
transformations and was inoculated into 2ml of L-Broth and grown overnight with
shaking at 37°C. These cells were then diluted into 50ml L-Broth and were grown at
37°C to mid-log phase (A60o=0.4-0.8). Cells were harvested at 6,000rpm in a
Beckman JA20 rotor in a J2MC centrifuge at 4°C for lOmin. Cells were resuspended
in 10ml ice cold 0.1M CaC^and left on ice for lOmin to lh. Centrifugation was
repeated and cells were finally resuspended into 2ml ice cold 0.1M CaCl2. Cells were
kept on ice for up to 4 days until use.
2.2.3.1.2 Transformations
Competent cells were transformed as outlined in Sambrook et al., 1989. 100|il of
competent cells were mixed with 10-100ng of plasmid DNA in TE. The DNA and
cells were left on ice for lOmin prior to heat shock at 42°C for 2min. Transformed
cells were then plated out onto LB agar plates containing 100|ag/ml ampicillin using
a glass spreader. Plates were inverted and incubated overnight at 37°C. Control
plates included pGEM3 as a positive control, or no plasmid as a negative control.
Cells which grew on the plates represented colonies which had been transformed by
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plasmids containing 6-lactamase, the gene encoding resistance to ampicillin. Plates
were stored at 4°C for up to 3 months.
2.2.3.1.3 Large scale preparation ofplasmid DNA
2ml of L-broth containing 100|ig/ml ampicillin was inoculated with a single bacterial
colony and grown overnight at 37°C with shaking. The overnight culture was diluted
into 40ml of L-broth or M9 minimal medium containing 100|j,g/ml ampicillin, grown
at 37°C to A6oo 0.4-0.7, then further diluted into 460ml LB medium or M9 minimal
medium and grown overnight in a 2 litre flask with shaking. Cells were harvested at
6,000rpm for 5min at 4°C using a Beckman JA-14 rotor in a Beckman J2-MC
centrifuge. The bacterial pellet was resuspended in 12ml of GTE, mixed immediately
with 24ml of freshly prepared alkaline-SDS solution, then stored on ice for 5min.
16ml of ice cold potassium acetate was added, mixed well, and stored on ice for a
further lOmin, before centrifugation in the JA-14 rotor at 6,000rpm, 4°C for lOmin.
The supernatant was strained through gauze into 250ml centrifuge pots and 32ml of
isopropanol added to precipitate DNA at room temperature for 30min. Plasmid DNA
was pelleted by centrifugation at 10,000 rpm for 5min at 4°C. The DNA pellet was
dried and resuspended in 2.2ml TE, then lg of CsCl was added for each ml of DNA
solution and dissolved. 50|il of ethidium bromide (lOmg/ml) was added; the resulting
solution was then transferred into a 3ml Beckman Quickseal tube and centrifuged
either for 4h at 100,000rpm, or overnight at 70,000rpm in a TLA100.3 rotor in a
Beckman Optima TLX Ultracentrifuge. Banded plasmid DNA was removed using a
needle and syringe through the tube wall and transferred to a new ultracentrifuge
tube. Fresh CsCl solution (prepared by adding lOOg CsCl to 100ml TE) was added to
the recovered plasmid DNA in the tube and centrifuged as before. The plasmid DNA
was collected and ethidium bromide removed by extraction using isopropanol, until
the isopropanol was no longer pink. The plasmid preparation was dialysed against
three 1 litre changes of TE at 4°C. Concentrations of recovered plasmid DNA were
calculated by measuring the A2eo in an Shimadzu UV-160A spectrophotometer




2.2.3.2.1 Restriction endonuclease digests
Typically, l-10|ag of plasmid DNA was cut using 1-10 units of restriction
endonuclease at 37°C for lh in lx recommended restriction buffer, in a final volume
of 10-30(tl. A tenth of the digest was saved for comparison with the recovered DNA
fragment after purification from a low melting point agarose gel.
2.2.3.2.2 DNA fragment purification
Fragments were separated by electrophoresis on a 1-2% SeaPlaque low melting point
agarose gel run at 100-150V. The gel was examined using a UV transilluminator and
a photograph taken. The appropriate DNA fragment was excised in a gel slice for
further DNA purification. DNA was purified by melting the gel slice at 70°C; for
every 100|il of melted gel slice 100(4.1 of Tris-saturated phenol was added, vortexed,
samples left on dry ice for lOmin, then spun in a microcentrifuge for lOmin. The
upper aqueous layer was extracted and added to Tris-saturated phenol (pH 8.0) in the
same ratio as above, vortexed, centrifuged for 2min and the aqueous layer again
removed. This was then extracted using lOOp.1 Tris-saturated phenol (pH 8.0) and
lOOp.1 chloroform:isoamylalcohol. The aqueous layer was finally extracted by
chloroformrisoamylalcohol. DNA from the aqueous layer was recovered by ethanol
precipitation and resuspension in lOjil dF^O. Recovery was checked using l(tl of
recovered DNA compared against an aliquot retained from the original restriction
digest.
2.2.3.2.3 Ethanol precipitation ofDNA
Precipitation of DNA was routinely carried out by addition of 15(0.1 5M NaCl and
250(il 100% ethanol per 100(4.1 ofDNA, incubation on dry ice for lOmin followed by
centrifugation in an Eppendorf centrifuge for lOmin. Ethanol was removed using a
drawn-out pasteur pipette, and the DNA pellet was air dried for 15min before
resuspension in 10|ol dF^O.
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2.2.3.2.4 Preparation of[ P]-labelled double stranded oligonucleotides
Pairs of complementary single stranded oligonucleotides were heated to 65°C for
lOmin, annealed by cooling slowly to room temperature, and end-labelled using the
Klenow fragment of DNA polymerase I by incubation for lOmin at room
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temperature in a lOpl reaction containing lOOpmol of complementary
oligonucleotides, lx Klenow buffer, 0.2mM each of dGTP, dCTP, dTTP, 0.5pl
Klenow (10 units/pl), 3pl [a32P]-dATP (3000Ci/mmol). Labelled oligonucleotides
were purified using SpinBind columns. The reaction was mixed with 2x the labelling
reaction volume of SpinBind DNA binding buffer, applied to the column, and spun
for 10s in an Eppendorf centrifuge. SpinBind DNA binding buffer was applied twice
more to the column, spun and the eluate discarded. The SpinBind high ethanol wash
buffer was then applied three times to the column, spun each time and the eluate
discarded. End-labelled oligonucleotides were eluted into 50(il df^O to give
1.4pmol/|il, assuming a 70% recovery from purification through the column.
Labelled oligonucleotides were stored at -20°C for up to 3 weeks. Generally, specific
activity was 5000cpm/pmol double-stranded oligonucleotides.
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2.2.3.2.5 Preparation of[ P]-labelled DNA restriction fragments
lOpg of plasmid was cut with the appropriate restriction enzymes; for DNase I and
methylation interference analysis restriction enzymes were chosen so that only one
end would be labelled (at a 5' overhang), with the other end being blunt or having a 3'
overhang. The fragment was purified (Section 2.2.3.2.2) and end-labelled using the
Klenow fragment of DNA polymerase I by incubation for lOmin at room
temperature in a 10pl reaction containing DNA restriction fragment at a
concentration equivalent to lpg plasmid, lx Klenow buffer, 2mM each dGTP, dCTP,
dTTP, 0.5pl Klenow (lOunits/pl), 3pl [a32P]-dATP (3000 Ci/mmol). Fragments
were purified through SpinBind columns as described (Section 2.2.3.2.4) and eluted
into 50pl dH20. Purified labelled fragments were stored at -20°C for up to 3 weeks.
Generally, the specific activity was 2000-5000cpm/fmol.
2.2.3.2.6 Maxam and Gilbert DNA sequencing reactions
Two types of Maxam and Gilbert reactions were used as size markers in DNase I
footprinting and in methylation interference reactions; G+A and G reactions. G+A
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reaction: 5pl of [ P]-end labelled DNA fragment, labelled at a single end, was
incubated with 25pl formic acid to chemically modify G and A bases. The length of
incubation depended on the length of the labelled DNA (the longer the DNA
fragment, the shorter the exposure) for fragment Fg (-812 to -599), 45s. G reaction:
190jil TE was added to lOpl of [32P]-labelled DNA fragment which was then
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incubated with DMS to chemically modify G bases. The concentration of DMS
added and length of incubation depended on the length of the labelled DNA; for
fragment Fa, lftl of DMS diluted 1 in 5 in dF^O for 30s; for the fragment encoding
-599 to -249 of the 116-HSD1 promoter, 20(il of DMS diluted 1 in 15 in dH20 for
30s. Both G+A and G reactions were then processed in the same way. Reactions
were stopped by the addition of 200p.l of the appropriate Maxam and Gilbert stop
solution. DNA was precipitated by the addition of 750p.l ethanol, placed on dry ice
for 5min, and spun in an Eppendorf centrifuge for 5min at 14,000rpm. Pelleted DNA
was washed by resuspending in 250(4.1 0.3M sodium acetate (pH 7.0) and 750(4.1
ethanol, precipitated on dry ice and centrifuged as before. DNA pellets were
resuspended in 75(4.1 of 1M piperidine (diluted fresh from the bottle 1:9 with dF^O)
and heated to 90°C for 20min to cleave chemically modified bases. Cleaved DNA
was precipitated by the addition of 50(tl 0.3M sodium acetate (pFI 7.0) and 400fil
ethanol, then placed on dry ice for lOmin and centrifuged for lOmin at 14,000rpm in
an Eppendorf centrifuge. The ethanol precipitation was repeated by resuspending the
DNA pellet in 50(4.1 0.3M sodium acetate (pH 7.0), adding 400(4,1 ethanol, and placing
on dry ice for lOmin followed by centrifugation as before. The supernatant was
removed and DNA pellets resuspended in formamide loading buffer.
2.2.4 Protein techniques
2.2.4.1 Recombinant C/EBPa protein synthesis
Recombinant C/EBPa protein (rC/EBPa) was produced in bacteria as described
(Landschultz et al., 1988). pT5 plasmid (a gift of S. L. McKnight) directs expression
of the rat C/EBPa gene under the control of the T7 promoter. pT5 was transformed
into E. coli. strain BL21(DE3)pLysS which contains the bacteriophage T7 gene
encoding the bacteriophage RNA polymerase, under control of the E. coli lac
promoter (Studier et al., 1990). Cells were grown in M9 minimal medium
supplemented with antibiotics to mid-log phase (A6oo 0.6-1.0), then 0.4mM IPTG
was used to induce T7 RNA polymerase synthesis which in turn, initiates
transcription from the T7 promoter present in the pT5 plasmid. Cells were grown for
a further 2-3h after addition of IPTG and harvested by centrifugation, and
resuspended in PBS containing 5M urea, ImM benzamidine, ImM EDTA, 0.2%
Triton X-100. Cells were then frozen at -80°C, quick thawed at 37°C, and sonicated.
The resulting lysate was passed over a DEAE-cellulose column that had been
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equilibrated with PBS containing 5M urea, ImM benzamidine, ImM EDTA. The
flowthrough was collected in fractions and dialysed against 2 changes of PBS.
Fractions were snap frozen and stored at -80°C in 50|il aliquots. Protein
concentrations were determined (Section 2.2.4.2.4) and C/EBPa assayed in each
fraction by gel mobility shift analysis (Section 2.2.5.1) using a [32P]-labelled double-
stranded C/EBP-binding oligonucleotide (Oe, Table 2.1). Fractions with most
rC/EBPa activity binding were used as the source of rC/EBPa.
2.2.4.2 Preparation ofnuclear extracts
2.2.4.2.1 Purification ofnuclei
Nuclei were made using freshly isolated adult male rat liver (HanAVistar).
Approximately lOg was chopped finely and homogenised in homogenisation buffer
by 10 strokes with an all glass dounce homogeniser. The homogenate was layered on
top of pre-chilled (placed at -20°C for at least lh) 5ml cushions of homogenisation
buffer from which the low fat milk was omitted, then centrifuged at 21,000rpm for
lh in a Sorvall AH627 swing-out rotor in a DuPont Sorvall OTD centrifuge; this
gave clean pelleted nuclei from which nuclear extracts were made. Two methods
were employed in making nuclear extracts; a standard method was used for making
extracts for use in gel mobility shift analysis and DNase I protection assays and a
lengthier procedure, involving further purification steps was used to make extracts
for in vitro transcription experiments.
2.2.4.2.2 Preparation ofnuclear extractsfor analysis ofprotein-DNA interactions
Nuclear extracts were prepared essentially as described (Dignam et al., 1983). Nuclei
were resuspended using a glass homogeniser in a volume of Nuclear resuspension
buffer equivalent to using 2.5 x vol. of pelleted nuclei. Resuspended nuclei were
stirred slowly for 30min at 4°C then centrifuged for 60min at 42,000rpm in a
Beckman Optimal TLX Ultracentrifuge using a TLA 100.3 rotor. The supernatant
was then dialysed for 3h against 50 vol. of Dialysis buffer. The protein concentration
of the nuclear extract was determined (Section 2.2.4.2.4) and was routinely 2-
lOpg/ml; 15pl aliquots were snap frozen in liquid N2.
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2.2.4.2.3 Preparation ofnuclear extracts for in vitro transcription
Freshly prepared nuclei were resuspended in 5ml Nuclear lysis buffer (IVT) and
homogenised by several strokes with an all glass Dounce homogeniser. 18ml of
Nuclear lysis buffer (IVT) was added, then 0.1 vol. of 4.0M (NH^SO^ followed by
gentle mixing for 30min by shaking on ice, then centrifugation for lh at 42,000rpm
at 2°C in a Beckman Optimal TLX Ultracentrifuge using a TLA 100.3 rotor. The
supernatant was transferred to a fresh centrifuge tube and 0.3g solid (NH4)2S04 per
ml of supernatant was slowly added and gently shaken on ice for 30min before
centrifuging as above for 20min at 42,000rpm. The supernatant was discarded and
the pellet resuspended in 600jil Nuclear dialysis buffer (IVT) by pipetting up and
down every 15min for 2h to ensure complete recovery of pelleted proteins.
Resuspended proteins were dialysed twice for a total of 4h at 4°C against 100 vol. of
Nuclear dialysis buffer (IVT). After dialysis, a white precipitate formed which was
removed by centrifugation in a microcentrifuge for 2min. The protein concentration
of the nuclear extract was determined (Section 2.2.8) and the supernatant was
aliquoted and snap frozen in liquid N2.
2.2.4.2.4 Estimation ofprotein concentration of extracts
Protein concentrations were estimated using a commercially available assay
(BioRad) based on the Bradford method (Bradford, 1976). A working solution of
BioRad Protein assay reagent was prepared by diluting 1 part BioRad Protein Assay
concentrate in 5 parts dH^O and filtering through Whatman #1 paper. A standard
curve was constructed in duplicate as follows, standards containing 0, 1.5, 3, 6, 12 or
18(Xg of bovine gamma globulin were made up to 20(tl with dt^O. A range of
sample concentrations were prepared in duplicate in which the final volume was
made up to 20fil with dF^O. 1ml of diluted BioRad protein assay reagent was added
to each standard and sample and vortexed. The colour was allowed to develop for
5min before being transferred to 1ml plastic cuvettes for measurement of A595 in a
Shimadzu UV-160 spectrophotometer. A calibration curve was obtained from the
standards, from which the protein concentration of the samples could be calculated.
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2.2.5 Analysis ofprotein-DNA interactions
2.2.5.1 Gel mobility shift assays
Gel mobility shift assays were carried out as described (Singh et al., 1986). Each
reaction contained 30fmol of [32P]-labelled DNA fragment or 0. lpmol of [32P]-
labelled double-stranded oligonucleotide, 4(0.1 of 5x Gel mobility shift assay buffer,
3|ig of the non-specific DNA competitor poly (dl-dC).(dl-dC) and 6-10pg nuclear
extract or 0.5(Xg bacterial extract containing rC/EBPa protein, in a final reaction
volume made up to 20(il with dH^O. Reactions were pre-incubated for 15min at
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room temperature prior to addition of [ P]-labelled DNA. A further 15min
incubation at room temperature preceded loading onto either a 4% or 5% non-
denaturing polyacrylamide gel (Section 2.2.1.2.2) which had been pre-run for 30min
at 100V. Gels were loaded and electrophoresed at 200V in 0.5xTBE to resolve the
protein-DNA complexes from unbound DNA. The gel was dried for lh at 80°C
under vacuum in a BioRad 583 Gel Drier and protein-DNA complexes were
observed after exposure at -80°C to autoradiographic film overnight.
Competition gel mobility shift assays used approximately 10- or 100-fold molar
excess of unlabelled specific or non-specific competitor fragment or oligonucleotide,
which were included in the pre-incubation reaction prior to addition of [32P]-labelled
DNA. Where antibodies to specific transcription factors were used in gel retardation
assays, lpl antibody was included in the pre-incubation prior to the addition of [32P]-
labelled DNA.
2.2.5.2 DNase I protection analysis
DNase I protection analysis was carried out essentially as described (Galas &
Schmitz, 1978). Each reaction contained 5pl of 5x DNase I protection buffer, lpg of
poly (dl-dC).(dl-dC), 50-100fmol of [32P]-labelled DNA and up to 80pg of protein
extract (either nuclear extract or bacterial extract containing rC/EBPa) in a final
reaction volume of 25pl. Reactions were pre-incubated on ice for 15min prior to the
addition of [32P]-labelled DNA. This was followed by a further 15min incubation on
ice before addition of DNase I. The amount of DNase I and time of exposure to
DNase I varied, depending on the batch and was determined in prior experiments
using a range of DNase I concentrations and times of digestion. Reactions were
stopped by addition of EDTA to 0.1M and NaCl to 400mM (which dissociates most
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proteins from DNA). Each reaction was added to a protein removal cartridge (NBL),
the membrane washed with 400mM NaCl and eluate collected, lpl of 10|LLg/pil of
yeast tRNA was added to the eluted DNA, which was then ethanol precipitated, and
washed in 70% ethanol before resuspension in formamide loading buffer. Samples
were heated to 90°C for 3min prior to loading on a denaturing polyacrylamide gel
which had been pre-run at 1000V for 30min. The gel was electrophoresed at 1800V
until the bromophenol blue had reached the bottom.
2.2.5.3 Methylation interference analysis
l-2xl06cpm of single end-labelled DNA was partially methylated using l|il dimethyl
sulphate (DMS) in 200pl TE buffer for 2.5min. The reaction was terminated by the
addition of 50jil DMS stop mixture and 750p,l 95% ethanol. Methylated DNA was
precipitated by placing on dry ice for 5min followed by centrifugation at 14,000rpm
for lOmin in an Eppendorf centrifuge. The supernatant was discarded and the pellet
washed with 70% ethanol, air dried and resuspended in TE to give 20,000cpm/(il.
The partially methylated DNA was then incubated with protein, either from nuclear
extract or bacterial extract containing rC/EBPa, then electrophoresed at 200V on a
non-denaturing polyacrylamide gel to separate free DNA from complexed DNA.
After electrophoresis the top plate of the gel was removed and the gel covered with
Saranwrap and exposed to autoradiographic film overnight at 4°C. The
autoradiograph was developed, and once dry this was lined up with the original gel;
the protein/DNA complexes and free DNA were cut out of the gel using a scalpel.
DNA was eluted from gel slices by electroelution in a BioRad Electro-Eluter (Model
422) using membrane caps with a molecular weight cut-off of 3,500Da. Gel slices
were placed in the electroeluting apparatus containing DNA elution buffer and eluted
onto membranes by electrophoresis at 10mA per chamber used, for 30min. The
current was then reversed and the eluted DNA was recovered. DNA was extracted
using equal volumes of phenol and chloroforrmisoamylalcohol, then ethanol
precipitated. Pelleted DNA was washed in 70% ethanol and resuspended in 50pil
dH20. DNA was cleaved at methylated guanine residues by incubation with 50pl of
20% piperidine at 90°C for 30min. DNA was precipitated by addition of lOOpl 0.6M
sodium acetate (pH 7.0) and 500pl of 95% ethanol, left on dry ice for 5min and spun
in an Eppendorf centrifuge for 20min. Pelleted DNA was washed in 70% ethanol and
resuspended in lOpl of formamide loading dye. Samples were denatured by heating
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to 90°C for 3min and loaded onto a pre-run 10% denaturing polyacrylamide gel.
Once run, gels were dried under vacuum and exposed to autoradiographic film.
2.2.6 In vitro transcription
In vitro transcription analysis made use of the G-free cassette method (Sawadogo &
Roeder, 1985). The G-free cassette assay relies on the use of a synthetic DNA
template (of defined length) which does not contain any G residues in the non-coding
strand. When a promoter is cloned in front of the G-free cassette, the in vitro
transcription reaction can be performed in the absence of GTP and in the presence of
a GTP-analogue (O-methyl-GTP) which does not support chain elongation;
transcripts of defined length are produced at the insertion of O-methyl-GTP at the
first G after the G-free cassette. Transcripts can then be visualised on a gel.
Reactions were carried out essentially as described (Sawadogo & Roeder, 1985).
Construction of plasmids used (pi 16-599-C2AT and pi 1B-88-QAT) for in vitro
transcription are described in section 2.1.5.3. Control plasmids used for in vitro
transcription were Ad370, Ad270, Adl70 (Vaulont et al., 1989) and p(C2AT)19
(Sawadogo and Roeder, 1985). In vitro transcription reactions were carried out in a
final volume of 20(tl. 12(tl of nuclear extract and l(tl (0.8-1.0(tg) of template plasmid
DNA were incubated on ice for lOmin. To each sample, 7(tl of transcription mixture
(4(0.1 5x transcription buffer, l(tl [a32P]-UTP (800Ci/mmol), l(tl RNasin (40U/|il))
was added followed by incubation at 30°C for 45min. To each sample, 274(il of
Transcription stop buffer containing 2(4.1 lOmg/ml tRNA and 4(4.1 lOmg/ml proteinase
K was added, followed by further incubation for 30min at 37°C. In vitro transcribed
RNA was extracted with lOOpl phenolxhloroform and centrifuged at 14,000rpm in
an Eppendorf centrifuge to separate organic and aqueous phases. The aqueous phase
was then precipitated by addition of 750(tl ethanol, left on dry ice for 15min, and
RNA pelleted at 14,000rpm in an Eppendorf centrifuge. Pelleted RNA was
resuspended in 5)4.1 formamide loading dye, the sample denatured at 90°C for 3min
and electrophoresed on a pre-run 4% denaturing polyacrylamide gel.
62
CHAPTER 3
C/EBPa and C/EBPB bind to the
proximal promoter of the rat 11B-HSD1 gene
3.1 Introduction
The major site of 11B-HSD1 expression is liver, where it may play an important role
in glucocorticoid action by maintaining high intrahepatic levels of active
glucocorticoid through its reductase activity (Jamieson et al., 1995). Glucocorticoids
play a major role (with insulin and glucagon) in regulating blood glucose
homeostasis, and recent evidence suggests that elimination of 11B-HSD1 activity in
transgenic mice leads to decreased fasting glucose levels and decreased glucose 6-
phosphatase activity (Y. Kotelevtsev, personal communication). The regulation of
118-HSD1 expression is therefore potentially important in energy homeostasis.
Regulation of 118-HSD1 mRNA levels by glucocorticoids, sex steroids and growth
hormone are described in Chapter 1. However, the mechanism of transcriptional
regulation has not previously been investigated, in particular, the basis for tissue
specific expression of 11B-HSD1.
Part of the rat 11B-HSD1 gene, including the promoter and 5'-flanking region, has
been cloned and sequenced, and putative regulatory elements within the promoter
identified (Moisan et al., 1992). In liver, one major transcription initiation site is
utilised, but in kidney two additional transcription starts are used as well as the major
one found in liver (Moisan et al., 1992). The 118-HSD1 gene lacks a TATA box, but
putative transcription factor binding sites are present, including CACCC boxes at
-80, -280, -290 and -325, a CCAAT sequence at -73, glucocorticoid response
element half sites at -375 and +62 and predicted binding sites for the liver enriched
transcription factor C/EBP (Figure 3.1).
In this chapter I have investigated (a) whether the liver enriched transcription factor
C/EBP is able to bind to the promoter region of the 11B-HSD1 gene (the GCAAT
sequence at -67 is a predicted C/EBP site) and (b) the nature of the factors which
bind to the proximal promoter. Surprisingly, I show that C/EBP does not bind
significantly to the GCAAT sequence at -67 but that it binds with highest affinity to
the transcription start.
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-1000 TCAAAGTAGA GGTAAAAAGA AGGTTAGCGC TGCAGCTTAT GAGAGAGCAG
-95 0 TTTGGCTATA GCCAAAGGTG GTCTAGATCC TCTGGTCTGA CCTTCTTTTC
ERE
-900 CCAGCATCCT CTTCTGCTCC TCGCTCCTCC ACAGCATTTA CATAACCCAG
-850 TTTAACAACC TGCTACCTTC CTTCCTGTTT TGGCGCCCAT CATTCCTTCT
C/EBP
^
-800 TTATTCCCTG TAGTAATAAG GGCACTTCCA TTGCACTTGC CTGAGAGTCT
-750 TGAACTGAGC TTGGGTTTCC TGCCATCTGG GTCTGGCTGG TTTGCAACTT
C/EBP
-700 CTCTTTGATG TTGCAATGCT TTTTCATTGA ACTGGAGTGT GGGACTTCTG
-650 TAGCTTACTG GCTTATTTTC TTTCTCCTAA GACATGCCCA TTTTTTTCCT
HNFl
-600 TGAGCTCATT TTGCTGTTTT GTGCTGTTAA TTTTTAATTG CTTCAGACTT
C/EBP ^ C/EBP
-550 GGGTGTTGGG GGTGGGGCAA GGCTGAGATT TGGCTTGAGT TTGGCTCTAT
-500 TTGTATCCTT CATATTTCCC AAAAGCCCCA CATGCTCGCT CTCTCTCTCT
HNFS
-450 CTCTCTCTCT CTCTCTCTCT CTCTCTCTCT CTCTCTCTCT GTGTGTGTGT
GRE
-400 GTGTGTGTGT GTGTGTATGT GTGTGTGTCC TTCCTCCCTC CTTCTCTCCA
CACCC ,
-350 TCCCTCCTTC CTTCCTTTCC TCCCACCCTC CCTCCTCCTC TCCTTCTATC
CACCC
^ CACCC
-300 CCGCCCTTCC ACCCCTCCAC CCTCCCTCCC TGACAAGCCA TTCTTGCAAG
-2 50 GCCATTGCTG CTGTGTGCAA AGGATGTCTC GGTAGGAGAT GCTCAGGAAC
AP2
-200 CCAGCCCTGC ACAGTCATGA GCCTGGCCAT CTGGAAGTTG CCTCTTACTC
-150 AATGAAATGG AGTAAACATT GTCCATTATG AAATCCATCA CGCAGGCTCC
CACCC CCAAT
-100 CAGGGACGAA TGGGATCCCA CCCAAAGCCA ATCATTGCTC TGACAGGGAA
^
C/EBP
-50 GTTGGCTAGT GCTGCCTGAG ACTACTCCAG CCTCCCCCGT CCCTGATGTC
+1 lACAATTCAGA GGCTGCTGCT GCCTGGGAAG GTTGTAGAAA GAGCTGCAGG
GRE ^
+51 TTTTCTTTGT GTGTCCTACA GAGCTCCCTG AGCCAGGTCC CTGTTGGACG
Figure 3.1 Sequence of the proximal promoter of the rat llfi-HSDl gene showing
putative transcription factor binding sites
Nucleotide sequence of lkb of the rat 116-HSD1 gene promoter showing putative
transcription factor binding sites; CACCC boxes, a CCAAT box, oestrogen and
glucocorticoid response element half sites, identified by (Moisan et al., 1992) are
shown, as well as putative binding sites for C/EBP, HNF-1, HNF-5 and AP2
identified by comparison of known transcription factor binding sequences (Locker,
1993).
3.2 Results
3.2.1 The llfi-HSDl promoter binds rat liver nuclear proteins
To investigate potential transcription factor interaction with the rat 118-HSD1
promoter, DNase I protection analysis and gel mobility shift assays were carried out
on a fragment of the rat 11B-HSD1 gene encoding -88 to +47 (fragment FA) (for
details of all DNA fragments used, refer to Chapter 2, Figure 2.1). In gel mobility
shift assays, 4 or 5 specific complexes (the exact number varied from experiment to
experiment) were formed by rat liver nuclear extract on fragment FA (Figure 3.2).
Competition analysis was used to demonstrate the specificity of these complexes; all
of the complexes were competed by a 10- or 100-fold molar excess of unlabelled
fragment FA, but not by a 10- or 100-fold molar excess of a similar sized non-specific
fragment, FNS (Figure 3.2).
To identify where transcription factors were binding on the 11B-HSD1 promoter,
DNase I protection analysis was carried out on fragment FA encoding -88 to +47
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( P-label was incorporated at the 3' end of the fragment, on the lower strand) (Figure
3.3). Three regions of protection were observed. At the lowest concentration of liver
nuclear proteins (5|J.g), a single, clear region of protection was observed over the
transcription start (+1) from -8 to +9 (Figure 3.3). At higher concentrations of liver
nuclear extract additional footprints were formed between +27 to +39, and weaker
footprints at -54 to -36 (Figure 3.3). In some experiments a footprint was formed
between -74 and -61 (encompassing the GCAAT sequence in the C/EBP binding
site) but was not apparent in all DNase I protection experiments (Figure 3.18). In
addition to the three regions that were protected from DNase I digestion by liver
nuclear extract (Figure 3.3), a number of sites showed increased sensitivity to
DNase I in the presence of rat liver nuclear extract; these were located primarily at
the edges of the stronger footprints (at -8 to +9 and at +27 to +40) and also between
the two footprints (Figure 3.3). Footprint analysis of the top strand revealed
protection at the transcription start between -10 and +12, however no footprint was
apparent between +27 and +39 (Figure 3.4).
64
Figure 3.2 Factors in rat liver nuclear extract bind to the rat llfi-HSDl promoter
Gel mobility shift assay using the 11B-HSD1 promoter fragment, FA (-88 to +47) and
rat liver nuclear extract. 8(ig rat liver nuclear extract was incubated with 30fmol of
[32P]-labelled FA in the absence of added competitor DNA fragment, or in the
presence of 10- or 100-fold molar excess of unlabelled competitor DNA, either FA
(lanes 3, 4) or a non-specific competitor, FNS, (lanes 5, 6). Lane 1 contained no
nuclear extract. Arrows indicate specific protein-DNA complexes.
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Figure 3.3 Factors in rat liver nuclear extract bind to the transcription start of the
1 lfi-HSDl promoter (lower strand)
DNase I protection analysis of the lower strand of the rat 1113-HSD1 gene promoter
between -88 and +47 (FA). Panel A and panel B change show the same reactions,
with panel B having been electrophoresed for longer. Lane 1, G+A Maxam and
Gilbert sequencing reactions. Lane 2, no nuclear extract added. Lanes 3-6 contain
increasing amounts of rat liver nuclear extract; 5|ig (lane 3), 10(ig (lane 4), 20jxg
(lane 5) and 50|Ltg (lane 6). Brackets indicate regions of DNA protected from DNase































3.2.2 C/EBP-related factors in rat liver nuclear extract bind to the llfi-HSDl
promoter (-88 to +47)
To explore the identity of factors producing footprints on FA, gel mobility shift
analysis was carried out using a series of oligonucleotides, either as labelled binding
sites or unlabelled competitors. The oligonucleotides used are detailed in Chapter 2,
Table 2.1 and include 0A, corresponding to the strong footprint over the transcription
start; overlapping oligonucleotides Ob and Oc, encompassing the GCAAT and
CCAAT sequences at -73 and -67 respectively, and oligonucleotide Oe encoding an
optimal binding site for the liver enriched transcription factor C/EBP. Oe
corresponds to an extended version of a consensus sequence devised by Nye and
Graves (Nye & Graves, 1990) and binds bacterially expressed recombinant C/EBPa
(rC/EBPa) in gel mobility shift assays (data not shown; but see also Figure 3.17).
This oligonucleotide was included to assess the possible involvement of C/EBP-
related proteins in binding either to the CCAAT sequence at -73 or to the
transcription start (which shows a weak resemblance to a consensus C/EBP site). 0E
was used initially to demonstrate the presence of C/EBP or C/EBP-related proteins in
rat liver nuclear extract. Competition gel mobility shift analysis of complexes formed
by liver nuclear extract on the C/EBP-binding oligonucleotide, 0E, identified 2
specific complexes which were fully competed by a 10-fold molar excess of specific
competitor oligonucleotide (0E), but not by a 100-fold molar excess of the non¬
specific oligonucleotide, Ons, encoding the oestrogen response element (ERE) from
the rat prolactin gene (Maurer & Notides, 1987) (Figure 3.5). This result confirmed
that C/EBP or C/EBP-related proteins are present in rat liver nuclear extract. Some
members of the C/EBP family, including C/EBPa, C/EBPB and C/EBP8 are resistant
to heat treatment (Chang et al., 1990; Johnson et al., 1987; Roman et al., 1990).
When gel mobility shift assays were performed using rat liver nuclear extract which
had been heated to 65°C for lOmin, the same pattern of binding to FA was produced
for both heat-treated and non-heat treated extracts (with the possible exception of the
lowest mobility complex which was lost upon heat treatment) (Figure 3.6),
suggesting that members of the C/EBP family resistant to heat treatment are present
in the complexes formed by rat liver nuclear extract on the proximal 116-HSD1
promoter (-88 to +47).
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Figure 3.4 Factors in rat liver nuclear extract bind to the transcription start of the
llfi-HSDl promoter (upper strand)
DNase I protection analysis of the upper strand of the rat 116-HSD1 gene promoter
between -88 and +47 (FA ). Lane 1, no nuclear extract added. Lanes 2-6 contain
increasing amounts of rat liver nuclear extract; 3pg (lane 2), 6pg (lane 3), 12|ig (lane
4), 18(ig (lane 5) and 40[ig (lane 6). Brackets indicate regions of DNA protected
from DNase I digestion by rat liver nuclear extract. Nucleotide postions were
estimated by comparison with similar gels on which molecular size standards were
run.
 
Figure 3.5 Factors from liver nuclear extract bind to a synthetic C/EBP binding
oligonucleotide
Gel mobility shift analysis of rat liver nuclear extract binding to Oe, encoding an
optimal C/EBP binding site. 8pg rat liver nuclear extract was incubated with O.lpmol
of [32P]-labelled Oe in the absence of added competitor oligonucleotide (lane 2) or in
the presence of 10- or 100-fold molar excess of competitor oligonucleotide (lanes 3-
6), as indicated above the lanes. Lane 1 contained no nuclear extract. Arrows indicate
specific protein-DNA complexes.
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Figure 3.6 Heat treatment of rat liver nuclear extract does not alter complex
formation on fragment FA, encoding -88 to +47 of the llfi-HSDl promoter
Gel mobility shift analysis of heat treated rat liver nuclear extract binding to [32P]-
labelled FA. Lane 2 contains 5fig of liver nuclear extract which has not been heat




Initially, it seemed probable that an initiator-binding protein may be responsible for
the footprint formed at the transcriptional start, which displayed some similarity to an
initiator element (a comparison of the 11B-HSD1 gene from -10 to +10 with the TdT
initiator binding sequence (Smale and Baltimore, 1989) and a C/EBP binding
sequence (Nye and Graves, 1990) are shown in Figure 3.7). However, no
competition of complexes formed on FA was seen by oligonucleotide Ot,
corresponding to the TdT initiator element (Smale and Baltimore, 1989) (Figure 3.8),
suggesting that TdT initiator binding proteins are not involved in binding to the 116-
HSD1 initiator element, and consistent with the results of heat treatment
demonstrating that all protein binding to FA was relatively heat stable. In contrast,
0E, encoding an optimal C/EBP site, proved a strong competitor, eliminating
complex formation on FA at 10-fold molar excess of competitor (Figure 3.8) again
suggesting the involvement of C/EBP or C/EBP related proteins in binding to FA.
The DNA binding specificity of the liver nuclear protein(s) which bind to the
transcription start site were examined in gel mobility shift assays using a double
stranded oligonucleotide 0A, corresponding to the protected region and the flanking
sequences (-14 to +15). At least four protein-DNA complexes were formed on Oa by
rat liver nuclear extract (Figure 3.9), indicating heterogeneity of protein binding to
this site. The identity of the protein(s) binding to the transcriptional start were
explored using a series of oligonucleotides (for oligonucleotide sequences see
Chapter 2, Table 2.1) as competitors in gel mobility shift assays. Competition with
unlabelled oligonucleotide 0A demonstrated the specificity of these complexes
(Figure 3.9). 0E, encoding an optimal binding site for the C/EBP family of
transcription factors competed for rat liver nuclear protein binding as effectively as
oligonucleotide Oa. Furthermore, a 100-fold molar excess of an oligonucleotide
corresponding to the P3(I) C/EBP binding site in the PEPCK gene, Oq (Park et al.,
1990), also competed for liver nuclear protein binding to oligonucleotide 0A,
although not as effectively as oligonucleotides Oa or Oe (Figure 3.9), implicating the
C/EBP family of proteins in binding to the transcription start of the 11B-HSD1 gene.
Oligonucleotides 0B and Oc (encoding the CCAAT sequence at -73 and the GCAAT
sequence at -67) showed little or no competition (Figure 3.9). When the same
oligonucleotides were used as competitors for liver nuclear protein binding to
fragment FA (-88 to +47 of the 116-HSD1 gene) the same rank order of competition
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Figure 3.7 Comparison of the llfi-HSDl transcription start region with TdT initiator
and C/EBP binding sequences
Sequence comparison of -10 to +10 of the 118-HSD1 gene (Green), the transcription
start is underlined, with a known C/EBP binding site (orange) (Nye & Graves, 1990),
and the TdT initiator binding element (blue) (Smale & Baltimore, 1989). Matching
nucleotides are indicated by the boxes.
CAGAGCCCTCATTCTGGAGA T<IT
■ Si H H H B H H ®§
CCCTGATGTCACAATTCAGA 11B-HSD1
TCCCAATTGCCCAATCAGGA C/EBP
Figure 3.8 The TdT initiator element does not compete for complexformation on FA
Competition gel mobility shift assay using fragment Fa (encoding -88 to +47 of the
116-HSD1 gene) and rat liver nuclear extract. 8(ig rat liver nuclear extract was
incubated with 30fmol of [32P]-labelled FA in the absence of added competitor
oligonucleotide (lane 2) or in the presence of 10- or 100-fold molar excess of
competitor oligonucleotides (lanes 3-12), as indicated above the lanes. Lane 1
contained no nuclear extract. Arrows indicate specific protein-DNA complexes.
Oligonucleotides used were: Ob, 11J3-HSD1 (-88 to -57); Oc, 116-HSD1 (-71 to -52);
Oe, optimal C/EBP site; 0T, TdT initiator element; 0NS, prolactin ERE (non-specific
control).
 
Figure 3.9 Liver nuclear proteins form complexes with the transcription start
oligonucleotide Of\
Gel mobility shift analysis demonstrating binding of rat liver nuclear extract to Oa,
encoding -14 to +15 of the 11B-HSD1 gene. 10|J.g rat liver nuclear extract was
incubated with O.lpmol of [32P]-labelled 0A in the absence of added competitor
DNA fragment (lane 2) or in the presence of 10- or 100-fold molar excess of
competitor oligonucleotide (lanes 3-14), as indicated above the lanes. Lane 1
contained no nuclear extract. Arrows indicate specific protein-DNA complexes;
* indicates a non-specific complex.
Oligonucleotides used were: 0A, 11B-HSD1 (-14 to +15); Ob, 11B-HSD1 (-88 to
-57); Oc, 11B-HSD1 (-71 to -52); Od, PEPCK P3(I) site; 0E, optimal C/EBP site;
Ons, prolactin ERE (non-specific control).
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was observed, with 0A> Oe> 0D» 0B> Oc (Figure 3.10). The lack of competition
by 0B and Oc (encoding the CCAAT box at -73 or the GCAAT sequence at -67
respectively of the 1113-HSD1 gene) (Figure 3.9 and Figure 3.10), is consistent with
the absence of a footprint over these sequences in DNase I protection analysis, and
suggests that these sequences, present in a position typical of such regulatory
elements, play little or no role in the expression of 11B-HSD1 in rat liver. These
results suggest that all the nuclear proteins which bind to fragment FA and
oligonucleotide 0A have identical or very similar DNA-binding specificity, and are
probably members of the C/EBP family of transcription factors.
Bakker and Parker have reported that C/EBP binds to oligonucleotides encoding
binding sites for Activating Transcription Factor (ATF)/CREB, but binds weakly or
not at all to oligonucleotides encoding AP-1 sites (Bakker and Parker, 1991). To see
if a similar pattern of specificity existed for rat liver nuclear proteins which bind to
Fa and Oa, a series of oligonucleotides encoding CREs or AP-1 sites were used as
competitors in gel mobility shift assays (refer to Chapter 2, Table 2.1 for
oligonucleotide sequences) (Figure 3.11). Oj, encoding a CRE from the bovine
preprotachykinin A gene (PPT-A) (Kageyama et al., 1991) proved the strongest
competitor, fully competing complex formation on FA at 100-fold molar excess
(Figure 3.11). Both Oi and 0K (encoding respectively a somatostatin CRE
(Montminy et al., 1986) and an AP-1 site which binds Fos/Jun, J. Quinn, Personal
communication) effectively competed at 100-fold molar excess. Either very little or
no competition was observed with the other oligonucleotides used; Ol (encoding a
sequence in the arginine vasopressin (AVP) gene which binds Fos/Jun, J. Quinn,
Personal communication), 0M (encoding a sequence at -60 of the rat PPT-A gene
promoter which does not bind anything, J. Quinn, personal communication) and 0N
(encoding an E-box-like sequence, J. Quinn, personal communication). None of the
oligonucleotides were as effective as 0A at competing complex formation; this
pattern of specificity is consistent with the results of Bakker & Parker, 1991 who
found that ATF sites competed approximately 5-fold less well than C/EBP sites and
that AP-1 sites competed weakly, if at all. The same rank order of competition was
seen with liver nuclear extract binding to Oa, with Oa> Oj> Or> Ok> Ol= 0M= On =
Ons (Figure 3.12).
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Figure 3.10 Protein-DNA complexes formed on the llfi-HSDl promoter (-8S/+47)
contain C/EBP-related transcription factors
Competition gel mobility shift assay using fragment Fa (encoding -88 to +47 of the
11B-HSD1 gene) and rat liver nuclear extract. 8p.g rat liver nuclear extract was
incubated with 30fmol of [32P]-labelled FA in the absence of added competitor
oligonucleotide (lane 2) or in the presence of 10- or 100-fold molar excess of
competitor oligonucleotides (lanes 3-14), as indicated above the lanes. Lane 1
contained no nuclear extract. Arrows indicate specific protein-DNA complexes.
Oligonucleotides used were: 0A, 11B-HSD1 (-14 to +15); Ob, 11B-HSD1 (-88 to
-57); Oc, 11B-HSD1 (-71 to -52); Od, PEPCK P3(I) site; 0E, optimal C/EBP site;
0NS, prolactin ERE (non-specific control).
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Figure 3.11 ATF/CREB binding oligonucleotides compete complex formation on the
llfi-HSDl promoterfragment
Gel mobility shift analysis using rat liver nuclear extract and the 11B-HSD1
promoter fragment -88 to +47 (FA). 10|lg rat liver nuclear extract was incubated with
30fmol of [32P]-labelled FA in the absence or in the presence of 10- or 100-fold molar
excess of competitor oligonucleotide (lanes 3-18), as indicated above the lanes. Lane
1 contained no nuclear extract. Arrows indicate specific protein-DNA complexes.
Oligonucleotides used were: 0A, 11B-HSD1 (-14 to +15); somatostatin CRE; Oj,
PPT-A CRE; Ok, AP-1 site; 0L, AVP API site; 0M, PPT-A (-60); On, E-box; Ons,




Figure 3.12 ATF/CREB binding oligonucleotides compete complex formation on the
1 lfi-HSDl transcription start
Gel mobility shift analysis using rat liver nuclear extract and the 11B-HSD1
promoter oligonucleotide (0A). 10|ig rat liver nuclear extract was incubated with
30fmol of [32P]-labelled FA in the absence or in the presence of 10- or 100-fold molar
excess of competitor oligonucleotide (lanes 3-18), as indicated above the lanes. Lane
1 contained no nuclear extract. Arrows indicate specific protein-DNA complexes;
* indicates a non-specific complex.
Oligonucleotides used were: Oa, 11B-HSD1 (-14 to +15); 0I; somatostatin CRE; Oj,
PPT-A CRE; Ok, AP-1 site; Ol, AVP API site; 0M, PPT-A (-60); 0N, E-box; Ons,
prolactin ERE (non-specific control).
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Members of the C/EBP family include C/EBPa (Johnson et al., 1987; Landschultz et
al., 1988), C/EBPG (Akira et al., 1990; Chang et al., 1990; Poli et al., 1990), C/EBPy
(Roman et al., 1990), C/EBPS (Cao et al., 1991; Williams et al., 1991) and C/EBPe
(Williams et al., 1991), all of which contain a basic-leucine zipper domain required
for dimerisation and DNA binding, and which can form homo- or heterodimers
through the leucine zip region (reviewed in Chapter 1, Section 1.4.2.1.2). Most of the
C/EBP DNA-binding activity in rat liver under normal conditions consists of
C/EBPa and C/EBPB (Williams et al., 1991). We have used antisera specific for
C/EBPa or C/EBPB in gel mobility supershift analysis to determine the relative
contributions of C/EBPa and G in binding to the transcription start of the rat 11B-
HSD1 gene. Incubation of C/EBPa antiserum with rat liver nuclear extract and
fragment Fa resulted in decreased intensity of the upper two protein-DNA complexes
(the lower two complexes were unaffected), and the appearance of additional lower-
mobility 'supershifted' complexes (Figure 3.13). Similarly, when antiserum against
C/EBPG was added, a reduction was seen in the intensity of the complexes formed on
Fa, and an additional low-mobility supershifted complex became apparent (Figure
3.13). Addition of C/EBPa and C/EBPG antisera together virtually eliminated three
of the four complexes formed on Fa and attenuated the remaining complex, whereas
control antiserum (raised against COUP-Transcription Factor; COUP-TF) did not
affect nuclear protein binding to Fa (Figure 3.13). This demonstrates the presence of
either C/EBPa or C/EBPG in the majority of the complexes formed on Fa-
Qualitatively similar results were seen with oligonucleotide Oa (Figure 3.14), which
spans the transcription start. Most of the complexes formed on Oa contained either
C/EBPa and/or C/EBPG (Figure 3.14). The one, high mobility, specific complex
which was not supershifted when both antisera were added together, was competed
in gel mobility shift analysis by C/EBP binding oligonucleotides. This indicates that
the factor giving rise to this complex may also be related to C/EBP, but that it is not
C/EBPa or C/EBPG.
3.2.3 Recombinant C/EBPa protein binds to the llfi-HSDl transcription start
To further investigate the involvement of C/EBPa in binding to the transcription start
of 11B-HSD1, a 35kDa fragment of rat C/EBPa lacking the N-terminal 60 amino
acids (encoded by pT5; (Landschulz et al., 1989)) expressed in E. coli, was used, in
gel mobility shift assays, DNase I protection and methylation interference
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Figure 3.13 C/EBPa and C/EBPfi from rat liver nuclear extract bind to the llfi-
HSD1 promoter
Gel mobility supershift analysis of complexes formed on the 11B-HSD1 promoter by
rat liver nuclear extract. lOptg rat liver nuclear extract was incubated with 30fmol of
[32P]-labelled FA in the absence of antisera (lane 2), or with antisera added (lane3,
lptg of C/EBPa antisera; lane 4, lptg of C/EBPB antisera; lane 5, 1 pig C/EBPa
antisera and lptg C/EBPB antisera; lane 6, 1 pig COUP-TF antisera). Lane 1 contained
no nuclear extract. Supershifted complexes are indicted by arrows.
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Figure 3.14 C/EBPa and C/EBPfi form complexes on the transcription start of the
llfi-HSDl promoter
Gel mobility supershift analysis of complexes formed on the 11G-HSD1 promoter by
rat liver nuclear extract. lOpg rat liver nuclear extract was incubated with O.lpmol of
[32P]-labelled Oa in the absence of antiserum (lane 2), or with antiserum added; (lane
3, lpg of C/EBPa antiserum; lane 4, lpg of C/EBPG antiserum; lane 5, ljig C/EBPa
antiserum and 1 jug C/EBPB antiserum; lane 6, ljtg COUP-TF antiserum). Lane 1
contained no nuclear extract. Supershifted complexes are indicted by arrows;





Figure 3.15 Bacterially expressed rC/EBPa binds to the llfi-HSDl promoter
Gel mobility shift analysis using recombinant C/EBPa protein and 11B-HSD1
promoter fragment FA, encoding -88 to +47. 0.1|ig bacterial extract containing
rC/EBPa protein was incubated with 30fmol of [32P]-labelled FA in the absence or in
the presence of 10- or 100-fold molar excess of competitor DNA fragment (lanes 3-
6), as indicated above the lanes. Lane 1 contained no nuclear extract. Arrows indicate
specific protein-DNA complexes.
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experiments. Bacterially expressed rC/EBPa formed 3 discrete specific complexes
on fragment Fa (Figure 3.15). Addition of competitor oligonucleotides at 10- or 100-
fold molar excess gave the same pattern of competition as seen with liver nuclear
extract, with Oa (-14 to +15 of 11B-HSD1) > Oe (optimal C/EBP site) > Oq (PEPCK
P3(I) C/EBP site) » Ob, Oc and O^s (respectively, the 11G-HSD1 CCAAT box at -
70, the 11G-HSD1 GCAAT sequence at -65 and the non-specific control) (Figure
3.16). The mobility of the complexes produced on fragment Fa by rC/EBPa was
similar to that of the liver nuclear protein complexes which were supershifted by the
C/EBPa antiserum (Figure 3.16; compare with Figure 3.13). A single specific
complex was formed by rC/EBPa on oligonucleotide Oa, of similar electrophoretic
mobility to that of the major complex (containing C/EBPa) formed by liver nuclear
proteins on Oa, which again showed the same specificity with competitor
oligonucleotides as seen with liver nuclear proteins (Figure 3.17).
Comparison of the footprints produced by rat liver nuclear proteins and rC/EBPa on
fragment Fa showed clearly that both protect very similar regions from digestion by
DNase I, including the strongly protected region (-8 to +9) over the transcription start
site (Figure 3.18). Similar weak footprints were generated by liver nuclear proteins
and rC/EBPa at -54 to -36 and over the CCAAT box at -73 (Figure 3.18) (this very
weak footprint was not observed in some experiments). rC/EBPa, however, only
weakly protected the site at +27 to +39, indicating that C/EBP-related factors are
capable of binding to the region between +27 and +39, but suggesting that the
protein in liver nuclear extracts which binds to this site is probably not C/EBPa. In
addition, rC/EBPa did not generate the DNase I hypersensitive sites observed in the
presence of rat liver nuclear extract (Figure 3.18).
3.2.4 Additional evidence for C/EBP binding to the transcription start
Methylation interference analysis was used to compare the specific contacts made to
fragment Fa by rC/EBPa and liver nuclear proteins. Methylated DNA was incubated
with liver nuclear extract or bacterial extract containing rC/EBPa and subjected to
preparative gel mobility shift analysis. Five complexes (C1-C5) produced by liver
nuclear extract, and three complexes (C1-C3) produced by rC/EBPa were excised
from the gel, as well as the free DNA not bound by protein. Methylated DNA was
eluted, cleaved at methylated G residues, and electrophoresed on a denaturing
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Figure 3.16 Recombinant C/EBPa-llfi-HSDl promoter complexes are competed by
C/EBP-binding oligonucleotides
Gel mobility shift analysis using recombinant C/EBPa protein and 11B-HSD1
promoter fragment FA. O.lftg bacterial extract containing rC/EBPa protein was
incubated with 30fmol of [32P]-labelled FA in the absence or in the presence of 10- or
100-fold molar excess of competitor oligonucleotide (lanes 3-14), as indicated above
the lanes. Lane 1 contained no nuclear extract. Lane 15 contains lOpg of liver
nuclear extract instead of recombinant C/EBPa. Arrows indicate specific protein-
DNA complexes.
Oligonucleotides used were: Oa, 11B-HSD1 (-14 to +15); Ob, 116-HSD1 (-88 to
-57); Oc, 116-HSD1 (-71 to -52); Od, PEPCK P3(I) site; Oe, optimal C/EBP site;
Ofsjs, prolactin ERE (non-specific control).







Figure 3.17 Recombinant C/EBPa protein forms a complex with the 11J3-HSD1
transcription start site oligonucleotide, 0A
Gel mobility shift analysis using rC/EBPa protein and the oligonucleotide
encompassing the 11B-HSD1 transcription start 0A. O.ljig bacterial extract
containing rC/EBPa protein was incubated with O.lpmol of [3~P]-labelled 0A in the
absence or in the presence of 10- or 100-fold molar excess of competitor DNA
fragment (lanes 3-14), as indicated above the lanes. Lane 1 contained no nuclear
extract. Lane 15 contains 10pg of rat liver nuclear extract added instead of rC/EBPa.
Arrows indicate specific protein-DNA complexes.
Oligonucleotides used were: Oa, 11B-HSD1 (-14 to +15); Ob, 11B-HSD1 (-88 to
-57); Oc, 11B-HSD1 (-71 to -52); Od, PEPCK P3(I) site; 0E, optimal C/EBP site;
Ons, prolactin ERE (non-specific control).
 
Figure 3.18 Recombinant C/EBPa binds similar sites to liver nuclear proteins on the
llfi-HSDl promoter
DNase I protection analysis of the 11B-HSD1 promoter fragment FA, encoding -88 to
+47 using rat liver nuclear extract and recombinant C/EBPa protein. Lane 1, Maxam
and Gilbert sequencing reaction used as size markers; lane 2, no added protein; lane
3, 50|ig of rat liver nuclear extract; lane 4, 0.5|ig of bacterial extract containing
rC/EBPa. Brackets indicate regions of DNA protected from DNase I digestion by rat
liver nuclear extract. Arrows indicate nucleotides hypersensitive to DNase I. Dashed
bracket indicates weak region of protection.
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polyacrylamide gel. DNA methylated at positions -1 and +2 and to a lesser extent at
position +7, was under-represented in the DNA recovered from complexes C1-C5
produced by liver nuclear proteins on fragment Fa (Figure 3.19 and Table 3.1). In
contrast, DNA methylated at these three positions, -1, +2 and +7 was enriched in the
free DNA, not bound to protein (Table 3.1 and Figure 3.19). Similarly, DNA
methylated at -1, +2 and, to a lesser extent, +7 prevented binding of rC/EBPa to
fragment Fa (Figure 3.20). Mutation of oligonucleotide Oa at -1 (0G) or -1 and +2
(Oh) reduced (Og), or virtually eliminated (0H), binding of both liver nuclear extract
and rC/EBPa in gel mobility shift assays (Figure 3.21). Furthermore, the use of Og
(mutated at -1) and Oh (mutated at -1 and +2) as competitors in gel mobility shift
analysis of complexes formed by liver nuclear extract or rC/EBPa (Figure 3.22 and
3.23 respectively) on oligonucleotide (Oa) revealed an affinity order Oa> Og> Oh.
These data demonstrate the importance of the G residues at -1 and +2 for C/EBP
binding to the 1113-HSDl transcription start.
3.3 Discussion
In this chapter I have described binding by members of the C/EBP transcription
factor family to the proximal promoter of the rat 11B-HSD1 gene. DNase I protection
analysis identified similar sites of binding by rat liver nuclear proteins and rC/EBP.
The main binding site, apparent at the lowest concentrations of liver nuclear extract,
was between -8 and +9, encompassing the transcription start. Gel mobility shift
assays using oligonucleotide competitors identified C/EBP-related factors binding
between -88 to +47, and more specifically, to the transcription start. G residues at -1
and +2 on the lower strand were shown to be important for binding of liver nuclear
proteins and rC/EBPa to the transcription start. At higher concentrations of liver
nuclear extract a second footprint became apparent within exon 1, between +27 and
+39. Additionally, two partially protected regions were observed 5' of the
transcription start, at -74 to -61 and -54 to -36. DNase I hypersensitive sites were
generated by liver nuclear extract but not by rC/EBPa. The hypersensitive
nucleotides were located at borders of footprints and between footprints with spacing
at approximately 10 base pair intervals, a pattern of hypersensitivity associated with
DNA bending (Hochschild & Ptashne, 1986). This may reflect an interaction
between C/EBP (and possibly associated proteins) at the transcription start with
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Figure 3.19 Specific nucleotide contacts are made at the transcription start by
factorsfrom rat liver nuclear extract
Methylation interference analysis of the rat 11B-HSD1 gene promoter using rat liver
nuclear extract. Lane 1, Maxam and Gilbert G+A sequencing reaction used as size
marker; lane 2, cleavage pattern of total methylated DNA with no extract added; lane
3, free DNA excised from a gel mobility shift reaction that included rat liver nuclear
extract; lanes 4-8, DNA eluted from complexes excised from preparative non-
denaturing gels (Cl=lowest mobility complex, C5=highest mobility complex).
Arrows indicate G residues that, when methylated, interfere with binding by
rC/EBPa protein.
M+G 0 F CI C! O a C5
1 2*V 4 5* 6 7 8
Total DNA Complexed DNA
(mean ± SEM)
Free DNA
+16 100 100 100
+13 54 55.8 ± 2.5 48
+7 59 52.3 ± 4.6 75
+2 77 59.3 ± 3.3 185
-1 36.8 36.8 ± 3.3 139
-7 32.5 32.5 ± 2.5 85
-9 71.3 71.3 ± 5.0
Table 3.1 Quantitation of interference by DNA methylation of liver nuclear extract
binding to the transcription start of 11fi-HSDl
Densitometric scanning of the autoradiograph shown in Figure 3.19. Positions of
guanine nucleotides which have been analysed are indicated in the left hand column.
For each lane the optical density of the G residue at +16 has been arbitrarily set to
100%, and the optical density of all other G bands in that lane is expressed as a
percentage of the +16 signal. Total DNA; results from the densitometric scanning of
lane 2 in Figure 3.19, containing total DNA (which had not been excised from a gel).
Complexed DNA; combined data from the densitometric scanning of lanes 4-8 in
Figure 3.19 expressed as mean ± SEM. Free DNA; results from the densitometric
scanning of lane 3 in Figure 3.19 corresponding to DNA that did not bind nuclear
extract.
Figure 3.20 Recombinant C/EBPa forms specific nucleotide contacts at the
11J3-HSD1 transcription start
Methylation interference analysis of the rat 116-HSD1 gene promoter using
rC/EBPoc. Lane 1, Maxam and Gilbert G+A sequencing reaction used as size marker;
lane 2, free DNA excised from a gel mobility shift reaction that included rC/EBPa
protein. Lanes 3-5, DNA eluted from complexes excised from preparative non-
denaturing gels (Cl=lowest mobility complex, C3=highest mobility complex); lane
6, cleavage pattern of total methylated DNA with no extract added. Arrows indicate











Figure 3.21 Effect of mutation at -1 and +2 on binding of rat liver nuclear extract
and rC/EBPa to the transcription start
Gel mobility shift analysis comparing complexes formed by rat liver nuclear extract
and rC/EBPa protein on the 11B-HSD1 transcription start oligonucleotide, 0A and
derivatives mutated at -1 (Og) or -1 and +2 (0H). All lanes contain O.lpmol of [32P]-
labelled oligonucleotide. Lanes 1, 4 and 7 contain Oa; lanes 2, 5 and 8 contain Og;
lanes 3, 6 and 9 contain Oh. Lanes 4-6 contain 10p,g of rat liver nuclear extract and
lanes 7-9 contain 0.1 (LLg bacterial extract containing rC/EBPa. Arrows indicate
specific protein-DNA complexes; * indicates a non-specific band.
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Figure 3.22 Mutation at -1 and +2 reduces binding of rat liver nuclear proteins to
the transcription start
Gel mobility shift analysis using rat liver nuclear extract and the 11B-HSD1
promoter oligonucleotide, 0A. 10|ig rat liver nuclear extract was incubated with
lpmol of [32P]-labelled Oa in the absence or in the presence of 10- or 100-fold molar
excess of competitor oligonucleotide (lanes 3-10), as indicated above the lanes. Lane
1 contained no nuclear extract. Arrows indicate specific protein-DNA complexes;
* indicates a non-specific band.
Oligonucleotides used were: 0A, 11B-HSD1 (-14 to +15); Oc, 11B-HSD1 (-14 to +15
mutated at -1); Oh, 116-HSD1 (-14 to +15 mutated at -1 and +2); 0NS, prolactin ERE
(non-specific control).
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Figure 3.23 Mutation at -1 and +2 reduces binding of rC/EBP to the transcription
start
Gel mobility shift analysis using rC/EBPa and the 11B-HSD1 promoter
oligonucleotide, 0A. O.ljig rC/EBPa was incubated with O.lpmol of [32P]-labelled
Fa in the absence or in the presence of 10- or 100-fold molar excess of competitor
oligonucleotide (lanes 3-10), as indicated above the lanes. Lane 1 contained no
nuclear extract. Arrows indicate specific protein-DNA complexes; * indicates a non¬
specific band.
Oligonucleotides used were: Oa, 116-HSD1 (-14 to +15); Og, 11B-HSD1 (-14 to +15
mutated at -1); 0H, 11B-HSD1 (-14 to +15 mutated at -1 and +2); 0NS, prolactin ERE
(non-specific control).
COMPETITOR 1 oNS " oA " oG lr_o^ 1
• <= WELLS
proteins bound elsewhere on the promoter forming a nucleoprotein complex. The
absence of hypersensitive sites when rC/EBPa is bound to the promoter suggests that
other proteins (or possibly the N-terminal 60 amino acids of C/EBPa, missing from
the protein used here (Landschultz et al., 1988)) are necessary to generate the
hypersensitive sites. C/EBPa and C/EBPB were identified in complexes formed at
the transcription start and it is likely that they are involved in the regulation of 116-
HSD1 transcription in liver.
The C/EBP family of transcription factors is widely expressed and shows a
differential pattern of expression (Williams et ah, 1991). C/EBPa and C/EBPB
mRNAs show a similar distribution, with highest levels in liver, moderate expression
in lung, kidney, adipose tissue, placenta and specific regions of brain, and lower
levels elsewhere (Kuo et ah, 1990; Williams et ah, 1991), a pattern of expression
resembling that of 11B-HSD1 (Agarwal et ah, 1989; Moisan et ah, 1990a). In
contrast, C/EBP8 is expressed at highest levels in lung (Williams et ah, 1991), and
low levels in liver under basal conditions (Cao et ah, 1991), although it is induced in
liver under certain pathological conditions (Alam et ah, 1992). The majority of the
complexes formed on the 116-HSD1 promoter fragment FA and transcription start
oligonucleotide 0A contained C/EBPa and/or C/EBPB. The two lowest mobility
complexes formed on FA and Oa contained predominantly C/EBPa, and faster
migrating complexes possibly contained heterodimers of C/EBPa and C/EBPB or
other C/EBP-like factors. Only one, high mobility, specific complex was not
supershifted when both antisera were added together to gel mobility shift assays.
This complex was, however, competed on gel mobility shift analysis by C/EBP-
binding oligonucleotides, indicating that it is likely to involve a member of the
C/EBP family. It is possible that the high mobility specific complex contains (i) a
degradation product of either C/EBPa or C/EBPB that has lost the epitope for the
antibody, (ii) an alternative translation product of C/EBPa or C/EBPB protein with a
truncated N-terminus which lacks part of the transactivation domains and
consequently binds DNA but does not activate transcription, (Descombes & Schibler,
1991; Ossipow et al., 1993), (iii) that it contains the C/EBP-related protein, DBP
(Mueller et al., 1990). However, all of these possibilities are unlikely. DBP has a
molecular size of 39kDa (Mueller et al., 1990) and would be expected to migrate
through the gel with a mobility comparable to, or only slightly faster than, C/EBPa.
71
The peptide against which the C/EBPB antiserum was raised includes part of the
leucine zipper region, and corresponds to the C-terminal 19 amino acids of the
protein, which is present in LIP (Descombes and Schibler, 1991), a shorter C/EBPB
translational product, and which would be present in any degradation products of
C/EBPB still able to bind to DNA. The C/EBPa antiserum was raised against a
peptide corresponding to the N-terminus of a 14kDa degradation product of C/EBPa,
which was the major degradation product when C/EBPa was isolated from liver
(Landschultz et al., 1988). It is possible that the high mobility specific complex
formed at the transcription start of 11B-HSD1 contains homodimers of C/EBP8. At
28kDa (Cao et al., 1991), C/EBP8 is smaller than either C/EBPa (predominantly
42kDa and 30kDa) and C/EBPB (32kDa), and would not be recognised by the
antisera used, which were specific for either C/EBPa or C/EBPB.
The relative levels of C/EBP family members varies according to cell type,
developmental stage and pathological state (Alam et al., 1992; Descombes &
Schibler, 1991; Raught et al., 1995; Williams et al., 1991; Yeh et al., 1995). The ratio
of C/EBPa and C/EBPB in liver changes in different conditions; thus, under
conditions in which the acute-phase response is activated, C/EBPa expression is
decreased and C/EBPB and C/EBP8 expression is dramatically increased (Alam et
al., 1992). C/EBPB is a weak transcriptional activator compared to other members of
the family (Poli et al., 1990), and it is likely that, by changing the ratio of C/EBPa/B,
expression of C/EBP-regulated genes is altered. Evidence suggests that this occurs;
on induction of the acute-phase response, albumin expression is transiently
decreased, possibly due to reduced expression of C/EBPa (Burke et al., 1994), and
expression of aracid glycoprotein is rapidly induced with the concomitant exchange
of C/EBPa by C/EBPB/C/EBP8 (Alam et al., 1992). In addition, evidence suggests
that transcriptional activation, and probably DNA-binding, by members of the
C/EBP family is influenced by phosphorylation (Macdougald et al., 1995; Ray and
Ray, 1994). Alteration of the ratio of C/EBPa to C/EBPB, or the phosphorylation
state of either, may alter transcription initiation at the 118-HSD1 promoter.
The position of the C/EBP site, spanning the transcription start of 11B-HSD1 is
unusual. Many C/EBP binding sites have been described in other genes, both
upstream and, in some cases, downstream from the transcription start. However,
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there is a binding site for C/EBP at +1 to +18 of the gene encoding the clotting factor
IX (Crossley & Brownlee, 1990). A naturally occurring mutation at +13 which
results in haemophilia B Leyden both disrupts binding of C/EBP to this site and
prevents transactivation of the promoter by C/EBP in transfected cells (Crossley and
Brownlee, 1990). Binding of C/EBP to the site at -8 to +9 of the 11B-HSD1 gene
promoter may be important in the basal expression of the gene possibly functioning
as an initiator-binding protein. Initiator sequences overlap the transcription start site
and determine the start of transcription in promoters which lack a TATA box, or
increase the strength of a TATA-containing promoter. A variety of proteins,
including TFII-I, USF, YY1 and HIP1, have been found to bind to initiator elements
of specific genes (Du et al., 1993; Means & Farnham, 1990; Roy et ah, 1991; Seto et
ah, 1991). In addition to binding to Inr elements at the transcriptional start sites of
specific genes, these proteins also act as transcription factors binding to sites
upstream or downstream of regulated genes (Kovesdi et ah, 1986; Means and
Farnham, 1990; Riggs et ah, 1991; Roy et ah, 1991). C/EBPa has been shown to
interact with TBP in vivo, and in vitro, C/EBPa interacts with TBP and TFIIB
(Nerlov & Ziff, 1995). The 116-HSD1 promoter lacks a TATA box; it is possible
that C/EBP binding to the transcription start site of this gene performs the function of




with the rat 11B-HSD1 gene between -812 and +74
4.1 Introduction
The rat 11B-HSD1 gene promoter contains consensus binding sites for C/EBP and
other factors (Chapter 3, Figure 3.1) within its 5' flanking region, and is regulated in
vivo by glucocorticoids, growth hormone and oestrogen (reviewed in Chapter 1,
Section 1.3.1.3). Transient transfections using a deletion series of the rat 11B-HSD1
promoter fused to a luciferase reporter gene (deleted 5' from -1799 and fused within
exon 1 at +47 with the luciferase reporter) have been carried out on HepG2 cells and
2S-FAZA cells to examine whether the 11B-HSD1 promoter is indeed regulated by
C/EBP, and to localise the DNA sequence elements required for the responsiveness
to hormones. HepG2 cells are a human hepatoma-derived cell line which express a
limited range of liver specific genes (Aden et al., 1979; Knowles et al., 1980), have
very little C/EBP (Becker et al., 1991; Williams et al., 1991), and no 11B-HSD1 (Y.
Koteletsev, personal communication). 2S-FAZA cells are derived from rat liver and
have a number of properties typical of differentiated liver (Deschatrette et al., 1980;
Malawista & Weiss, 1974), and they express endogenous 11B-HSD1 in a
hormonally-regulated fashion (Voice et al., 1996). Cotransfection of HepG2 cells
with C/EBPa and the 1 lB-HSDl-luciferase deletion series demonstrated the
responsiveness of the promoter to C/EBPa (Figure 4.1). Deletion of 11B-HSD1
promoter DNA from -1799 to -812 had little effect on either basal expression of
luciferase, or on the induction of luciferase activity by cotransfected C/EBPa
(approximately 15-20 fold induction). Deletion of DNA between -812 and -599
resulted in an increase of basal level expression (approximately 2.5 fold), but had
little or no effect on the level of C/EBPa-stimulated activity (with approximately 10-
fold induction caused by C/EBPa) (Figure 4.1). Further deletion between -599 and
-88 had no effect on basal promoter activity in HepG2 cells, but dramatically reduced
the response to C/EBPa; deletion to -174 reduced the C/EBP-induction to
approximately 4-fold, and further deletion to -88 virtually eliminated the effect of
C/EBP, with a residual 1.5-fold stimulation by C/EBPa (Figure 4.1). Transfections
of 2S-FAZA cells using the 11B-HSD1 promoter deletion series fused to a luciferase
reporter gene demonstrated that the rat 11B-HSD1 promoter between -1799 and +47
is responsive to insulin and glucocorticoids (Voice et al., 1996). Upon deletion of
promoter DNA from -599 to -249 the responsiveness to insulin was lost (M. Voice,
personal communication). The responsiveness to glucocorticoids was retained to
-174 but was lost upon deletion to -88 (M. Voice, personal communication).
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Figure 4.1 The 1 Ifi-HSDl gene is activated by C/EBPa in transfected HepG2 cells
HepG2 cells were cotransfected with a series of plasmids containing 11B-HSD1
promoter DNA, linked to luciferase at +47 within exon 1. 5xl05HepG2 cells in a
60mm dish were cotransfected with a total of 10pg DNA comprising 5pg 11B-
HSD1-luciferase plasmid, l(ig pCHIIO encoding B-galactosidase, lpg pMSV-
C/EBPa (where appropriate) made to lOfig with pGEM3, the calcium phosphate
procedure. 48h after transfection, cells were harvested and lysed to assay luciferase
and B-galactosidase activities; the ratio of luciferase to B-galactosidase activity as
calculated. Data shown are means ± SEM, calculated from 4 experiments, each
carried out in quadruplicate; data are normalised to the basal (-C/EBP) ratio of
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However, no sequences exist that exactly match the consensus half site GRE
sequence TGTYCT (Beato, 1987) or the insulin response element, CCCGCCTC
(Locker, 1993), in the 11B-HSD1 gene between -599 and -88.
These transfection experiments indicate that C/EBPa can act on the 11B-HSD1
promoter to regulate 11B-HSD1 expression. I was therefore interested in identifying
the sites to which C/EBP binds, and the identity of the proteins binding to the regions
responsive to hormonal signals.
4.2 Results
4.2.1 Rat liver nuclear proteins bind to multiple sites on the I lfi-HSDl gene between
-812 and + 74
DNase I protection analysis was used to identify sites of liver nuclear protein
interaction with the 11B-HSD1 promoter between -812 and +74. Parallel reactions
were carried out with rC/EBPa protein to identify the footprints which may be due to
C/EBP-related factors. A series of overlapping restriction fragments covering the
11B-HSD1 promoter between -812 and +74 were each labelled at the 5' end on the
lower strand (Figure 4.2). In most cases the fragment was first subcloned into pGEM
in order to generate suitable restriction sites for end-labelling with the Klenow
fragment of DNA polymerase I. Two fragments, (-812 to -599 and -322 to +47) were
derived from a series of 5' deletion plasmids in which a Sail linker was introduced at
the deletion end point (V. Lyons, personal communication). I shall describe the
results of the DNase I protection analysis by splitting the 11B-HSD1 promoter
between -812 and +74 into 3 sections; (i) -812 to -599; (ii) -599 to -130; (iii) -130 to
+74.
4.2.1.1 Proteins from rat liver nuclei bind to the 1 lfi-HSDl gene between -812 and
-599
Four footprints were formed by liver nuclear extract on the fragment extending from
-812 to -599. Figure 4.3 shows a representative experiment (of four carried out). An
identical footprint was formed by liver nuclear extract and rC/EBPa between -792
and -780. This site was characterised in more detail (Section 4.2.4). A region
between -771 and -747 was protected by liver nuclear extract but not rC/EBPa. A
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Figure 4.2 11J3-HSD1 gene fragments used in DNase Iprotection analysis
Summary of 11J3-HSD1 gene fragments used for analysis of liver nuclear extract and
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Figure 4.3 DNase 1 footprints formed by liver nuclear extract and rC/EBPa on the
llfi-HSDl promoter between -812 and -599
DNase I protection analysis of the 11B-HSD1 promoter fragment encoding -812 to
-599 using liver nuclear extract and rC/EBPa. Panels were from a single gel with
multiple loadings. Each panel shows the results from the same reactions run for
different lengths of time. Lane 1 shows a Maxam and Gilbert sequencing reaction
used as a molecular size marker (M+G); lane 2 has no extract added; lane 3 contains
lOOpg of liver nuclear extract (L) and lane 4 has 1.3|ig of rC/EBPa (C) added.
Strong regions of protection are indicated by brackets; dashed bracket indicates a
region of protection for which the boundaries have not been defined; inner brackets
refer to regions protected by liver nuclear extract; outer brackets, protection by
rC/EBPa. Nucleotides showing enhanced sensitivity to DNase I are indicated by
arrows.
 
Figure 4.4 DNase I footprints formed by liver nuclear extract and rC/EBPa on the
llfi-HSDl promoterfragment encoding -599 to -249
DNase I protection analysis of the 11B-HSD1 promoter encoding -599 to -249 using
liver nuclear extract and rC/EBPa. All panels were from a single gel with multiple
loadings, run for different lengths of time. Lane 1 shows a Maxam and Gilbert
sequencing reaction used as molecular size markers (M+G); lane 2 has no extract
added; lane 3 contains 100(ig of liver nuclear extract (L) and lane 4 has 1.3|ig of
rC/EBPa (C) added. Strong regions of protection are indicated by solid brackets,
weak regions of protection by dashed lines; inner brackets refer to regions protected
by liver nuclear extract; outer brackets, protection by rC/EBPa. Nucleotides showing






third footprint was formed by liver nuclear extract between -711 and -663, and
within this region a rC/EBPa footprint was formed covering -696 to -677. This latter
site was characterised in more detail by gel mobility shift analysis (refer to Section
4.2.3). Liver nuclear extract induced a strong region of hypersensitivity at the 3'
boundary of this footprint which was not observed with recombinant C/EBPa.
Downstream of the hypersensitive region, an additional footprint was formed by liver
nuclear extract only, although it was not seen in all footprinting reactions using this
fragment. However, on this gel (Figure 4.3) using this promoter fragment it was not
possible to accurately read the sequence of this protected region, and the exact
boundaries of this site remain to be defined.
4.2.1.2 Proteins from rat liver nuclei bind to the llfi-HSDl gene between -599 and
-130
Two overlapping fragments, encoding -599 to -249 and -322 to +47, were used to
analyse nuclear protein binding sites between -599 and -130. The results of DNase I
protection experiments using fragment -599/-249 are shown in Figure 4.4. Three
regions were protected from DNase I digestion by rat liver nuclear extract, all of
which were similarly protected by rC/EBPa protein. Two of these sites, at -572 to
-551 and -542 to -529, were strongly protected and the third site at -492 to -470, was
partially protected from DNase I digestion (Figure 4.4). No binding of either liver
nuclear proteins or rC/EBPa was observed to the (CT)26(GT)19 repeat at -462 to
-373. Hypersensitive sites induced by liver nuclear extract (but not by rC/EBPa)
were observed at -496, -506 and -514, a spacing interval close to 10 base pairs. The
limit of single base resolution on the gel shown in Figure 4.4 was about -300.
Therefore, to identify protein binding sites 3' of -300, the fragment encoding -322 to
+47 was used, from which data could be obtained to approximately -130 (Figure
4.5). Part of this region is also covered by the smaller 116-HSD1 promoter
fragments, -249/-174 (Figure 4.6), -174/-88 (Figure 4.7) and -174/+74 (Figure 4.8).
Between -322 and -130, two regions were similarly protected from DNase I digestion
by liver nuclear extract and rC/EBPa protein. These footprinted regions were located
at nucleotides -244 to -226 (Figure 4.5 and Figure 4.6) and at -180 to -139 (Figure
4.5). When the fragments -174/-88 (Figure 4.7) and -174 to +74 (Figure 4.8) were
used the latter footprint extended from -146 to -164 (Figure 4.7) or from -146 to -163
(Figure 4.8), possibly as a consequence of the fragment not extending the full extent
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Figure 4.5 DNase I footprints formed by liver nuclear extract and rC/EBPa on the
llfi-HSDl promoterfragment encoding -322 to +47
DNase I protection analysis of the 11B-HSD1 promoter encoding -322 to +47 using
liver nuclear extract and rC/EBPa. Panels were from a single gel with multiple
loadings. Each panel shows the results of the same reactions run for different lengths
of times. Lane 1 shows a Maxam and Gilbert sequencing reaction used as a
molecular size marker (M+G); lane 2 has no extract added; lane 3 contains 100(ig of
liver nuclear extract (L) and lane 4 has 1.3p.g of rC/EBPa (C) added. Strong regions
of protection are indicated by brackets; inner brackets refer to regions protected by
liver nuclear extract; outer brackets, protection by rC/EBPa.
 
Figure 4.6 DNase 1 footprints formed by liver nuclear extract and rC/EBPa on the
llfi-HSDl promoterfragment encoding -249 to -174
DNase I protection analysis of the 11B-HSD1 promoter encoding -249 to -174 using
liver nuclear extract and rC/EBPa. Panels were from a single gel with multiple
loadings. Each panel show the results of the same reactions run for different lengths
of times. Lane 1 shows a Maxam and Gilbert sequencing reaction used as a
molecular size marker (M+G); lane 2 has no extract added; lane 3 contains 100|Lig of
liver nuclear extract (L) and lane 4 has 1.3(ig of rC/EBPa (C) added. Strong regions
of protection are indicated by brackets; inner brackets refer to regions protected by
liver nuclear extract; outer brackets, protection by rC/EBPa.
M+G 0 L C
Figure 4.7 DNase I footprints formed by liver nuclear extract and rC/EBPa on the
llfi-HSDl promoterfragment encoding -174 to -88
DNase I protection analysis of the 11G-HSD1 promoter fragment encoding -174 to
-88 using liver nuclear extract and rC/EBPa. Panels were from a single gel with
multiple loadings. Each panel show the results of the same reactions run for different
lengths of times. Lane 1 shows a Maxam and Gilbert sequencing reaction used as a
molecular size marker (M+G); lane 2 has no extract added; lane 3 contains 100|ig of
liver nuclear extract (L) and lane 4 has 1.3|ig of rC/EBPa (C) added. Strong regions
of protection are indicated by brackets; inner brackets refer to regions protected by
liver nuclear extract; outer brackets, protection by rC/EBPa.
M+G 0 L C M+G 0 L C
of the footprint produced on the -322/+47 fragment (Figure 4.5). Clusters of
hypersensitive sites were occasionally seen to appear at the boundaries of footprinted
regions (Figure 4.4 and Figure 4.8).
4.2.1.3 Proteins from rat liver nuclei bind to the llfi-HSDl gene between -130 and
+74
To identify binding sites for liver nuclear proteins in the remaining promoter region
between -130 and +74, fragments encoding -174 to +74 (Figure 4.8) and -174 to -88
(Figure 4.7) were used in DNase I protection analysis. Between -130 and -88 there
was one strong region of transcription factor interaction with the promoter, at -125 to
-112 (Figure 4.8) (in Figure 4.7 the protected region is between -124 and -112),
which was seen with both liver nuclear extract and rC/EBPa protein (Figure 4.7 and
Figure 4.8). The remaining footprints seen between -88 and +47 have already been
discussed in Chapter 3. Hypersensitive sites are again formed at the boundaries of
footprinted regions (Figure 4.8).
The results of the DNase I protection analysis over the whole promoter region,
between -812 to +74 are summarised in Figure 4.9. These results show that liver
nuclear proteins bind to at least 14 sites on the 116-HSD1 promoter between -812
and +47, including the site at around -600 (Figure 4.3) for which the boundaries are
not known, and that 12 of these sites can be wholly or partially occupied by C/EBP
related proteins.
Further characterisation was carried out on the liver nuclear proteins which bind to
the promoter between -812 and -599, described below (Section 4.2.2), and, in
addition two sites of C/EBP binding within this region, between -702 to -679 and
-804 to-776 were further characterised (Sections 4.2.3 and 4.2.4).
4.2.2 Further characterisation of the proteins in liver nuclear extract which form
complexes on the 11J1-HSD1 gene between -812 to -599
Although the footprints generated by liver nuclear proteins and rC/EBPa between
-599 and +47 were very similar, a number of differences were observed in binding to
the fragment encoding -812 to -599. Deletion of 5'-flanking DNA from -812 to -599
increased basal expression of luciferase activity in transfected HepG2 cells,
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Figure 4.8 DNase I footprints formed by liver nuclear extract and rC/EBPa on the
llfi-HSDl promoterfragment encoding -174 to +74
DNase I protection analysis of the 11G-HSD1 promoter fragment encoding -174 to
+74 using liver nuclear extract and rC/EBPa. Panels were from a single gel with
multiple loadings. Each panel show the results of the same reactions run for different
lengths of times. Lane 1 shows a Maxam and Gilbert sequencing reaction used as a
molecular size marker (M+G); lane 2 has no extract added; lane 3 contains lOOpg of
liver nuclear extract (L) and lane 4 has 1.3pg of rC/EBPa (C) added. Strong regions
of protection are indicated by solid brackets; inner brackets refer to regions protected
by liver nuclear extract; outer brackets, protection by rC/EBPa. Nucleotides showing
enhanced sensitivity to DNase I are indicated by arrows.
 
Figure 4.9 Summary of the regions of the 11J3-HSD1 promoter protected from
DNase I digestion by liver nuclear extract and recombinant C/EBPa protein
Blue lines refer to promoter regions protected by liver nuclear extract; red lines show
regions protected by rC/EBPa. Solid lines indicate strong regions of protection, thin,
dashed lines indicate weak regions of protection, a thick dashed line indicates
uncertainty about the exact boundary of the footprint. The strong DNase I
hypersensitive site at -660 is indicated by a green line.
-792^^^^^^^-780 -771
-812 TA GTAAGGAAGA AATAAGGGAC ATCATTATTC CCGTGAAGGT
-747
-770 AACGTGAACG GACTCTCAGA ACTTGACTCG AACCCAAAGG ACGGTAGACC
-720 CAGACCGACC AAACGTTGAA GAGAAACTAC AACGTTACGA AAAAGTAACT
-696 -677
-663
-670 TGACCTCACA^CCCTGAAGAC ATCGAATGAC CGAATAAAAG AAAGAGGATT
"572bm
-620 CTGTACGGGT AAAAAAAGGA ACTCGAGTAA AACGACAAAA CACGACAATT
-551 -542 -529
-570 AAAAATTAAC GAAGTCTGAA CCCACAACCC CCACCCCGTT CCGACTCTAA
-492_ _________ J?°
-520 ACCGAACTCA AACCGAGATA AACATAGGAA GTATAAAGGG TTTTCGGGGT
-470 GTACGAGCGA GAGAGAGAGA GAGAGAGAGA GAGAGAGAGA GAGAGAGAGA
-420 GAGAGAGAGA CACACACACA CACACACACA CACACACACA CACACACAGG
-370 AAGGAGGGAG GAAGAGAGGT AGGGAGGAAG GAAGGAAAGG AGGGTGGGAG
-320 GGAGGAGGAG AGGAAGATAG GGCGGGAAGG TGGGGAGGTG GGAGGGAGGG
-244 -226
-270 ACTGTTCGGT AAGAACGTTC CGGTAACGAC GACACACGTT TCCTACAGAG
-180.
-220 CCATCCTCTA CGAGTCCTTG GGTCGGGACG TGTCAGTACT CGGACCGGTA
.-139 -125.
-170 GACCTTCAAC GGAGAATGAG TTACTTTACC TCATTTGTAA CAGGTAATAC
-112 -71 ,
-120 TTTAGGTAGT GCGTCCGAGG GTCCCTGCTT ACCCTAGGGT GGGTTTCGGT
-62 -54 -36
-70 TAGTAACGAG ACTGTCCCTT CAACCGATCA CGACGGACTC TGATGAGGTC
-8
mmmmm
-20 GGAGGGGGCA GGGACTACAG TGTTAAGTCT CCGACGACGA CGGACCCTTC
+39
+31 CAACATCTTT CTCGACGTCC AAAAGAAACA CACAGGATGT CTCG
decreasing the fold induction by C/EBPa (Figure 4.1). Therefore, competition gel
mobility shift analysis was carried out on fragment FB, encoding -812 to -599, to
determine the relative involvement of C/EBP-related proteins in binding to this
region. Several specific complexes were formed on FB (the exact number varied
between experiments and was difficult to determine, as lower-mobility complexes
predominantly ran as a smear) (Figure 4.10). However, all of the complexes were
specific as demonstrated by competition with a 100-fold molar excess of specific
competitor fragment FB, but not by the non-specific fragment competitor, FNS (Figure
4.10).
Oligonucleotides were used as competitors in gel mobility shift analysis to further
explore the DNA-binding specificity of the factors in liver nuclear extract which bind
to Fb. Oligonucleotides 0A, 0E, Of and Od (see Table 2.1 for sequences) encoding
respectively, -14 to +15 of the 118-HSD1 promoter, an optimal C/EBP binding site,
-702 to -679 of the 116-HSD1 gene and the P3(I) C/EBP binding site from the
PEPCK gene, at 100-fold molar excess over FB proved the best competitors,
dramatically reducing the intensity of the highest mobility complexes, and
diminishing the intensity of lower mobility complexes (Figure 4.11). The pattern of
competition with all the oligonucleotides (with the exception of 0F, see below) was
similar to that described for the -88 to +47 fragment (described in Chapter 3, Figure
3.8), with Oa=Oe>Od>Ob=Oc=Ons (Figure 4.11). For 0A, Oe and 0D, the
competition at 100-fold molar excess was more complete than at 10-fold molar
excess. Of showed similar competition at both 10- and 100-fold molar excess
suggesting that effective competition was complete at a 10-fold molar excess of
oligonucleotide. All of the oligonucleotides which competed (Chapter 3 and see
Section 4.2.3 for 0F) encode binding sites for C/EBP-related proteins. In contrast to
the competition with FB (Figure 4.10), the oligonucleotides used failed to compete all
of the complexes formed, several were either not competed, or were competed poorly
by the oligonucleotides, suggesting that either these complexes are specific but do
not contain C/EBP related proteins, or that they are non-specific. However, as the
complexes appeared to be fully competed by FB these complexes are probably
specific. Clearly the 3 highest mobility complexes contain C/EBP-related proteins as
they are completely competed (note incomplete competition by 10-fold molar excess
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Figure 4.10 Liver nuclear extract binds to the llfi-HSDl gene fragment encoding
-812 to -599
Competition gel mobility shift assay using the 11B-HSD1 promoter fragment
encoding -812 to -599 (FB) and liver nuclear extract. lOjig of rat liver nuclear extract
was incubated with 30fmol of [32P]-labelled FB in the absence of added competitor
(lane 2) or in the presence of 10- or 100-fold molar excess of competitor DNA, as
indicated above the lanes (lanes 3-6). Lane 1 contains no nuclear extract. Arrows
indicate specific protein-DNA complexes.
 
Figure 4.11 C/EBP-related proteins from rat liver nuclear extract bind to the llfi-
HSD1 gene between -812 and -599
Competition gel mobility shift assay using the 11B-HSD1 promoter fragment
encoding -812 to -599 (FB) and liver nuclear extract. 10)ig of rat liver nuclear extract
was incubated with 30fmol of [32P]-labelled FB in the absence of added competitor
(lane 2) or in the presence of a 10- or 100-fold molar excess of competitor
oligonucleotide, as indicated above each lane (lanes 3-16). Lane 1 contains no
nuclear extract. Arrows indicate specific protein-DNA complexes.
Oligonucleotides used were, 0A, 11B-HSD1 (-14 to +15); 0B, 11B-HSD1 (-88 to
-57); Oc, 11B-HSD1 (-71 to -52); Od, PEPCK P3(I) site; Oe, optimal C/EBP site; Of,
11B-HSD1 (-682 to -705); Ons, prolactin ERE (non-specific control).
COMPETITOR 1 0NS 11 Of 11 Oa 11 Oe 11 0D 11 Ob 11 Oc 1
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of 0D, which is the weakest C/EBP competitor). Of appears to be the strongest
C/EBP site based on competition experiments (Figure 4.11).
Of the four footprints generated on this fragment by liver nuclear extract (Figure
4.3), one (-792 to -780) was reproduced by rC/EBPa, and a second (-711 to -663)
may be due, in part, to a C/EBP-related protein binding at -696 to -677. When
rC/EBPa protein was examined for its ability to bind to FB, 4 specific complexes
were formed which were partially competed by a 10-fold molar excess, and fully by
a 100-fold molar excess, of competitor FB (Figure 4.12). All of the complexes
formed by rC/EBPa on FB were competed similarly by a 10-fold molar excess of
C/EBP binding oligonucleotides with Oa=Oe=Of>Od (Figure 4.13). Oc proved a
very weak competitor at 100-fold molar excess and no competition was observed for
0NS or Ob. This was similar to that described for the -88 to +47 fragment, described
in Chapter 3, with Oa=Oe>Od>Ob=Oc=Ons.
To specifically identify whether complexes formed on FB by liver nuclear proteins
included C/EBP a and/or C/EBPG, monospecific polyclonal antisera were included in
gel mobility supershift experiments (Figure 4.14). C/EBPa antibody supershifted the
lower mobility complexes (Figure 4.14). Complexes were also supershifted using
C/EBPB antisera. When C/EBPa and C/EBPG were used in the same supershift
reaction all complexes except one were supershifted. This complex was, however,
competed by the C/EBP binding oligonucleotides (Figure 4.13), suggesting that this
complex contains a C/EBP related factor. These results suggest therefore that all of
the protein complexes formed on this fragment involved members of the C/EBP
family. However, not all of the protein-DNA complexes were competed by C/EBP-
binding oligonucleotides (Figure 4.11). It is possible that in the experiment shown in
Figure 4.14 residual complexes (not readily apparent) were not supershifted by the
antibodies. Alternatively the complexes which were not competed by C/EBP-binding
oligonucleotides may be associated with C/EBPa and/or C/EBPG and were therefore
supershifted, or alternatively these complexes are maybe masked by the supershifted
complexes. These results demonstrate clearly that C/EBP-related factors from liver
nuclear extract bind to FB which is consistent with footprinting results. Of the 2 sites
protected by rC/EBPa on -812 to -599, one was protected identically by proteins
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Figure 4.12Recombinant C/EBPa binds to the 11J5-HSD1 gene fragment encoding
-812 to -599
Competition gel mobility shift assay using the 11B-HSD1 promoter fragment
encoding -812 to -599 (FB) and rC/EBPa. 0.2|ig of rC/EBPa was incubated with
30fmol of [32P]-labelled FB in the absence of added competitor (lane 2) or in the
presence of a 10- or 100-fold molar excess of competitor DNA, as indicated above
each lane (lanes 3-6). Lane 1 contains no nuclear extract. Lane 7 contained 10(j,g of
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Figure 4.13 Complexes are formed by recombinant C/EBPa on the I lfi-HSDl gene
fragment encoding -812 to -599
Competition gel mobility shift assay using the 116-HSD1 promoter fragment
encoding -812 to -599 (FB) and rC/EBPa. 0.2|ig of rC/EBPa was incubated with
30fmol of [32P]-labelled FB in the absence of added competitor (lane 2) or in the
presence of a 10- or 100-fold molar excess of competitor oligonucleotide, as
indicated above each lane (lanes 3-16). Lane 1 contains no nuclear extract. Lane 17
contains lOjag of rat liver nuclear extract instead of rC/EBPa. Arrows indicate
specific protein-DNA complexes.
Oligonucleotides used were, Oa, 116-HSD1 (-14 to +15); 0B, 11B-HSD1 (-88 to
-57); Oc, 116-HSD1 (-71 to -52); 0D, PEPCK P3(I) site; 0E, optimal C/EBP site; Of,








Figure 4.14 C/EBPa and C/EBPfi are present in the complexes formed on the llfi-
HSD1 gene fragment encoding -812 to -599
Gel mobility supershift assay using the 11B-HSD1 promoter fragment encoding -812
to -599 (Fb) and liver nuclear extract. lOptg of liver nuclear extract was incubated
with 30fmol of [32P]-labelled FB in the absence of antibody (lane 2) or with antisera
added as indicated above each lane (lanes 3-6). Lane 1 contains no nuclear extract.














from liver nuclear extract, the other corresponded to part of a footprint formed by
liver nuclear extract. Both of these binding sites were further characterised.
4.2.3 Proteins from rat liver nuclei bind an oligonucleotide encoding -702 to -679 of
the 1 lfi-HSDl gene
Oligonucleotide Of encodes -702 to -679 of the rat 11B-HSD1 gene, encompassing
the recombinant C/EBPa footprint at -696 to -677 which may form part of the larger
footprint seen with liver nuclear extract (-711 to -663). In competition gel mobility
shift analysis in which liver nuclear extract binding to 0F was competed by a series
of oligonucleotides, the strongest competitor was 0F, completely competing complex
formation at a 10-fold molar excess (Figure 4.15). Other C/EBP-binding
oligonucleotides also competed, with Oe>Oa>Od»Ob=Oc=Ons (Figure 4.15).
Competition analysis of rC/EBPa binding to 0F showed that Of was a very high
affinity site, with similar rank order of competition as seen for liver nuclear extract
(Of>Oe>Oa>Od» Ob=Oc=Ons) (Figure 4.16). These gel mobility shift experiments
therefore show that the footprint between -702 and -679 represents a high affinity site
for C/EBP related proteins, with at least as high an affinity for rC/EBPa as 0E.
Addition of antisera to gel mobility shift experiments demonstrated that the majority
of the complexes formed on 0F by liver nuclear extract include C/EBPa, as most of
the complexes were supershifted by the addition of C/EBPa antibody (Figure 4.17).
Addition of C/EBPB antiserum alone supershifted a small proportion of the
complexes, with all but one complex supershifted by addition of both antisera
together (Figure 4.17). The remaining complex was unaffected by addition of the
antisera. There is probably minimal involvement of heterodimer formation between
C/EBPa and C/EBPB on this site as the amount of complexed DNA not supershifted
by C/EBPa is about equal to the amount supershifted by C/EBPB (Figure 4.17).
4.2.4 Weak complex formation by liver nuclear extract on the oligonucleotide
encoding -804 to - 776 of the rat 1 lfi-HSDl gene
Liver nuclear extract and C/EBPa formed similar footprints between -792 and -780
(Figure 4.3 and 4.9). However, when an oligonucleotide, Os, corresponding to -804
to -776 was used in gel mobility shift analysis, although complexes were formed by
liver nuclear extract on Os, there was no distinct pattern of binding as had been
80
Figure 4.15 C/EBP-related transcription factors from liver nuclear extract bind to
oligonucleotide Op, encoding -702 to -679 of the llfi-HSDl promoter
Competition gel mobility shift assay using the 11B-HSD1 oligonucleotide encoding
-712 to -679 (Of) and liver nuclear extract. lOpig of liver nuclear extract was
incubated with O.lpmol of [32P]-labelled 0F in the absence of added competitor (lane
2) or in the presence of a 10- or 100-fold molar excess of competitor oligonucleotide,
as indicated above each lane (lanes 3-16). Lane 1 contains no nuclear extract. Arrows
indicate specific protein-DNA complexes, * indicates a non-specific band.
Oligonucleotides used were, Oa, 11B-HSD1 (-14 to +15); Ob, 11B-HSD1 (-88 to
-57); Oc, 118-HSD1 (-71 to -52); Od, PEPCK P3(I) site; 0E, optimal C/EBP site; Of,
11B-HSD1 (-682 to -705); 0NS, prolactin ERE (non-specific control).
COMPETITOR 1 Ons 11 Of 11 Oa 11 Oe " Od 11 Ob 11 Oc 1
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Figure 4.16 Recombinant C/EBPa binds specifically to oligonucleotide Of, encoding
-702 to -679 of the llfi-HSDl gene
Competition gel mobility shift assay using the oligonucleotide 0F encoding -712 to
-679 and rC/EBPa. 0.2|ig of rC/EBPa was incubated with O.lpmol of [32P]-labelled
Op in the absence of added competitor (lane 2) or in the presence of a 10- or 100-fold
molar excess of competitor oligonucleotide, as indicated above each lane (lanes 3-
18). Lane 1 contains no nuclear extract. Lane 19 contained 10|ig of rat liver nuclear
extract instead of rC/EBPa. Arrows indicate specific protein-DNA complexes.
Oligonucleotides used were, 0A, 11G-HSD1 (-14 to +15); Ob, 11G-HSD1 (-88 to
-57); Oc, 1113-HSD1 (-71 to -52); Od, PEPCK P3(I) site; Oe, optimal C/EBP site; Of,







observed previously with other oligonucleotides; instead, a smear of complexes was
formed (Figure 4.18). The complexes formed on Os appeared to be predominantly
non-specific as excess Os only weakly competed for complex formation, even at a
100-fold molar excess. Furthermore, only weak competition was observed with Oa,
Op, Oe and Od (Figure 4.18). In addition, rC/EBPa failed to form specific complexes
on Os (Figure 4.19). It therefore appears that, despite the fact that this region is
protected from DNase I digestion by liver nuclear extract and rC/EBPa in
footprinting experiments, an oligonucleotide encompassing the footprinted region is
unable to specifically bind proteins when analysed using gel mobility shift analysis.
4.3 Discussion
The importance of C/EBPa in regulating 11B-HSD1 promoter activity has been
demonstrated by transient co-transfections of HepG2 cells (a liver derived cell line)
using C/EBPa and a plasmid deletion series in which 11B-HSD1 promoter DNA is
fused to a luciferase reporter gene. The basal activity of the reporter gene in the
absence of C/EBPa, was lower for a plasmid encoding -812 to +47 of 11B-HSD1
than for the -599 to +47 plasmid (K. Chapman, personal communication), suggesting
that deletion from -812 to -599 removed a repressor element. This region contained 4
sites protected by rat liver nuclear extract from digestion by DNase I, only one of
which was similarly bound by rC/EBPa. Of the other 3 sites the boundaries of 2
were determined (-771 to -663 and -773 to -747), but comparison with known
transcription factor binding sites did not reveal any strong similarities; the identity of
the liver nuclear factors protecting these sites is therefore not known. A region
footprinted by rC/EBPa within the large footprint at -711 to -663 bound C/EBPa,
C/EBPI3 and an unidentified C/EBP-related factor(s) in a similar ratio to C/EBP
binding to the whole fragment encoding -812 to -599. These results clearly
demonstrate high affinity C/EBP binding to a part of the larger footprint at -711 to
-663 and furthermore suggest that the vast majority of the C/EBP binding to the -812
to -599 fragment may be attributed to the binding to this high affinity site. The
binding of C/EBP to this region suggests that there may be an interaction between
C/EBP and the unidentified liver nuclear factor(s) giving rise to the larger footprint.
Alternatively, the larger footprinted region may be due to C/EBP from liver nuclear
extract distorting DNA, giving less access to DNase I and therefore a larger footprint.
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Figure 4.17 C/EBPa and C/EBPfi bind to oligonucleotide 0F, encoding -702 to -679
of the llfi-HSDl promoter
Gel mobility supershift assay using oligonucleotide 0F and liver nuclear extract.
10pg of liver nuclear extract was incubated with O.lpmol of [32P]-labelled 0Fin the
absence of antibody (lane 2) or with antisera added as indicated above each lane
(lanes 3-6). Lane 1 contains no nuclear extract. Supershifted complexes are indicated
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Figure 4.18 Liver nuclear extract binds weakly to oligonucleotide 0$, encoding -804
to -776 of the llfi-HSDl promoter
Competition gel mobility shift assay using oligonucleotide Os encoding -804 to -776
and liver nuclear extract. 10|lg of liver nuclear extract was incubated with 0. lpmol of
[32P]-labelled Os in the absence of added competitor (lane 2) or in the presence of a
10- or 100-fold molar excess of competitor oligonucleotide, as indicated above each
lane (lanes 3-18). Lane 1 contains no nuclear extract. Complexes are indicated by the
bracket.
Oligonucleotides used were, Oa, 11B-HSD1 (-14 to +15); Ob, 11B-HSD1 (-88 to
-57); Oc, 11B-HSD1 (-71 to -52); Od, PEPCK P3(I) site; Oe, optimal C/EBP site; Of,
11B-HSD1 (-682 to -705); Os, 11B-HSD1 (-804 to -776); Ons, prolactin ERE (non¬
specific control).
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Figure 4.19 Recombinant C/EBPa does not bind to oligonucleotide Os, encoding
-804 to -776 of the llfi-HSDl promoter
Competition gel mobility shift assay using oligonucleotide Os encoding -804 to -776
and rC/EBPa. 0.2pg of rC/EBPa was incubated with O.lpmol of [32P]-labelled Os in
the absence of added competitor (lane 2) or in the presence of a 10- or 100-fold
molar excess of competitor oligonucleotide, as indicated above each lane (lanes 3-
18). Lane 1 contains no nuclear extract.
Oligonucleotides used were, Oa, 11B-HSD1 (-14 to +15); Ob, 11B-HSD1 (-88 to
-57); Oc, 11B-HSD1 (-71 to -52); Od, PEPCK P3(I) site; Oe, optimal C/EBP site; Of,
11B-HSD1 (-682 to -705); Os, 11B-HSD1 (-804 to -776); Ons, prolactin ERE (non¬
specific control).
■oNS"Os"0AfEDbc' - -i<=WELLS
At the 3' boundary of this footprint at -711 to -663 was a strong region of
hypersensitivity to DNase I induced by rat liver nuclear extract but not by rC/EBPa.
This hypersensitive region seen in vitro is probably identical to a DNase I
hypersensitive site formed at -650 of the 11B-HSD1 gene seen in intact nuclei from
rat liver (only 2 hypersensitive regions are seen in the 1lfi-HSDl gene between -5kb
and +1.5kb in rat liver nuclei; at -650 and close to the transcription start; K.
Chapman, personal communication). DNase I hypersensitive sites generally
correspond to important gene regulatory regions (Kornberg & Lorch, 1995). These
results implicate this region as important for transcriptional control of 11G-HSD1 in
rat liver. Liver nuclear proteins and rC/EBPa formed a strong footprint between -792
and -780, however, but they failed to form distinct complexes on an oligonucleotide
encompassing this site; it may be that the length of the oligonucleotide needs to be
extended to allow adequate binding by liver nuclear proteins, or that complex
formation at this site may require factors to bound at other sites on the promoter.
Further deletion of the 11B-HSD1 promoter, from -599 to -174 or -88 decreased the
degree of induction of luciferase activity by C/EBPa (K. Chapman personal
communication). Between -599 and -88, 6 sites were bound by factors from liver
nuclear extract (Figure 4.9) all of which are similarly bound by rC/EBP suggesting
that C/EBP is the only factor in liver nuclear extract binding to this region and that it
is therefore responsible for the activity of these minimal 11B-HSD1 promoters in
liver cells. No binding of liver nuclear proteins was seen to the promoter region
containing the (CT)26(GT)19 repeats and the CT rich region. Although widespread in
mammalian genes, the functions (if any) of these repeat sequences, especially (GT)n
repeats is unknown (Hamada & Kakunaga 1982). In Drosophila, repeated sequences
have been associated with chromatin formation and nucleosome positioning (Miller
et al., 1985) GT repeats form left-handed Z DNA in vitro (van Holde & Zlatanova,
1993), and have been suggested to inhibit transcription in vivo in mammalian
systems. Deletion of the repeat sequence in 11B-HSD1 gene has little or no effect on
luciferase activity in transiently transfected cells therefore, the physiological
significance of the repeats (if any) remains to be determined.
In rat liver and in cultures of liver derived cells (2S FAZA and primary cultures of
hepatocytes), 11G-HSD1 expression is hormonally regulated. Glucocorticoids
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increase 11G-HSD1 expression (Jamieson et al., 1995; Low et al., 1994c; Voice et al.,
1996) and insulin decreases 11B-HSD1 expression (Jamieson et al., 1995; Voice et
al., 1996), which is in keeping with a role for glucocorticoids in maintaining glucose
homeostasis. Preliminary data from transfections of 2S FAZA cells have suggested
that the region required for responsiveness to glucocorticoids lies between -174 to -
88 and that the region required for insulin responsiveness lies between -599 and -174
(M. Voice, personal communication). However, the region between -599 and -88
does not contain any sequences which resemble binding sites for either GR or a
transcription factor known to mediate signalling by insulin. Furthermore, the only
footprints generated between -599 and +47 appear to be generated by C/EBP-related
proteins. However, there is a match to a half site GRE consensus sequence
(TGTYCT) (Beato, 1987) at -370 (TGTCCT), which is outside the region implicated
in the response to glucocorticoids and there is also a possible GR binding site at -140
to -126, located between the 2 C/EBP binding sites at -180 to -139 and -125 to -117.
This site (AGTAAACATTGTCCA) matches the consensus GRE half site at 5 of the
6 nucleotides in one half site, and 4 out of 6 in the other. No footprint over this
region is observed, however, the lack of detectable GR binding to this region may be
due to a rapid dissociation of GR from DNA, allowing DNase I access to cleave the
promoter DNA. GR may be mediating its effect by an interaction with adjacent
C/EBP; the synergistic activation of gene transcription by C/EBPB and GR has been
described (Nishio et al., 1993); as has synergy between GR and C/EBPa where chick
neuronal retina development by glucocorticoids is dependent upon C/EBPa (Ben-Or
& Okret, 1993). It is also possible that the glucocorticoid effect on 11G-HSD1
expression is indirect and mediated by C/EBP. Glucocorticoids, regulate the
expression of C/EBPa and C/EBPB genes; dexamethasone increases C/EBPB
expression in primary cultures of rat hepatocytes cultures (Matsuno et al., 1996). In
differentiated 3T3-L1 adipocyte cells C/EBPa expression is repressed by
administration of glucocorticoids (MacDougald et al., 1994) although in rats,
glucocorticoids have no effect on the expression of C/EBPa mRNA in liver (Ruppert
et al., 1990). Regulation of 11G-HSD1 by insulin could also be mediated by C/EBP,
as insulin treatment is known to result in the phosphorylation of C/EBPB (Wegner et
al., 1992) as well as decreasing hepatic C/EBPB mRNA and protein levels in vivo.
Insulin has no effect on C/EBPa expression in liver (Bosch et al., 1995), however, in
cultured foetal brown adipose tissue, insulin induced expression of C/EBPa and
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C/EBP8 but had no effect on C/EBPB (Guerra et al., 1994). Alteration of the ratio of
C/EBPa to C/EBPB, or the phosphorylation state of either may alter transcription
initiation at the 11B-HSD1 promoter. The effects of hormones on activity and
expression of C/EBPs therefore appears complex and is probably tissue specific and
may depend on differentiation status of the cells.
Hepatic 11B-HSD1 expression is also regulated by growth hormone and by
oestrogen. Oestrogen dramatically represses expression of 11B-HSD1 mRNA in rat
liver and kidney, but not in hippocampus (Low et al., 1993). Although this effect is
due, in part, to the sex steroid specific pattern of growth hormone secretion (Low et
al., 1993), it is also likely to involve a mechanism independent of growth hormone as
administration of female specific pattern of growth hormone to males only
reproduced the fold difference in hepatic 11B-HSD1 expression seen between male
and female rats (Low et al., 1994b). It is possible that the effects of both growth
hormone and oestrogen are mediated through C/EBP. The growth hormone
regulation of Class I alcohol dehydrogenase (ADH) is mediated via C/EBP binding
to the ADH promoter (Potter et al., 1993). Cross talk between oestrogen receptor and
C/EBP has been described, with oestrogen administration causing decreased
expression of C/EBP regulated genes (Stein and Yang, 1995), possibly through a
direct interaction between ER and C/EBP (Stein and Yang, 1995).
Members of the C/EBP family play a role in, or have been implicated in, the
expression of numerous hormonally regulated genes in liver, and regulate genes
involved in glucose homeostasis (Park et al., 1993; Park et al., 1990) and the APR
(Alam et al., 1992; Cappelletti et al., 1996). Glucocorticoids also regulate similar sets
of genes to C/EBP and in liver, together with the metabolic hormones insulin and
glucagon, they co-ordinately regulate the expression of genes involved in the
maintenance of blood glucose homeostasis, and together with cytokines (principally
IL-6 and IL-1), induce the network of genes required for the acute-phase response.
Hepatic glucocorticoid regulated genes include those encoding enzymes involved in
the regulation of glucose homeostasis such as PEPCK and G6Pase (Garland, 1986;
Sasaki et al., 1984), and attenuation of hepatic 116-HSD1 expression (by treatment
with oestrogen) is associated with decreased expression of mRNA encoding enzymes
involved in gluconeogenesis, including PEPCK (Jamieson et al., 1996). A role for
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11B-HSD1 in expression of glucocorticoid inducible hepatic genes is also
demonstrated by transgenic mice lacking 116-HSD1, which have reduced fasting
glucose levels and decreased expression of G6Pase (Kotelevtsev et al., 1996a).The
key role of C/EBPa in regulating genes which regulate blood glucose levels is
apparent in mice lacking the C/EBPa gene which die of hypoglycaemia shortly after
birth (see Chapter 1, Section 1.5.5.1) (Wang et al., 1995). In liver, glucocorticoids
also coordinately induce a network of genes involved in the acute phase response
(APR) (reviewed in Baumann and Gauldie, 1994). C/EBP6 and C/EBP8 have both
been implicated as key regulators of the APR genes, and probably form part of an
intracellular signalling pathway for IL-6 (Baumann and Gauldie, 1994). C/EBP6
plays an important role in regulating the immune response, and mice which lack the
C/EBPB gene have defective immune responses and impaired induction of APR
genes (Tanaka et al., 1995; Screpanti et al., 1995). During the APR, hepatic
expression of C/EBPa decreases and expression of C/EBPB and C/EBP8 increases
(Alam et al., 1992) and glucocorticoids themselves induce expression of C/EBPB and
C/EBPS. The binding of both C/EBPa and C/EBPB (and possibly other members of
the C/EBP family) to the promoter of the 11B-HSD1 gene suggests that C/EBP may
indirectly regulate the level of active intracellular glucocorticoids in liver by
governing the transcription of hepatic 11B-HSD1. This therefore provides a
mechanism for 'cross-talk' between the hormonally responsive glucocorticoid
signalling pathway permitting a complex coordinated control of the networks of
genes involved in energy metabolism, and the cellular response to stress.
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CHAPTER 5
The proximal promoter of the
11B-HSD1 gene is transcriptionally active in vitro
5.1 Introduction
The rat 11B-HSD1 gene contains 9 binding sites for C/EBP between -599 and +8
with the major binding site at the transcription start (Chapters 3 & 4). Binding of
C/EBP to the transcription start is unusual, but C/EBPa binding at the transcription
start has been reported and shown to be important for expression of the gene
encoding clotting factor IX in liver (Crossley and Brownlee, 1990). The functional
relevance of C/EBP binding to the transcription start of the 11B-HSD1 gene could
not be determined by transfection experiments, where cotransfection of a C/EBPa
expression plasmid had little effect on the activity of an 1 lB-HSDl(-88/+47)-
luciferase construct in HepG2 cells (see Chapter 4). HepG2 cells contain low levels
of C/EBPa (Friedman et al., 1989) which may be predominantly bound to the
relatively high affinity site at +1 resulting in only a minimal stimulation by
exogenous C/EBPa. It is also possible that C/EBP13 may play an essential role in
stimulating transcription of the minimal promoter of the 11G-HSD1 gene.
Alternatively, in transfected cells increased 11B-HSD1 transcription by C/EBPa may
require upstream C/EBP sites in addition to the site at +1. It is difficult to look at the
effects of mutating nucleotides close to the transcription start in transfected cells, as
these mutations may themselves interfere with the interaction of the basal
transcription machinery with the transcription initiation site, making interpretation of
results difficult.
Therefore, to show the functional relevance of C/EBP binding to the transcription
start, in vitro transcription experiments were carried out using either -599/+S or
-88/+8 of the 11B-HSD1 gene linked to a G-free cassette (Sawadogo and Roeder,
1985), with comparison made between activity produced in nuclear extracts made
from rat liver, which expresses C/EBP, or from HeLa cells which do not express
C/EBP (Williams et al., 1991).
5.2 Results
5.2.1 The 11J3-HSD1 promoter is transcriptionally active in vitro
Nuclear extracts produced from liver (in which 11B-HSD1 enzyme activity is highly
expressed) and from HeLa cells (in which 11B-HSD1 activity is undetectable; S.
Low, personal communication) were used to in vitro transcribe two different
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plasmids, pi 161(-599)-(C2AT)i9 and pi 161(-88)-(C2AT)i9, containing 11B-HSD1
DNA from -599 to +8 or -88 to +8 respectively fused to a 370bp G-free cassette
(Sawadogo and Roeder, 1985) (Described in Chapter 2, Section 2.1.5.3). G-free
cassettes (encoding transcripts of 370, 270 or 170 nucleotides) linked to the
adenovirus major late promoter (AdMLP) (Sawadogo and Roeder, 1985; Vaulont et
al., 1989) were used as size markers (Figure 5.1, lanes 1-3). In vitro transcription of
either pi 161(-599)-(C2AT)i9 or pilBl(-88)-(C2AT)i9 in liver nuclear extracts
produced the predicted 370 nucleotide transcript, with both plasmids showing a
similar level of activity (Figure 5.1). However, neither pi 181(-599)-(C2AT)i9 nor
pi 181(-88)-(C2AT)i9 were transcriptionally active in nuclear extracts from HeLa
cells (Figure 5.1). In contrast, the internal control plasmid, pAdM(170), which does
not require tissue-specific factors for transcriptional activity, was active both in rat
liver nuclear extract and in HeLa nuclear extract. This demonstrates that the proximal
promoter of 11B-HSD1, between -88 and +8 is sufficient to confer both tissue-
specificity upon a linked transcript and to direct transcription in liver nuclear
extracts.
Attempts were made to directly demonstrate a role for C/EBP in the in vitro
transcription of the 11B-HSD1 promoter, using pi lBl(-599)-(C2AT)19. Addition of
oligonucleotide 0E (encoding an optimal C/EBP site; Chapter 2, Table 2.1) at greater
than 50-fold molar excess over the DNA template pi 161(-599)-(C2AT)19 did indeed
reduce transcription in vitro from pi 161(-599)-(C2AT)19 in rat liver nuclear extract,
but in addition, also reduced transcription from the internal control plasmid,
pAdML(170) (data not shown). Furthermore, depletion of C/EBP by incubation of
rat liver nuclear extract with biotinylated 0E linked to streptavidin-coated magnetic
beads similarly reduced transcription in vitro of pi 161(-599)-(C2AT)19 and
pAdM(170) (data not shown).
5.3 Discussion
Here I show that only 96 base pairs of the rat 11B-HSD1 promoter region (between
-88 and +8) are sufficient to direct transcription in vitro in rat liver nuclear extracts,
but not in nuclear extracts made from HeLa cells (which do not express 11B-HSD1
or C/EBP). These results suggest that factors present in liver, but not in HeLa cells,
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Figure 5.1 The llfi-HSDl promoter is transcriptionally active in vitro
In vitro transcription analysis of the 116-HSD1 promoter using liver and HeLa
nuclear extracts. Lanes 1-3 contain respectively, lpg pML(C2AT), lpg pAdM(270)
or lp.g pAdM(170) transcribed in 100(ig of liver nuclear extract (used as size
markers). Lanes 4 & 5 contain lpg of pllBl(-599)-(C2AT)i9 (lane 4) or lp,g pi IB 1 (-
88)-(C2AT)i9 (lane 5) transcribed in lOOpg of liver nuclear extract. Lanes 6 & 7
contain lpg of pi lBl(-599)-(C2AT)i9 together with 0.1p.g of pAdM(170) (as an
internal control) transcribed in lOOjxg of liver nuclear extract (lane 6) or 40pg HeLa
nuclear extract (lane 7). Lanes 8 & 9 contain lpg of pi lBl(-88)-(C2AT)i9 together
with 0.1 [Xg of pAdM(170) transcribed in lOOpg of liver nuclear extract (lane 8) or
40|ig HeLa nuclear extract (lane 9). Reactions were carried out in the absence of
nuclear extract (lanes 10-13); in addition, plasmid DNA was omitted from the
reaction in lane 10. Lanes 11-13 contain respectively l|Xg of pAdM(170), ljxg of
pllBl(-599)-(C2AT)i9 and l|Xg of pi 1B1(-88)-(C2AT)i9. Lane 14 contains 100|Xg of
liver nuclear extract only, lane 15 contains 40|Xg of HeLa nuclear extract only and
lane 16 contains lOOjxg of liver nuclear extract and lfxg of p(C2AT)i9. The predicted
transcripts of approximately 370, 270 and 170 nucleotides produced by the control
plasmids are indicated on the left side of the figure. A solid arrowhead indicates the
370 nucleotide transcript produced from pi 1B1(-599)-(C2AT)i9 and pllBl(-88)-
(C2AT)i9 and an open arrowhead indicates the 170 nucleotide transcript produced
from the internal control plasmid pAdM(170).
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are responsible for the transcriptional activity of this minimal promoter in vitro. In
contrast, the AdMLP, which requires ubiquitously expressed transcription factors for
activity, is active in both rat liver and HeLa nuclear extracts. Within the region of
11B-HSD1 DNA present in pi 161(-88)-(C2AT)i9 are 3 sites to which rat liver nuclear
proteins bind, all of which correspond to C/EBP sites (Chapter 3).
The three regions to which C/EBP binds on the 11G-HSD1 promoter (between -88
and +8) are the transcription start (the major site of interaction), between -54 and -36
(weak binding) and between -71 and -62 (very weak binding which was occasionally
observed) (Chapter 3). It is therefore likely that the factors responsible for the
differential expression of 11G-HSD1 in liver and HeLa cells include C/EBP, as it is
the only protein in rat liver nuclear extract which binds to the proximal promoter.
However, it was not possible to determine whether addition of rC/EBP to HeLa
nuclear extract activated transcription from pi lBl(-599)-(C2AT)19, as background
radioactivity levels in the in vitro transcription reactions were increased by addition
of rC/EBP (data not shown), resulting in smear formation, making it impossible to
observe distinct transcripts on gels. Activation of the promoter is unlikely to directly
involve factors other than C/EBP, although it is possible that transcription factors
may recognise the 11G-HSD1 promoter indirectly through C/EBP. It is also possible
that transcriptional activation of the minimal 11G-HSD1 promoter by C/EBP requires
C/EBPG in addition to C/EBPa. C/EBPa binding to the transcription start may
perform the function of an initiator binding protein; in vivo, C/EBPa interacts with
TBP of the basal transcription complex (Nerlov and Ziff, 1995), and such an
interaction may be essential for transcription of the 11G-HSD1 gene. It is noteworthy
that although rC/EBPa reproduced the footprint generated by rat liver nuclear extract
at the transcription start site it was unable to reproduce the DNase I hypersensitive
sites generated by rat liver nuclear extract in the DNase I protection analysis
(Chapter 3). Therefore a direct role for C/EBP in influencing 11B-HSD1 transcription
through binding to the transcription start still remains to be demonstrated.
The failure to directly demonstrate involvement of C/EBP in 11B-HSD1 expression
was disappointing. Depletion of C/EBP available to transcribe the 11B-HSD1
promoter in vitro, either by removal from the extracts or by addition of competitor
oligonucleotide, did indeed result in a subsequent decrease in transcriptional activity
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of pi lBl(-599)-(C2AT)19, but the activity of the internal control was also decreased.
It is possible that expression of the AdMLP in liver nuclear extracts is modulated by
C/EBP. There is little evidence to support this, although the AdMLP does contain a
CCAAT sequence, to which C/EBP is capable of binding and which has been shown
to play a role in governing transcription initiation in vitro (Maity et al., 1988;
Connelly & Manley, 1989). Other workers have also reported data from in vitro
transcription experiments in which addition of excess competitor oligonucleotides
containing CCAAT sequences resulted in decreased tyrosine aminotransferase
promoter activity, accompanied by a similar reduction in pAdML(270) activity




control of 11B-HSD1 expression
6.1 Introduction
116-HSD1 is highly expressed in liver but it is also expressed at moderate levels in
many other tissues including brain, adipose tissue and adrenal (Monder & White,
1993). Experiments described in this thesis, together with transfection experiments
using hepatoma cells, have established the role played by C/EBP in controlling 118-
HSD1 expression in liver. However, C/EBPa is widely expressed, being most highly
expressed in liver, adipose tissue, lung (Williams et al., 1991) and hippocampus
(Kuo et ah, 1990). C/EBPB and C/EBPS have similar distributions to C/EBPa but the
levels of expression in tissues differs (Williams et ah, 1991). C/EBP may therefore
play a role in the expression of 118-HSD1 in other tissues, but it is possible that
additional transcription factors may regulate 11B-HSD1 expression in tissues other
than liver.
The control of active intracellular glucocorticoids by 11B-HSD1 in adipose cells is
important as evidence suggests that glucocorticoids play a role in regulating adipose
tissue distribution and metabolism (Orth et ah, 1992). For example, in Cushings
Disease, increased glucocorticoid levels are associated with enhanced lipoprotein
lipase and glycero-phosphate dehydrogenase activities (Orth et ah, 1992). Adipose
tissue like liver, plays a central role in energy homeostasis and members of the
C/EBP family play a major role in the differentiation of adipocytes and in regulating
gene expression in adipose tissue (MacDougald & Lane. 1995) Adipocyte
differentiation has been most extensively studied using the 3T3-L1 cell line, and
involves the combined activities of members of the C/EBP transcription factor
family; C/EBPa is expressed late in the differentiation process while C/EBPB and
C/EBP8 are expressed early (Cao et ah, 1991). C/EBPa in particular, has been
implicated in the transcriptional regulation of genes in fully differentiated adipocytes
(Tae et ah, 1994) and abnormalities of lipid accumulation and metabolism are seen in
mice which lack the C/EBPa gene (Wang et ah, 1995). These experiments raise the
possibility that C/EBPa plays a role in expression of 11B-HSD1 in adipose tissue, as
it does in liver.
In mammary adipose tissue, 11B-HSD dehydrogenase activity has been reported
(Quirk et ah, 1990). Work in this laboratory has shown 11B-HSD1 mRNA is present
in adipocytes as well as in fully differentiated 3T3-F442A cells (A. Napolitano,
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personal communication), an adipocyte cell line derived from mouse 3T3-cells
(Green & Kehinde, 1974; Green & Kehinde, 1975). Furthermore, in intact, fully
differentiated 3T3-F442A cells and in the related 3T3-L1 cell line, 11G-HSD1
encodes an enzyme with 1 lB-reductase activity and minimal dehydrogenase activity
(A. Napolitano, personal communication). No 11G-HSD1 mRNA is detectable in
undifferentiated 3T3-F442A cells by northern analysis (A. Napolitano, personal
communication) although it can be detected by RT-PCR (K. Chapman, personal
communication). As 3T3-F442A cells have been widely used as a model for adipose
differentiation and function, they therefore represent an attractive model system in
which to identify the key transcription factors required for switching on expression
of 11B-HSD1 in adipocytes.
The adrenal gland is the site of corticosteroid synthesis (Chapter 1), and the
expression of 11B-HSD1 in adrenal suggests that it may potentially play a role in
modulating output of glucocorticoids from the adrenal cortex. The presence and
location of 11B-HSD1 in adrenal appears to be species dependent.
Immunohistochemistry shows 11G-HSD1 is present throughout the bovine adrenal
cortex (B. Williams, personal communication), while no 11B-HSD1 mRNA was
detected in sheep adrenals (Yang & Matthews, 1995). In rat adrenal, RT-PCR and
northern analysis of rat adrenal total RNA demonstrated the presence of 11B-HSD1
mRNA (data not shown). In rat, 11B-HSD1 mRNA was localised to the adrenal
cortico-medullary junction (Shimojo et al., 1996) and was shown to act as an oxo-
reductase (Shimojo et al., 1996). Most if not all of the steroidogenic enzymes
expressed in adrenal cortex are transcriptionally regulated by a member of the steroid
hormone receptor superfamily, SF-1 (steroidogenic factor 1) (Rice et al., 1991). SF1
is highly expressed in steroidogenic tissues (Lala et al., 1992) and indeed is essential
for their development; mice lacking SF-1 have no adrenal glands or gonads
(Sadovsky et al., 1995). The rat 11G-HSD1 gene contains DNA sequences which
resemble predicted binding sites for SF1 (Table 6.1). Based on the sequences of the
SF-1 binding sites in the cholesterol side chain cleavage enzyme, steroid 21-
hydroxylase and aldosterone synthase genes (Lala et al., 1992) and the pattern of
proteins from adrenocortical cells which bind to these sites, we have classified the
putative SF-1 sites in the 11B-HSD1 gene into 'complex' and 'simple' sites (Table
6.1). The 'complex' site contains the sequence AGGTCA (ERE half site, see Chapter
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1, Section 1.2.5). Sites containing this sequence from the aldosterone synthase and
cholesterol side chain cleavage genes formed multiple complexes in gel mobility
shift assays using adrenal nuclear extract (Lala et al., 1992). The 'simple' sites deviate
from the AGGTCA consensus sequence in the 3 nucleotides at the 3' end, but have a
conserved CA dinucleotide immediately 5' to the AGGTCA hexanucleotide (Parker
& Schimmer, 1993).'Simple sites' form a single complex with adrenal nuclear extract
CAAGG (Lala et al., 1992). Because of the central role SF1 appears to play in
steroid biosynthesis, I have investigated whether SF-1, from bovine adrenal gland,
may play a role in regulating 116-HSD1 expression.
SF1 binding site Sequence Predicted complex formation Oligonucleotide
11B-HSD1 +655 agagaggtcagagt Complex Oo
11G-HSD1 -250 cttgcaaggccaat Simple Op
11G-HSD1 -530 gggcaaggctga Simple Oq
11G-HSD1 -910 agaaggtcagacc Complex Or
P450C21 -210 acagagaggtcagg Complex -
P450C21 -140 tctccaaggctga Simple -
Table 6.1 Predicted SF-1 binding sites in the llfi-HSDl gene
SF-1 binding sites were classified as 'simple' or 'complex' according to sequence and
type of complex formation (see text for details). The match to the 'complex'
AGGTCA, or 'simple' CAAGG consensus sequences are underlined. 'Complex' and
'simple' SF-1 sites from the P450C21 gene are shown (Rice et al., 1991).
In this chapter I describe some preliminary data showing tissue specific proteins
binding to the 11G-HSD1 promoter from adrenal and 3T3-F442A cells.
6.2 Results
6.2.1 Nuclear proteins from 3T3-F442A cells bind to the llfi-HSDl proximal
promoter between -88 and +47
6.2.1.1 Specific complexes are formed by undifferentiated and differentiated 3T3-
F442A nuclear extracts
3T3-F442A cells, maintained in medium containing newborn calf serum, were grown
to confluence then induced to differentiate by switching into growth medium
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Figure 6.1 Factors in nuclear extracts from rat liver, undifferentiated or
differentiated 3T3-F442A cells bind to the optimal C/EBP binding oligonucleotide
Gel mobility shift assay using the C/EBP optimal binding oligonucleotide, 0E and
nuclear extracts made from rat liver and undifferentiated or differentiated 3T3-
F442A cells. 1 Ojxg of nuclear extract from liver (lane 2) undifferentiated (lanes 3) or
differentiated (lanes 4) 3T3-F442A cells was incubated with 30fmol of [32P]-labelled
Fa. Lane 1 contains no nuclear extract. Arrows indicate protein-DNA complexes.
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containing foetal calf serum and insulin (this was carried out by A. Napolitano).
Exposure to both foetal calf serum and insulin was necessary to achieve optimal
differentiation into adipocytes. Nuclear extracts made from undifferentiated and
differentiated 3T3-F442A cells bound to the optimal C/EBP binding oligonucleotide,
0E (Figure 6.1). Comparison of complexes formed by extracts from undifferentiated
and differentiated 3T3-F442A cells showed a similar pattern of binding, although the
extract from undifferentiated cells gave rise to more low mobility complexes than did
the extract from undifferentiated cells (Figure 6.1) There also appeared to be more
overall complex formation by extracts from differentiated cells. The mobility of the
complexes formed by 3T3-F442A nuclear extracts was similar, but not identical to
those fromed by liver nuclear extract (Figure 6.1). This pattern of binding is
consistent with the presence of C/EBP-family members in both undifferentiated 3T3-
F442A cells (C/EBPG and/or C/EBP8), and differentiated 3T3-F442A cells,
(C/EBPa; Cao et al., 1991).
Undifferentiated and differentiated 3T3-F442A cell nuclear extracts form similar
specific complexes on the 11B-HSD1 promoter fragment FA, encoding -88 to +47
(Figure 6.2). No qualitative differences were observed between the two extracts, but
quantitative differences exist with the intensity of complexes formed by extract from
undifferentiated cells being less in comparison to those formed by extracts from
differentiated cells (Figure 6.2). Both nuclear extracts form 5 complexes which
migrate to the same positions on the gel and, which are partially competed by a 100-
fold molar excess of specific competitor Fa, but not by non-specific competitor, Fns
(Figure 6.2). The intensity of the lowest mobility complex formed by differentiated
3T3-F442A nuclear proteins is much stronger than the equivalent complex formed by
undifferentiated 3T3-F442A nuclear extracts.
6.2.1.2 C/EBP-related proteins from undifferentiated and differentiated 3T3-F442A
cells bind -88 to +47 of the 11J3-HSD1 gene
The specificity of the 3T3-F442A nuclear proteins which bind to FA was explored
using a series of oligonucleotides as competitors in gel mobility shift assays. A
similar pattern of competition was observed for nuclear extract from either
undifferentiated (Figure 6.3) or differentiated (Figure 6.4) cells. Oligonucleotide 0A
(encoding -14 to +15 of 116-HSD1 gene) and the C/EBP binding oligonucleotides
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Figure 6.2 Factors in nuclear extracts from undifferentiated or differentiated 3T3-
F442A cells bind to the UJ3-HSD] promoter fragment encoding -88 to +47
Competition gel mobility shift assay using the 11B-HSD1 promoter fragment
encoding -88 to +47 (FA) and nuclear extracts made from undifferentiated or
differentiated 3T3-F442A cells. 10p,g of nuclear extract from undifferentiated (lanes
1-6) or differentiated (lanes 8-12) 3T3-F442A cells was incubated with 30fmol of
[32P]-labelled FAin the absence of added competitor (lanes 2 and 8) or in the
presence of a 10- or 100-fold molar excess of competitor fragment, as indicated
above each lane (lanes 3-6 and 9-12). Lanes 1 and 7 contain no nuclear extract.
Arrows indicate specific protein-DNA complexes.
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Figure 6.3 C/EBP-relatedfactors from undifferentiated 3T3-F442A cells bind to the
llfi-HSDl promoterfragment encoding -88 to +47
Competition gel mobility shift using the 11B-HSD1 promoter fragment encoding -88
to +47 (Fa) and nuclear extract from undifferentiated 3T3-F442A cells. 10pg of
nuclear extract was incubated with 30fmol of [32P]-labelled FA in the absence of
added competitor (lane 2) or in the presence of a 10- or 100-fold molar excess of
competitor oligonucleotide, as indicated above each lane (lanes 3-14). Lane 1
contains no nuclear extract. Arrows indicate specific protein-DNA complexes. *
indicates a non-specific complex.
Oligonucleotides used were: 0A, 11B-HSD1 (-14 to +15); Ob, 11B-HSD1 (-88 to
-57); Oc, 11B-HSD1 (-71 to -52); Od, PEPCK P3(I) site; 0E, optimal C/EBP site;





Figure 6.4 C/EBP-related factors from differentiated 3T3-F442A cells bind to the
1 lfi-HSD I promoter fragment encoding -88 to +47
Competition gel mobility shift assay using the 11B-HSD1 promoter fragment
encoding -88 to +47 (FA) and nuclear extract from differentiated 3T3-F442A cells.
10pg of nuclear extract was incubated with 30fmol of [32P]-labelled FA in the
absence of added competitor (lane 2) or in the presence of a 10- or 100-fold molar
excess of competitor oligonucleotide, as indicated above each lane (lanes 3-14). Lane
1 contains no nuclear extract. Arrows indicate specific protein-DNA complexes.
Oligonucleotides used were: 0A, 11B-HSD1 (-14 to +15); 0B, 11G-HSD1 (-88 to
-57); Oc, 1 lfi-HSD 1 (-71 to -52); 0D, PEPCK P3(I) site; Oe, optimal C/EBP site;





0E and Od, encoding respectively an optimal C/EBP binding site and the PEPCK
P3(I) site (see Table 2.1 for sequences), competed complex formation at a 10-fold
molar excess; the non-specific oligonucleotide 0NS and 11B-HSD1 promoter
oligonucleotides 0B and Oc did not compete complex formation (Figure 6.3 &
Figure 6.4). These results show that C/EBP-related factors from undifferentiated and
differentiated 3T3-F442A cells can bind to the 11B-HSD1 promoter between -88 and
+47.
6.2.2 Factors from adrenal cortex bind to the 1 lfi-HSDl promoter
Four putative SF-1 binding sites were identified in the 11B-HSD1 gene at +645, -250,
-530 and -910 (Table 6.1). Oligonucleotides were designed to encompass these
putative binding sites; 00, +629 to +650; Op, -264 to -239; Oq, -540 to -516; 0R,
-919 to -897 (see Table 2.1 for sequences of oligonucleotides) and were used in gel
mobility shift analysis with nuclear extracts made from bovine adrenal cortex.
6.2.2.1 The SF-1 (complex) binding site at +645
A complex pattern of binding was observed when nuclear proteins from adrenal
cortex were incubated with oligonucleotide 00, encoding a 'complex' site at +650,
within intron A of the rat 11B-HSD1 gene (Moison et al., 1992). Bovine adrenal
nuclear extract formed 4 complexes on 0Q- However, only 2 appeared to be specific,
being competed by 00, but not by Ons (Figure 6.5). The 2 specific complexes
appeared to be competed to varying degrees by the other oligonucleotides Op, Oq, Or
(encoding putative SF-1 sites in the 11B-HSD1 gene) but not by Oe, encoding an
optimal C/EBP site (Figure 6.5). 2 weak complexes were formed on 00 by liver
nuclear extract (Figure 6.6), both of which were specific and competed similarly by
both 00 and 0R (encoding 'complex' sites). Interestingly, the upper complex was
preferentially completed by oligonucleotides 00 and 0R (encoding the 2 complex
sites) with weak or no competition by Op, and Oq (encoding the 'simple' sites)
(Figure 6.6).
6.2.2.2 The SF-1 (simple) binding site at -250
Bovine adrenal nuclear extract formed a single specific complex on 0P, a putative
'simple' SF-1 binding site, which was competed most strongly by Op at 10-fold molar
excess of competitor, and was also competed by 00, Oq and Or at 100-fold molar
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Figure 6.5 Factors in bovine adrenal nuclear extract bind to the oligonucleotide
encoding +629 to +650 of the rat llfi-HSDl gene
Competition gel mobility shift assay using the 11B-HSD1 oligonucleotide encoding
+629 to +650 (00) and bovine adrenal nuclear extract. 10(ig of nuclear extract was
incubated with 0. lpmol of [32P]-labelled 00 in the absence of added competitor (lane
2) or in the presence of a 10- or 100-fold molar excess of competitor oligonucleotide,
as indicated above each lane (lanes 3-14). Lane 1 contains no nuclear extract. Lane
15 contains lOpg of liver nuclear extract instead of adrenal extract. Arrows indicate
specific protein-DNA complexes.
Oligonucleotides used were: 00, 11B-HSD1 (+629 to +650); Op, 116-HSD1 (-264 to
-239); 0Q, 11B-HSD1 (-540 to -516); 0R, 11B-HSD1 (-919 to -897); Oe, optimal
C/EBP site; Ons, prolactin ERE (non-specific control).
 
Figure 6.6 Rat liver nuclear proteins form complexes with the oligonucleotide
encoding +629 to +650 of the rat llfl-HSDl gene
Competition gel mobility shift assay using the 11B-HSD1 oligonucleotide encoding
+629 to +650 (00) and rat liver nuclear extract. lOfig of nuclear extract was
incubated with O.lpmol of [32P]-labelled 00 in the absence of added competitor (lane
2) or in the presence of a 10- or 100-fold molar excess of competitor oligonucleotide,
as indicated above each lane (lanes 3-12). Lane 1 contains no nuclear extract. Arrows
indicate specific protein-DNA complexes.
Oligonucleotides used were: 00, 11B-HSD1 (+629 to +650); Op, 11B-HSD1 (-264 to
-239); 0Q, 11B-HSD1 (-540 to -516); Or, 11B-HSD1 (-919 to -897); Ons, prolactin
ERE (non-specific control).
 
Figure 6.7 A single complex is formed by bovine adrenal nuclear extract and the
oligonucleotide encoding -264 to -239 of the rat 11J3-HSD1 gene
Competition gel mobility shift assay using the 116-HSD1 oligonucleotide encoding
-264 to -239 (0P) and bovine adrenal nuclear extract. lOjug of nuclear extract was
incubated with O.lpmol of [32P]-labelled Op in the absence of added competitor (lane
2) or in the presence of a 10- or 100-fold molar excess of competitor oligonucleotide,
as indicated above each lane (lanes 3-14). Lane 1 contains no nuclear extract. An
arrow indicates the specific protein-DNA complex.
Oligonucleotides used were: 00, 11B-HSD1 (+629 to +650); 0P, 11B-HSD1 (-264 to
-239); Oq, 116-HSD1 (-540 to -516); Or, 116-HSD1 (-919 to -897); Oe, optimal
C/EBP site; Ons, prolactin ERE (non-specific control).
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Figure 6.8 Factors in rat liver nuclear extract bind to the oligonucleotide encoding
-264 to -239 of the rat llfi-HSDl gene
Competition gel mobility shift assay using the 11B-HSD1 oligonucleotide encoding
-264 to -239 (Op) and rat liver nuclear extract. 10|ig of nuclear extract was incubated
with O.lpmol of [32P]-labelled 0P in the absence of added competitor (lane 2) or in
the presence of a 10- or 100-fold molar excess of competitor oligonucleotide, as
indicated above each lane (lanes 3-12). Lane 1 contains no nuclear extract. Arrows
indicate specific protein-DNA complexes. * indicates a non-specific complex.
Oligonucleotides used were: 00, 11G-HSD1 (+629 to +650); Op, 11B-HSD1 (-264 to
-239); Oq, 11B-HSD1 (-540 to -516); 0R, 11B-HSD1 (-919 to -897); Ons, prolactin
ERE (non-specific control).
 
excess of competitor, with a rank order of Op>Or>Oo=Oq (Figure 6.7). In this case,
the 2 stronger competitors, Op and 0R, encoded 'simple' (Q>) and 'complex' (0R) sites
(Table 6.1). Oligonucleotide 0E showed no competition, indicating that none of the
complexes contain C/EBP-related factors (Figure 6.7). Liver nuclear extract formed
several complexes on 0P (Figure 6.8). The fastest migrating complex was probably
non-specific, showing only poor competition by a 100-fold molar excess of 0P. Only
Op and Oq, encoding 'simple' sites competed complex formation (Figure 6.8); the 2
oligonucleotides encoding 'complex' sites, 00 and Or showed no competition (Figure
6.8). This result suggests that members of the steroid hormone nuclear receptor
superfamily, present in liver, are capable of binding to this site at -260. However, the
relevance of liver nuclear protein binding to this site is not clear as no footprint was
produced by liver nuclear extract over this sequence (Chapter 4).
6.2.2.3 The SF-1 (simple) binding site at -530
Adrenal nuclear extract formed 2 weak complexes on Oq (Figure 6.9) which were
non-specific as excess competitor unlabelled oligonucleotide Oq failed to compete
complex formation (Figure 6.9). Liver nuclear extract produced a similar result with
no specific complexes formed on Oq (Figure 6.10). This is consistent with the lack of
a liver nuclear protein footprint over this region (Chapter 4). However, another
possible explanation for this is that mistakes were identified in the original 116-
HSD1 promoter sequence and unfortunately as a result of this there is a mistake in
the oligonucleotide sequence at nucleotide -536 which has a C instead of a G residue.
6.2.2.4 The SF-1 (complex) binding site at -910
Bovine adrenal nuclear extract formed 3 specific complexes on oligonucleotide 0R,
encoding the putative 'complex' SF-1 binding site at -910 of 116-HSD1. These
complexes were competed most strongly by the two most related sequences, Or and
00, and overall the oligonucleotides showed differential competition of complexes
(Figure 6.11). All of the complexes were competed by addition of excess unlabelled
Or, demonstrating the specificity of binding. However, the fastest and slowest
migrating complexes were only partially competed by 0Q, and not competed at all by
Op or 00 and the middle complex showed partial competition by 0Q and Oq
suggesting that different proteins with differing DNA-binding specificities may give
rise to these complexes. Liver nuclear extract weakly bound to Or, forming no
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Figure 6.9 No specific complexes are formed by bovine adrenal nuclear proteins on
the oligonucleotide encoding -540 to -516 of the rat llfi-HSDl gene
Competition gel mobility shift assay using the 11B-HSD1 oligonucleotide encoding
-540 to -516 (Oq) and bovine adrenal nuclear extract. lOjLig of nuclear extract was
incubated with O.lpmol of [32P]-labelled Oq in the absence of added competitor (lane
2) or in the presence of a 10- or 100-fold molar excess of competitor oligonucleotide,
as indicated above each lane (lanes 3-14). Lane 1 contains no nuclear extract. Lane
15 contains 10|ig of liver nuclear extract instead of adrenal nuclear extract.
Oligonucleotides used were: 00, 11B-HSD1 (+629 to +650); 0P, 11B-HSD1 (-264 to
-239); Oq, 11B-HSD1 (-540 to -516); Or, 11B-HSD1 (-919 to -897); Oe, optimal
C/EBP site; 0NS, prolactin ERE (non-specific control).
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Figure 6.10 No specific complexes are formed by rat liver nuclear proteins on the
oligonucleotide encoding -540 to -516 of the rat 11J3-HSD1 gene
Competition gel mobility shift assay using the 116-HSD1 oligonucleotide encoding
-540 to -516 (Oq) and rat liver nuclear extract. lOpg of nuclear extract was incubated
with O.lpmol of [32P]-labelled Oq in the absence of added competitor (lane 2) or in
the presence of a 10- or 100-fold molar excess of competitor oligonucleotide, as
indicated above each lane (lanes 3-12). Lane 1 contains no nuclear extract.
Oligonucleotides used were: 00, 1113-HSD1 (+629 to +650); 0P, 11B-HSD1 (-264 to
-239); Oq, 116-HSD1 (-540 to -516); 0R, llfi-HSDl (-919 to -897); Ons, prolactin
ERE (non-specific control).
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Figure 6.11 Factors in bovine adrenal nuclear extract bind to the oligonucleotide
encoding -919 to -897 of the rat llfi-HSDl gene
Competition gel mobility shift assay using the 11B-HSD1 oligonucleotide encoding
-919 to -897 (0R) and bovine adrenal nuclear extract. 10(ig of nuclear extract was
incubated with O.lpmol of [32P]-labelled Or in the absence of added competitor (lane
2) or in the presence of a 10- or 100-fold molar excess of competitor oligonucleotide,
as indicated above each lane (lanes 3-12). Lane 1 contains no nuclear extract. Arrows
indicate specific protein-DNA complexes.
Oligonucleotides used were: 00, 1113-HSD1 (+629 to +650); Op, 116-HSD1 (-264 to
-239); Oq, 11B-HSD1 (-540 to -516); Or, 11B-HSD1 (-919 to -897); Ons, prolactin
ERE (non-specific control).
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discrete complexes (Figure 6.12). However, the smear of complexes formed on 0R
appeared to be specific as 0R and 00 were both effective competitors at 100-fold
molar excess. Op and Oq competed less well (Figure 6.12).
6.3 Discussion
6.3.1 Differentiated and undifferentiated 3T3-F442A cells contain factors which
specifically bind to the 11J3-HSD1 proximal promoter (-8S/+47) and which are
probably members of the C/EBPfamily of transcription factors
These results suggest that C/EBP-related factors from undifferentiated and
differentiated 3T3-F442A cells bind to the 11B-HSD1 promoter (between -88 and
+47) producing similar patterns of C/EBP binding, with perhaps an overall slight
reduction in binding by extracts from undifferentiated cells in comparison to extract
from differentiated cells. The lack of a qualitative difference between the gel shift
pattern produced by nuclear extracts from differentiated and undifferentiated cells
indicates that binding of C/EBP-related transcription factors between -88 and +47 of
the 11B-HSD1 promoter is unlikely to be the main factor turning on 11B-HSD1
expression. However, this does not rule out differentiation dependent binding of
C/EBP or another factor upstream of -88. This shift pattern is not what was initially
predicted as no binding by C/EBPa was expected using nuclear extracts made from
undifferentiated cells. 3T3-L1 cells (a different subclone of mouse 3T3 cells), have
been the most extensively characterised adipocyte cell line with regard to the role of
the C/EBP family members during adipose differentiation. In 3T3-L1 cells, C/EBPa
levels are low in undifferentiated cells and rise as cells differentiate (Cao et al.,
1991). However, the binding observed in undifferentiated cells may be due to other
members of the C/EBP family. C/EBP6 and C/EBP8 are highly expressed in
undifferentiated cells and levels decline as cells differentiate (Cao et al., 1991). The
experiments described in this chapter used nuclear extracts made from differentiated
cells 5 days after induction of differentiation, however, cells are not fully
differentiated until 10 days after induction of differentiation. At 5 days after
induction of 3T3-L1 cell differentiation C/EBPB and C/EBP8 levels are decreasing
and C/EBPa levels are increasing, with the result that levels of C/EBP8 are low but
C/EBPB and C/EBPa protein levels are higher and comparable (Cao et al., 1991). It
is noteworthy that extracts from differentiated cells appeared to form more lower
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Figure 6.12 Factors in rat liver nuclear extract bind to the oligonucleotide encoding
-919 to -897 of the rat llfi-HSDl gene
Competition gel mobility shift assay using the 11B-HSD1 oligonucleotide encoding
-919 to -897 (Or) and rat liver nuclear extract. lOpg of nuclear extract was incubated
with O.lpmol of [32P]-labelled 0R in the absence of added competitor (lane 2) or in
the presence of a 10- or 100-fold molar excess of competitor oligonucleotide, as
indicated above each lane (lanes 3-12). Lane 1 contains no nuclear extract. Bracket
indicates specific protein-DNA complexes.
Oligonucleotides used were: 00, 11B-HSD1 (+629 to +650); 0P, 11B-HSD1 (-264 to
-239); Oq, 11B-HSD1 (-540 to -516); Or, 11B-HSD1 (-919 to -897); Ons, prolactin
ERE (non-specific control).
COMPETITOR r Ons 1 00 11 Op '1 Oq '1 Or 1
W * <=VVELLS
mobility complexes (possibly containing C/EBPa) than did extracts from
undifferentiated cells. Alternatively, it is possible that the cultures of undifferentiated
cells from which extracts were made contain a number of cells which had
spontaneously differentiated, and therefore the 'undifferentiated extracts' were
actually made from that mixture of undifferentiated and differentiated cells,
accounting for the presence of C/EBPa in extracts from undifferentiated cells.
6.3.2 Factors from adrenal extract interact with the llfi-HSDl gene
The binding of an orphan member of the nuclear receptor family, SF-1, to the 116-
HSD1 gene was examined using adrenal extract as an abundant source of SF-1 (Rice
et al., 1991). 11B-HSD1 contains a number of predicted sites or half sites for
members of the nuclear receptor superfamily. The AGGTCA sequence, capable of
binding SF-1, corresponds to a consensus half site for Class II nuclear receptors and
forms the core element of Class III nuclear receptor binding sites (reviewed in
Chapter 1, Section 1.2.5). AGGTCA sequences are found in the 116-HSD1 gene at
+645 and -910. Some SF-1 sites bear only a loose resemblance to the consensus
AGGTCA sequence, and more closely conform to a consensus CAAGG (Parker &
Schimmer, 1993). Two such sequences occur within the sequenced region of the rat
11B-HSD1 gene, at -250 and -530. Experiments performed using oligonucleotides
encoding these 4 sites and in vitro translated SF-1 demonstrated that SF-1 is capable
of binding to all 4 sites (A. Butler & M. Parker, personal communication). In
contrast, another member of the steroid hormone receptor family, COUP-TF
(translated in vitro) only bound to 2 of the oligonucleotides, those containing the
AGGTCA sites (A. Butler & M. Parker, personal communication) indicating that at
-250 and -530 there is a degree of transcription factor binding specificity. Nuclear
extracts made from bovine adrenal cortex showed binding to 3 of the 4
oligonucleotides with different patterns of specificity for each, suggesting that
different factors, probably including SF-1, are binding to each of the
oligonucleotides. Only in one case was a single complex observed, which is likely to
be due to SF-1 binding.
Proteins from liver nuclei also bound to 3 of the oligonucleotides, encoding the
putative SF-1 sites at +655, -250 and -910. These data suggest that proteins in liver
nuclear extract, probably members of the steroid hormone receptor superfamily, can
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bind to these elements of the 116-HSD1 gene; liver contained several members of the
nuclear receptor superfamily including COUP-TF, PPARa and HNF-4 (all of which
were originally cloned from liver cDNA libraries; refer Chapter 1, Section 1.6.3).
Proteins from rat liver nuclear extract bound to oligonucleotides encoding the
AGGTCA sequence at both +655 and -910. Both sites were also bound by in vitro
translated COUP-TF, and it is possible that one of the factors in rat liver nuclear
extract which binds to these 2 sites is COUP-TF, although this remains to be tested.
Neither of these 2 regions have yet been examined by footprinting experiments. If
theses sites do represent bona fide targets for nuclear receptors, then they may be
targets for binding of HNF-4, RXR (and related proteins), PPARa and COUP-TF in
liver, as well as possibly PPARy in adipocytes, a crucial regulator of adipocyte gene
expression and differentiation (MacDougald & Lane, 1995) in the experiments
described in Chapter 4. However, no footprint was generated over the corresponding
region (Chapter 4), by rat liver nuclear extract, making the significance of the
binding to the oligonucleotide questionable.
Glucocorticoid biosynthesis occurs primarily in the adrenal cortex where active
glucocorticoids are produced via 11-deoxycortisol (man) and 11-deoxycorticosterone
(rat) (see Chapter 1), but the biological function of 11B-HSD1 in the adrenal is not
known. Unstimulated, isolated bovine adrenal cortical cells secrete more cortisone
than Cortisol (Burt et al., 1991), but acute ACTH stimulation results in increased
Cortisol secretion with no change in cortisone production. (Burt et al., 1991). Chronic
ACTH treatment of these cells resulted in decreased Cortisol production but increased
cortisone production (Williams et al., 1992). ACTH increases steroidogenic enzyme
activity thereby increasing Cortisol production (see Chapter 1) and it may possibly
also increase the activity/expression of 11B-HSD1, resulting in increased Cortisol
production. In humans, ACTH inhibited 11B-HSD activity (Walker et al., 1992),
suggesting that the adrenal is required for the inhibitory effects of ACTH. It was
suggested that the adrenal produced an intermediate of Cortisol production which
inhibited 11B-HSD activity (Walker et al., 1992). It is possible that another steroid
biosynthetic pathway exists that results in the production of a precursor to cortisone
or 11-dehydrocortisone on which 11B-HSD1 could act to produce active
glucocorticoids. Alternatively, adrenal 116-HSD2 may inactivate Cortisol before
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secretion by the adrenal, thereby modulating the amount of active glucocorticoid
released.
Another possible biological effect of glucocorticoids in the adrenal is to modulate
catacholamine release from the medulla (Shimojo et al., 1996); the gene encoding
phenylethanolamine N-methyl transferase which converts noradrenaline into
adrenaline (Shimojo et al., 1996). Blood passing through the adrenal cortex passes
directly into the medulla which expresses some 11G-HSD2 but not 11B-HSD1
(Shimojo et al., 1996). However, 11B-HSD1 is found at the cortico-medullary
junction (at least in rats), (Shimojo et al., 1996). The combined action of the 11B-
HSD enzymes therefore may govern the concentration of active glucocorticoids





Glucocorticoid receptors are present in virtually every cell type in the body and
glucocorticoids modulate the action of many genes and gene networks, in particular
those involved in maintaining blood glucose levels (Garland, 1986; Sasaki et al.,
1984), and those involved in the response of the body to stress and infection
(Baumann and Gauldie, 1994). 11B-HSD1 plays a key role in the metabolism of
glucocorticoids and through its reductase activity may enhance the induction of
genes by glucocorticoid hormones (Jamieson et al., 1996). Expression of 11B-HSD1
throughout the body is generally correlated with the level of expression of GR
mRNA (Whorwood et al., 1992) and is highest in the liver and other tissues which
are major targets of glucocorticoid action such as adipose tissue, kidney and brain
(Orth et al., 1992). Reductase activity of 11B-HSD1 predominates over its
dehydrogenase activity in intact cells (Jamieson et al., 1995; Low et al., 1994a; Voice
et al., 1996; Rajan et al., 1996), suggesting that the role of 11B-HSD1 is to supply
GR with ligand. In agreement with this, attenuation of hepatic 11B-HSD1 by
treatment with oestrogen led to a decrease in the expression of glucocorticoid
inducible hepatic genes (Jamieson et al., 1996), and mice with targeted disruption of
the 116-HSD1 gene have reduced fasting blood glucose levels (Kotelevtsev et al.,
1996b) and decreased fasting levels of hepatic G6Pase (Y. Kotelevtsev, personal
communication). Regulation of 11B-HSD1 expression is therefore key to the normal
actions of glucocorticoids. In this thesis I have shown the central role played by
C/EBP in the regulation of 116-HSD1 expression in liver. C/EBP appears to be the
predominant regulator of 116-HSD1 expression in liver, with at least 12 binding sites
between -812 and +74, including one encompassing the transcription start. Using in
vitro transcription I have shown that the binding of C/EBP to the transcription start
of the 118-HSD1 gene is likely to be of functional importance in the tissue specific
expression of 11B-HSD1 in liver, and finally I have shown that C/EBP-related
transcription factors may play a central role in expression of 11B-HSD1 in
adipocytes, but that in other tissues, e.g. adrenal gland, other transcription factors
may play a role in regulating expression of this important glucocorticoid
metabolising gene.
There was a strong correlation between the sites of hypersensitivity to DNase I
induced by rat liver nuclear extract in the DNase I footprinting experiments on the rat
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116-HSD1 promoter, and the sites which are hypersensitive to DNase I in intact rat
liver nuclei. Within the region between -4000 and +1500 (relative to the transcription
start) only two regions of the 11B-HSD1 gene showed hypersensitivity in intact
nuclei to DNase I; a discrete site at approximately -650 to 660, which reached a
maximum of approximately 50% cleavage, and a region of hypersensitivity spanning
approximately 200 nucleotides, including the transcription start, which was cleaved
100% by DNase I (K. Chapman, personal communication). The striking similarity
between the site at -660 seen in vitro in DNase I footprinting experiments (Chapter
4) and that seen in intact nuclei suggests that a nucleoprotein complex may be
formed by rat liver nuclear extract (at the region adjacent to the hypersensitive site),
which causes a distortion of the DNA, allowing greater access of DNase I.
Recombinant C/EBPa was unable to generate the hypersensitive sites and it is
possible that a large protein or a protein complex from liver might bind here and be
responsible for repressing expression (this region decreased basal levels of promoter
activity), and that it is exchanged with C/EBPa with a concomitant release of
repression. This might account for the incomplete cleavage seen at this site in intact
nuclei. This hypothesis however, remains to be tested.
In future experiments it will be important to identify the protein(s) which bind to the
region adjacent to the hypersensitive site as it may be a key regulatory factor
repressing transcription of the 118-HSD1 gene. The factor could be further
investigated by mutation of the nucleotides surrounding the C/EBP site which should
decrease binding of the unknown factor but not binding by C/EBP. It will be
interesting to examine the effect of mutation of this site on 11B-HSD1 promoter
activity in cells transfected with 116-HSDl-luciferase plasmids, in the absence or
presence of C/EBP. Additionally, it will be important to determine whether the
hypersensitive site is specific to liver to see if this is an important regulatory region
in other tissues.
The 11B-HSD1 promoter lacks a TATA box, furthermore, the transcription start
'initiator' of 11B-HSD1 did not appear to bind a 'classical' initiator binding protein,
instead, C/EBPa, C/EBPB and an unidentified C/EBP related factor bound to the
transcription start (Chapter 3). The involvement of C/EBP in binding to the
transcription start is unusual, but not unprecedented. C/EBP also interacts with the
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transcription start of the factor IX gene between +1 and +18 and disruption of C/EBP
binding by mutation at +13 results in haemophilia B Leyden (Crossley and
Brownlee, 1990). C/EBPa has been shown to interact with TBP in vivo and in vitro
(Nerlov and Ziff, 1995) demonstrating that it could potentially form part of the
initiation complex, or interact with the transcription initiation complex, possibly
acting as in initiator binding protein. Both in vitro transcription (Chapter 5) and
transfection experiments (Chapter 4, Figure 4.2) show that a minimal promoter (-88
to +47) confers activity upon a linked reporter gene; basal activity from a short
promoter containing just 88 base pairs of flanking sequence was the same, or higher,
than that of longer constructs in transfected HepG2 cells and activity of the -599 and
-88 constructs were also similar in in vitro transcription experiments. Interestingly, it
is possible that rat liver nuclear extract forms a nucleoprotein complex with the
fragment encoding -88 to +47. Rat liver nuclear extract induced the appearance of
hypersensitive sites (not induced by rC/EBPa) at approximately ten base pair
intervals. Again, this may correlate with the hypersensitive site seen in intact nuclei,
although, in contrast to the discrete site at -660, in intact nuclei, a region of
approximately 200 base pairs including the transcription start, showed
hypersensitivity to DNase I (K. Chapman, personal communication). It would be
interesting to compare factors binding from different tissues to the 11G-HSD1
promoter, particularly those in which 11B-HSD1 transcription is initiated from the
same promoter as used in liver e.g. in hippocampus, and it will also be of interest to
determine whether the different promoters used in kidney utilise the same factors to
regulate gene expression.
The promoter of the rat 11G-HSD1 gene appears to be predominantly regulated by
C/EBP, at least between -812 and +47, with 12 of the 14 footprints attributable to
members of the C/EBP family of transcription factors (Chapter 4, Section 4.2.1).
This, together with the presence of a C/EBP binding site at the transcription start
suggests that C/EBP plays a uniquely important role in the regulation of this gene in
liver. Most other C/EBP regulated genes contain only a single or a few C/EBP sites
interspersed with other transcription factor binding sites in their promoter regions. It
is tempting to speculate on the importance of the 11B-HSD1 enzyme in providing the
'cross-talk' between the hormonal signals transduced by C/EBP and the
glucocorticoid signalling pathways. Glucocorticoids regulate a wide range of genes
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with diverse functions, but they also regulate 'groups' of genes performing similar
functions e.g. genes involved in glucose metabolism (Cryer, 1992), and stress or
infection (Baumann & Gauldie, 1994). It is interesting to note that additional factors
which regulate these functions also regulate C/EBP. For example, in blood glucose
control, the other major hormonal regulators insulin and glucagon (acting via cAMP)
regulate C/EBP (Bosch et al., 1995; Matsuno et al., 1996), and in the acute phase
response cytokines regulate C/EBP expression. These factors all alter the activity of
C/EBP members, either by phosphorylation, or by altering gene expression, hence,
C/EBP may be a mechanism for the organism to communicate the nutrient or
'stressed' status of the whole organism to the transcription apparatus. The regulation
of 11G-HSD1 by C/EBP provides a mechanism by which C/EBP is able to regulate
the availability of glucocorticoid ligand to its receptor, amplifying the local effects of
glucocorticoid. Thus when C/EBP activity is low, 11B-HSD1 activity will be low and
glucocorticoid will not have as large an effect on promoting glucose availability.
When C/EBP activity increases, then 11G-HSD1 activity increases and
glucocorticoid availability and thus active GR is increased. It is also possible that
different members of the C/EBP-family have different effects on 11G-HSD1 activity
e.g. C/EBPa is associated with regulating energy metabolism (Darlington et al.,
1995) and C/EBPB and/or C/EBP8 have been primarily implicated in regulating
genes involved in the acute phase response (Wedel & Ziegler-Heitbrock, 1995). So
far, the major role of C/EBPa that has been investigated is that concerned with
energy homeostasis (Darlington et al., 1995) and it is important now to investigate
the effects C/EBPa may have in inducing the acute phase response. It would be
interesting to explore the effects of C/EBPB and C/EBP8 upon 11B-HSD1 promoter
activity in transfected cells, and to examine whether these C/EBP-related factors bind
to the same sites as C/EBPa in DNase I footprinting experiments. An indication of
the major role C/EBP may play in regulating 11B-HSD1 expression would be
obtained by examining 11B-HSD1 mRNA levels in C/EBPa and C/EBPB 'knock-out'
mice. It would be predicted that 11G-HSD1 expression would be reduced in these
animals. The 11G-HSD1 'knock-out' mice will be crucial for testing the role of 11B-
HSD1 in actions of glucocorticoids in liver and elsewhere, and it is possible that
C/EBP expression is increased in these animals to compensate for the lack of active
glucocorticoids.
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The predominant role of C/EBP in liver raises questions as to what is regulating 116-
HSD1 elsewhere, both in tissues that also express C/EBP and those that don't.
Adipose tissue contains C/EBP (MacDougald & Lane 1995), and some preliminary
data showed the prevalence of C/EBP in binding to the 116-HSD1 promoter between
-88 and +47 and probably also to the transcription start. It will be interesting to
compare DNase I footprints generated by liver and adipose tissue, especially at the
-660 hypersensitive site. Transfection of 3T3-F442A cells has proved difficult (K.
Chapman, personal communication), so it has not been possible to show a role for
C/EBP in transfected 3T3-F442A cells. The function of 118-HSD1 in adipose tissue
is even more speculative than the postulated role in liver. However, evidence from
this laboratory has demonstrated 116-HSD1 expression in both 3T3-L1 and 3T3-
F442A cells when differentiated into adipocytes with little or no expression of 116-
HSD1 in the undifferentiated fibroblast-like state. Adipose tissue is the biggest
energy store in the body, and it is therefore likely that 116-HSD1 regulates
glucocorticoid mediated metabolism of lipids. The probable regulation of 116-HSD1
in adipocytes by C/EBPa suggests that the regulation of the 116-HSD1 promoter in
adipose tissue is similar to that in liver.
One of the intriguing aspects of the work I have described in Chapter 6 is the
possible involvement of members of the nuclear receptor superfamily in the
regulation of 116-HSD1. 4 sequences from the 116-HSD1 gene were chosen for
further analysis and 3 proved to bind factors from nuclear extracts made from bovine
adrenal cortex, possibly SF-1, and all 4 bound SF-1 produced in vitro. Furthermore, 2
of these sites (both containing ER half sites AGGTCA) were also capable of binding
COUP-TF in vitro. An AGGTCA sequence is an integral part of the recognition
sequence of a number of receptors, including PPARy, a crucial differentiation factor
required to differentiate 3T3-F442A cells into adipocytes (MacDougald & Lane,
1995), raising the possibility that these sequences may play a role in the expression
of 116-HSD1 in those tissues which express particular members of the nuclear
receptor/steroid hormone receptor superfamily. It will be important to further explore
the possible roles of these nuclear factor binding sites in expression of 116-HSD1
using transfections, mutagenesis and footprinting experiments. In addition, it will be
informative to investigate the factors which bind to the 116-HSD1 promoter in
extracts made from other tissues which express SF1 e.g. the gonads.
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All of the work in this thesis has been carried out using in vitro techniques which
give an indication of the factors that are capable of binding to the 11B-HSD1 gene. It
would be extremely interesting to carry out in vivo experiments to determine where
factors in different tissues binding using in vivo footprinting which would provide
more 'biological relevance' to the findings obtained by the in vitro techniques
described in this thesis.
The gene for 11B-HSD1 is expressed in a tissue specific manner and is regulated by
specific transcription factors, particularly C/EBP, binding to the promoter to
modulate 11B-HSD1 expression. The work described in this thesis has provided an
important start towards elucidating the mechanisms that govern expression of 116-
HSD1 in a tissue-specific manner and has provided a testable hypothesis of a
mechanism of 'cross-talk' between the glucocorticoid signalling pathway and an
important group of transcription factors, the C/EBP family.
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